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ABSTRACT 
Tissue injury and metabolic dysfunction are salient features of obesity, diabetes, and hypertension. 
Inflammation and oxidative stress are considered key players behind this altered tissue 
homeostasis that drastically affect several vital organs including liver, heart, kidney and pancreas 
resulting in the development of hepatic steatosis, cardiomyopathy, nephropathy, pancreatic 
insulitis and abnormal glucose metabolism. Despite significant advancement in pharmaceutical 
interventions, the desired efficacy to manage these conditions is still lacking. In these situations, 
cytoprotective and functional attributes of the heme oxygenase (HO) system can be used as an 
alternative management tool. Although, the HO system is cytoprotective, its role in tissue injury 
and dysfunction in obesity, diabetes, and hypertension is not completely clear. To explore the 
importance of upregulating HO in these conditions, HO is induced through hemin in the rat models 
of obesity, diabetes and hypertension. My thesis work show that HO upregulation reduced the 
inflammation and oxidative stress-induced tissue injury in liver, heart, kidney, and pancreas 
through reduction of proinflammatory M1 macrophage marker (ED1) expression, cytokines (TNF-
α, IL-1β, IL-6), oxidative-markers (8-isoprostane, ET-1) and profibrotic/extracellular matrix 
proteins (TGF-β, collagen-IV, fibronectin) and enhancement of the anti-inflammatory M2-
macrophage markers (ED2, CD206, CD36, CD14), adiponectin and total-antioxidant capacity. HO 
upregulation improved glucose metabolism through potentiation of insulin signalling components 
(IRS-1, IRS-2, PI3K, GLUT4), reduced hyperglycemia, and enhanced several markers implicated 
in pancreatic repair and/or regeneration (c-Kit, Sca-1, Oct3/4, Pax2, β-catenin, Islet-1, Nkx6.1 and 
GLUT2). Collectively, the data from my thesis suggested the multifaceted cytoprotective 
mechanisms of the HO system against increasing tissue injury and metabolic dysfunction during 
obesity, diabetes and hypertension. Thus, HO upregulation through hemin may be part of 
therapeutic management strategies against tissue injury and metabolic dysfunction in obesity, 
diabetes and hypertension in the future. 
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PREFACE 
This thesis is composed of six chapters. The first chapter of the presented thesis is the detailed 
view of the key effectors of obesity, diabetes (T1D and T2D), hypertension associated tissue injury 
and metabolic dysfunction in liver, heart, kidney and pancreas, including inflammation, 
macrophage infiltration, proinflammatory cytokines and chemokines, oxidative stress, and insulin 
resistance. The first chapter of the thesis also includes the literature regarding mechanisms of 
pancreatic regeneration and regenerative markers or transcriptional factors expressed in the injured 
pancreas. In addition, the multifaceted cytoprotective role of HO system and Nrf2 has been 
discussed. 
In this thesis, my research work is presented as four manuscripts; (chapters 2, 3, 4 and 5) and 
unpublished chapter 6. In these chapters, the first page of the manuscript describes the scientific 
contribution of mine and others. Chapter-2 describes the effects of an upregulated HO system in 
inflammation-induced hepatic injury and glucose metabolism in the spontaneous hypertensive rats 
(SHR); a genetic model of essential hypertension characterized by high blood pressure and tissue 
injury.  Chapter-3 describes the effects of an upregulated HO system on cardiac tissue injury and 
hemodynamic and metabolic functions in Zucker fatty rats (ZF), a genetic obese model 
characterized by insulin resistance, glucose intolerance and hyper-triglycerides.  Chapters-4 and 5 
describe the effects of upregulated HO on hepatic and renal injury and improvement of their 
functions in Zucker diabetic fatty rats (ZDF), a model of T2D, characterized by glucose 
intolerance, hyperlipidemia, and obesity.  
Chapter-6 encompasses the unpublished study that describes the effects of an upregulated HO 
system on inflammation and oxidative stress-mediated pancreatic injury and repair and / or 
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regeneration in streptozotocin-(STZ)-induced diabetes. Moreover, the chapter also reports the 
effects of HO-induction on insulin signalling and glucose metabolism. 
Chapter-7 consists of a general discussion and conclusions from all results and highlights the 
significance of my studies in terms of resolution of tissue injury and improvement of glucose 
metabolism during obesity, diabetes (T1D and T2D), and hypertension. As well it outlines 
potential therapeutic benefits of a hemin-induced HO system that may be explored as a novel 
alternative approach against metabolic tissue injury and dysfunction. In the presented thesis, 
primary literature is usually cited, however, to limit the citation numbers, appropriate reviews were 
citied occasionally to describe the background and basic mechanisms. In addition, for a more 
detailed description of the HO system and cross talk between different effectors involved in 
metabolic tissue injury and dysfunction, my first-authored published manuscript is included in 
appendix A.  
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CHAPTER 1 
INTRODUCTION 
The prevalence of metabolic syndrome associated conditions, such as obesity, type-2 
diabetes (T2D) and hypertension, is increasing at a fast pace across the globe (1,2). Recent 
evidence equivocally confirms the presence of some conditions of metabolic syndrome in type-1 
diabetes (T1D) that is classically known as an autoimmune disease (3,4). Metabolic and vascular 
abnormalities during these conditions are life threatening and associated with higher mortality rate 
and financial expenditures (1,2). 
During obesity, increasing adiposity, dysregulated adipokine secretions and lipotoxicity 
are the major causative factors for tissue and metabolic dysfunction (5-7). Beyond that obesity is 
a risk factor for development of T2D with development of insulin resistance and insulin 
insufficiency in target organs such as liver and skeletal muscle (5-7). Similarly, increasing tissue 
injury and dysfunctional insulin signalling and altered glucose metabolism are distinctive features 
of T1D and hypertension (8-11) and hypertensive subjects are more prone to develop diabetes 
during their lifetime (12). Although, these conditions follow a distinct etiology, tissue injury and 
dysregulated glucose metabolism are a common feature of obesity, diabetes (T1D, T2D) and 
hypertension (5-11,13-17), and inflammation and oxidative stress are considered as the major 
destructive forces behind these comorbidities (5-11,13-17). 
It is well known that macrophages, an innate immunity component, play a major role in 
inflammation and oxidative stress-induced tissue injury and metabolic dysfunction (5-
7,10,14,15,18). An enhanced accumulation of macrophages was seen in injured and dysfunctional 
tissues during obesity, diabetes (T1D, T2D), and hypertension and suggested that these invading 
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macrophages were involved in tissue destruction and abnormal glucose metabolism 
(5,7,10,11,14,15,17,19). Thus, macrophages are the key regulators of metabolic tissue injury and 
dysfunction during obesity, diabetes and hypertension. 
 
1.1 Macrophage infiltration, inflammation and tissue injury 
1.1.1 Origin, phenotypes and functions of macrophages 
Macrophages are highly adaptive cells and possess tremendous diversity in their 
physiological functions that range from development, host defense, immunity to tissue repair (20-
22). Due to their intrinsic adaptive capability, macrophages play a deterministic role in progression 
and severity of several pathogenic conditions of infection, metabolism, cancer, allergies and 
autoimmune disease (20-22).  
On basis of their location, macrophages exist in two distinct types (20-22). The first type 
of macrophages is circulatory in nature and ubiquitously distributed in body (20-22). In contrast, 
the other types of macrophages known as resident macrophages which are stationary and generally 
organ specific (20-22). Although, both types of macrophages are derived from a common 
progenitor in the bone marrow, they possess significant differences in their functions and 
activation mechanisms due to transcriptional regulation (20-22). 
 
1.1.2 Macrophage phenotypic plasticity 
During various unfavorable conditions, macrophages can leave their existing phenotype 
and switch to a functional distinct phenotype to maintain tissue homeostasis (22,23). The process 
of this phenotypic conversion is known as macrophage polarization (Fig. 1-1) (22,23). The 
classical example of macrophage polarization is the conversion of the classical M1-macrophages 
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to alternative-activated M2-macrophages (Fig.1-1) (22-24). 
Both classical M1-macrophages and alternative-activated M2-macrophages represent a 
distinct activation and cytokine and chemokine expression profile (22-24). The classical M1-
macrophages are mainly activated by pro-inflammatory T-helper-1 cytokines such as tumor 
necrosis factor alpha (TNF-α), lipopolysaccharide (LPS), interferons and toll like receptor-ligands 
(22-24). Upon activation, classical M1-macrophages secrete pro-inflammatory cytokines such as 
TNF-α, interleukin-6 (IL-6) and interleukin-1beta (IL-1β) and reactive nitrogen species (RNS) and 
reactive oxygen species (ROS) and participate in inflammation and oxidative stress-mediated 
tissue injury (Fig. 1-1) (22-24).  
In contrast, alternative-activated M2-macrophages possess tremendous scavenging and 
phagocytic capabilities and are activated through anti-inflammatory T-helper-2 cytokines such as 
interleukin-13, interleukin-10 and interleukin-4 (22-24). Regarding functions, alternative-
activated M2-macrophages are related to tissue remodeling and repair processes (Fig. 1-1) (22-
24). The exact mechanism and determinants of this phenotypic conversion is still not fully 
understood. However, scientific evidence suggests that several inflammatory and oxidative 
signaling molecules such as nuclear factor kappa B (NF-B), signal transducer and activator of 
transcription (STAT), peroxisome proliferator-activated receptor, and cellular factors such as 
krupple like factor, interferon-regulatory factor and hypoxia inducing factor and pathogen-induced 
toxins are associated with this phenotypic conversion (23,25). Growing scientific evidence further 
suggests that several epigenetic components (histone modification, transcriptional activation or 
suppression of macrophage genes) and pathogenic stimuli and the local microenvironment 
surrounding macrophages, regulate this phenotypic interconversion (23,25,26).  
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Fig.1-1: Macrophage polarization process and functional roles of classical and alternative 
macrophages. Abbreviations used; Classical M1-macrophages; Alternative-activated M2-
macrophages; Cluster of differentiation-68 (ED1) macrophages; Cluster of differentiation-163 
(ED2) macrophages; Cluster of differentiation-206 (CD206) macrophages; Cluster of 
differentiation-14 (CD14) macrophages; Cluster of differentiation-36 (CD36) macrophages. 
 
1.1.3 Classical macrophages (M1-macrophages)  
1.1.3.1 ED1 macrophages 
The ED1 expressing macrophages are the pro-inflammatory classical M1-phenotype of 
macrophages (27,28). These macrophages are recognized by their surface expression of cluster of 
differentiation-(CD)-68 molecules (27,28). During various conditions of tissue inflammation and 
injury such as obesity, diabetes (T1D and T2D), and hypertension, an increased accumulation of 
ED1 macrophages in several tissues was reported (5,7,10,11,13,17,29,30). In all these pathological 
conditions, ED1 macrophages constitute a major part of the tissue infiltrate and participated in 
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inflammation initiation and tissue injury mechanisms (Fig.1-1) (5,7,10,11,13,17,29,30). Thus, 
during obesity, diabetes and hypertension, strategies targeted to reduce number and detrimental 
functions of ED1 macrophages will be advantageous to improve tissue health and functions. 
 
1.1.4 Alternative-activated macrophage (M2-macrophages) 
1.1.4.1 ED2 macrophages 
ED2 macrophages are the anti-inflammatory alternative-activated M2-phenotype of 
macrophages that express a glucocorticoid regulated surface protein CD163 and possess 
tremendous potential for scavenging the haptaglobin-hemoglobin complex (31,32).  
The occurrence of ED2 macrophages is documented in both rodent tissue and human tissues where 
the expression of ED2 macrophages is stimulated by a number of cellular factors (31,32). Heme 
proteins, glucocorticoids, IL-6 and IL-10 are known to stimulate ED2 expression while the pro-
inflammatory TNF-family of cytokines, IFN-γ, IL-4 and LPS were shown to reduce ED2 
expression (31-33). In normal physiology, ED2 macrophages are mainly associated with resolution 
of inflammation (10,11,13-15,17,31-33). 
During various conditions of obesity, diabetes (T1D, T2D) and hypertension, a significant 
depressed expression of ED2 was shown to be associated with increasing tissue injury in several 
tissues (liver, heart, kidney and pancreas) (10,11,13-15,17,28,33). In contrast, pharmaceutically 
enhanced expression of ED2 macrophages was shown to be associated with the attenuation of 
tissue injury and an improvement of glucose metabolism (10,11,13-15,17,33). Collectively this 
evidence suggests the significant role of ED2 macrophages in the regulation of tissue injury and 
metabolism during metabolic diseases. 
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1.1.4.2 CD206 macrophages 
CD206 macrophages belong to the class of anti-inflammatory alternative-activated M2-
phenotype of macrophages  that express mannose receptor protein on their surface (34). CD206 is 
expressed by several cells (resident macrophages, dendritic cells, lymphatic and non-vascular 
endothelial cells) and are mainly associated with  clearance of excessive mannose-linked 
glycoproteins (34). Recently, it is reported that the expression of CD206 is highly elevated during 
inflammation and tissue injury conditions and a soluble form of CD206 is confirmed in humans 
(35). Moreover, a number of studies documented the anti-inflammatory role of CD206 during 
several inflammatory conditions of obesity, diabetes, and hypertension in maintenance of tissue 
homeostasis and repair (Fig. 1-1) (11,13,14,17,33). For example, in obese, diabetic and 
hypertensive animals, increased CD206 expression was associated with reduction of inflammation 
and tissue injury (11,13,14,17,33).  
In addition, in diet-induced obese animals, increasing proinflammatory M1-macrophages 
and increasing M1/M2 macrophage ratio was closely associated with the development of insulin 
resistance while IL-10-induced accumulation of M2-macrophages (CD206, CD163, CD209a) 
decreases this ratio and improved insulin sensitivity (33).  
In a diabetic nephropathy model, pentraxin-3-induced renoprotective effects were associated with 
the shift of inflammatory M1-macrophages (iNOS+ and CD16/32+) towards M2-macrophages 
(CD206+ and an Arg1+) (36). Studies in rodents further reported that during diabetes, transition of 
pro-inflammatory classical M1-macrophages to an anti-inflammatory alternative-activated M2-
phenotype is greatly altered and contributes towards impaired wound healing and increased 
inflammation (37). However, under non-diabetic conditions, CD206 and CD36 participated in  
maintenance of the anti-inflammatory conditions through secretion of anti-inflammatory cytokines 
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such as IL-10 (37). Increased expression of CD206 and ED2 macrophages induced anti-
inflammatory cytokines IL-10 is shown to play an important role in protection against 
atherosclerosis through regulation of heme protein homeostasis in the situation of intraplaque 
hemorrhage (38,39). These studies collectively proposed the anti-inflammatory and regulatory 
functions of alternative CD206 macrophages during metabolic and vascular alterations. 
 
1.1.4.3 CD36 macrophages 
CD36 macrophages are alternative-activated M2-phenotype of macrophages that mainly 
participate in internalization of oxidized lipids (oxLDL) generated through various inflammatory 
and oxidative processes (11,13,37,40). CD36-deficient rodents are hyperlipidemic due to altered 
lipid metabolism (41). Recently, in adipose tissue macrophages specific lipoprotein lipase (LPL) 
inhibition and subsequent CD36 downregulation was shown to be associated with inhibition of 
atherogenic foam cells formation. However, the above reduction in LPL and CD36 significantly 
increased the circulatory fatty acid levels that participated in development of hepatic insulin 
resistance and systemic glucose intolerance (42). These observations collectively suggest that 
CD36 prevents the sequestering of fat into the circulation and inhibits the development of insulin 
resistance in liver of obese mice. Similarly, in diabetic patients, CD36-deficiency is closely 
associated with dysregulated lipid metabolism and enhanced atherosclerosis and cardiovascular 
mortality (43). CD36-deficient patients showed dysregulated lipid metabolism (hyperlipidemia, 
triglyceridemia), impaired glucose tolerance and insulin resistance (44,45). 
CD36 also participates in clearance of necrotic and apoptotic cells and associated 
inflammation through efferocytosis (46). In diabetic rodents,  along with other M2-macrophages 
CD206, CD36 participated in  maintenance of the anti-inflammatory conditions through secretion 
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of anti-inflammatory cytokines such as interleukin-10 (37).  Similarly, during obesity and 
hypertension pharmaceutically enhanced CD36 expression with other M2-macrophage markers 
was associated with reduction of hyperlipidemia, tissue injuries with improvement of glucose 
metabolism (11,13). Thus, CD36 is an important regulator of inflammation and dysregulated 
metabolism during obesity, diabetes and hypertension. 
 
1.1.5 Proinflammatory cytokines and chemokines in tissue injury  
1.1.5.1 Tumor necrosis factor-alpha (TNF-α) and mechanism of tissue injury  
Enhanced levels of circulatory and tissue TNF-α are reported in several conditions of 
inflammation and metabolic dysfunction during obesity, diabetes and hypertension (5-7,47-50). 
Both, proinflammatory M1-macrophages and dysregulated adipose tissue are the major producers 
of TNF-α during inflammation (5-7,51). As major roles, TNF-α, participates in inflammation 
initiation and tissue injury in these altered metabolic conditions (5-7,51). TNF-α-associated 
inflammation initiation is executed through activation of chemotaxis related protein MCP-1 that 
facilitates the accumulation of proinflammatory M1-macrophages at the site of tissue injury (7,51-
53). In addition, locally produced TNF-α is also known to activate downstream Iκκβ-NF-κB 
inflammatory signaling and the JNK-stress-kinase pathway (50,54-56). The TNF-α-mediated 
activation of these pathways further augments the production of TNF-α itself, and other 
proinflammatory cytokines such as IL-6 and IL-1β. The collective elevated levels of these 
cytokines initiate a vicious cycle of systemic inflammation that leads to tissue injury in various 
vital organs (50,54-56). The TNF-α-induced mechanism of tissue injury is reported by several 
studies during obesity, diabetes and hypertension (49-53,57-60). 
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In diet-induced or genetic obesity, Kupffer cells or adipose tissue-derived TNF-α enhanced 
macrophage infiltration in hepatic tissue via increased accumulation of triglycerides and 
chemotaxis proteins (interferon gamma-induced protein-10 and MCP-1) and participate in 
development of steatohepatitis (51). In addition, TNF-α-mediated enhanced macrophage 
infiltration and activation of oncogenic signalling mediators such as signal transducer and activator 
of transcription 3 (STAT3), extracellular signal-regulated kinase (Erk) and JNK participates in 
hepatocellular carcinoma development during obesity (57). In contrast, the blockage of TNF-α 
signalling through TNF-α knockdown or tumor necrosis receptor-1 (TNFR1) ablation was shown 
to be associated with amelioration of steatohepatitis and hepatocellular carcinoma development 
(51,57).  
Recent studies in both humans and rodents further suggested that obesity-induced 
augmentation of TNF-α converting-enzyme (TACE) and downregulation of fibrosis regulating 
sirtuin-1/metalloproteinase-inhibitor-3 axis are the important causes of enhanced fibrotic 
responses in the liver that subsequently develop into steatohepatitis and hepatic fibrosis (58,59). 
Moreover, TACE-induced TNF-α, self stimulates the release of profibrogenic procollagen-α1 (I), 
alpha smooth muscle actin and transforming growth factor beta (TGF-β) and induce hepatic 
fibrosis during obesity (58). In this condition, pharmaceutical inhibition of TACE through 
marimastat is shown to attenuate established hepatic steatosis (59). (Refer to chapter-4 for more 
details on hepatic injuries; PLoS One. 2013;8(11): e79270).  
Similarly, renal tissue is very sensitive to TNF-α-induced cytotoxic injuries (52,53). 
Elevated TNF-α levels are associated with podocyte injury and development of renal 
histopathological lesions in obese and T2D rodents (52,53). The TNF-α-mediated enhanced renal 
deterioration is governed through NF-κB-induced activation of TNFR2-receptor and subsequent 
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MCP-1-induced macrophage accumulation in renal tissue (52,53). In this condition of renal 
injuries, TNF-α blockage ameliorated the characteristic features of renal pathologies such as 
albuminuria, increased creatinine and renal lesions (52,53). (Refer to chapter-5 for more details on 
renal injuries; (PLoS One. 2014;9(1): e87936). 
Likewise, in liver and kidney, TNF-α overproduction also severely affect the health and 
functions of cardiac and vascular tissue (49,50,60). In obese rodents, increased lipotoxicity and 
elevated levels of TNF-α-induced Iκκβ-NF-κB-JNK-axis and IL-1β are shown to induce cardiac 
inflammation, fibrosis and cardiac hypertrophy through enhanced macrophage infiltration that 
resulted in reduced survival of cardiomyocytes (50). In both hypertensive and obese rodents, TNF-
α greatly suppresses protein kinase B (Akt)/endothelial nitric oxide (eNOS) signalling while 
overproducing the nitric oxide stress and phosphatase-and-tension-homologue (49,60). The 
collective effect of this vascular-signalling disturbance results in development of reduced 
vasodilatory response and increased systolic pressure and vascular inflammation and insulin 
resistance in obese and hypertensive rodents (49,60). In contrast, pharmaceutical or genetic 
blockage of TNF-α not only reduces cardiac and vascular injuries but also improves blood pressure 
(49,60). (Refer to chapter-3 for more details on cardiac injuries; Oxid Med Cell Longev. 2013; 
2013:253657). Thus, the versality in TNF-α-associated tissue destructive functions and close cross 
talk with inflammatory and stress mediators, makes it a potent stimulator of inflammation-induced 
tissues injuries during metabolic diseases.  
 
1.1.5.2 Interleukin-1 beta (IL-1β) and mechanism of tissue injury 
Proinflammatory IL-1β is a major regulator of tissue injury and metabolic dysfunction 
during obesity, diabetes and hypertension (5,61-73). Infiltrating macrophage are the major 
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producers of IL-1β during these conditions (5,61-73), however, some non-monocytic cells are also 
involved in IL-1β production (63).  
As major functions, IL-1β participates in inflammation-induced injury in several tissue 
compartments including adipose tissue, liver, heart, kidney and pancreas during obesity and 
diabetes and hypertension (5,61-73). Studies reported that IL-1β induced activation of nacht-lpr-
pyd domains-containing protein-3 (Nlrp3) inflammasome is the principle mechanism of tissue 
injury and metabolic dysfunction during obesity, diabetes and hypertension (63,69,70,74-76). 
Conversely, activated Nlrp3 also increased the both IL1-β production and activation in a caspase-
1 dependent manner (63,69,70,74-76). 
During obesity, IL-1β is associated with inflammation induced adipose tissue injuries 
(5,61,62) and  elevated production of IL-1β is principally governed by activation of either toll like 
receptor-4/myeloid-differentiation-primary-response-gene-88 or Nlrp3/caspace-1 signalling (62). 
The elevated levels of IL-1β by the above mechanisms, further augment monocyte production in 
bone marrow via hematopoietic progenitor cells and their chemotaxis towards the inflamed sites 
of adipose tissue leads to inflammation and adipose tissue injury (62).  
Nlrp3/caspace-1 associated elevated levels of IL-1β was also documented in both adipocytes and 
adipose tissue of obese and T2D patients where IL-1β further produces proinflammatory mediators 
like IL-6, IL-8, TNF-α and MCP-1 and enhance leukocyte infiltration in adipose tissue (75,76). 
Inhibition of caspace-1 or metformin therapy significantly reduced IL-1β expression and 
inflammation (75,76). Increasing adiposity is shown to be associated with enhanced Nlpr3-
mediated elevation of IL-1β and enhanced adipose and hepatic injuries in obese and T2D models 
of rodents, while weight reduction was associated with suppression of the Nlpr3-mediated IL-1β 
elevation (77).  
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IL-1β is also involved in hepatic deterioration during metabolic diseases (63,64,77). It is 
reported that increasing adiposity is one of the major reasons of IL-1β activation in hepatic resident 
macrophages (Kupffer cells) in a Nlrp3-inflammasome/caspace-1 dependent manner (63,64). The 
activated IL-1β further executes its tissue destructive role by two distinct mechanisms. In the first 
mechanism, IL-1β increases hepatic lipogenesis through stimulation of fatty acid synthase enzyme. 
While in the second mechanism, IL1-β enhances the accumulation of triglycerides in the liver. 
Both actions of IL-1β lead to enhanced production of proinflammatory mediators like TNF-α and 
MCP-1 and profibrotic collagen in the liver and participate in development of hepatic steatosis 
(63,64). In contrast, IL-1β blockage or Kupffer cells depletion protected from development of 
obesity-induced steatosis (63,64). Similarly, in T2D rodents, adipose tissue derived IL-1β and 
other proinflammatory cytokines (TNF-α, IL-6) and chemokines (MCP-1 and MIP-1α) 
synergistically induce hepatic and pancreatic injuries via enhancement of monocyte and leukocyte 
infiltration (65). In contrast, IL-1β antagonism was associated with reduction of these injuries in 
both organs. 
IL-1β is shown to be a major regulator of cardiovascular tissue inflammation and cardiac 
deterioration during metabolic syndrome-associated conditions (69-72). In diabetic rats, IL-1β-
induced vascular NADPH-oxidase and NF-κB and was shown to be associated with development 
of endothelial dysfunction and cardiac-vasculopathy while the IL-1β antagonist anakinra reduces 
the vascular inflammation and restored endothelium-dependent vascular relaxation (72). In 
addition, in a rodent experimental model of cardiac failure, inflammasome-mediated IL-1β 
activation is shown to induce cardiac inflammation, hypertrophy, and ventricular alteration (69). 
In contrast, the blockage of IL-1β was shown to be associated with suppression of cardiac 
inflammation and structural alteration and restoration of systolic performance. In T2D rodents, it 
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has been observed that, Nlrp3-inflammasome activation is a major regulator of production of 
inflammatory NF-κB and oxidative thioredoxin-interacting protein in local and systemic 
surroundings. These mediators increase oxidative stress and activate the IL-1β in a caspase-1 
dependent fashion. The increased IL-1β further induces the remodelling in myocardium and 
participates in development of diabetic cardiomyopathy (70). 
Hypertensive conditions are also a potent cause of cardiac injury through overproduction 
of IL-1β and other proinflammatory mediators (71). In hypertensive rodents, IL-1β along with 
TNF-α, IL-6 and chemokines (MCP-1, MIP-1α,) is shown to be associated with cardiac tissue 
inflammation and injury through overexpression of fibrotic mediators (TGF-β, collagen-IV) and 
markers of cardiac failure (71).  
Recently, in a comprehensive study, it is shown that during both diabetes (T1D and T2D) 
increasing inflammatory and oxidative stress are the major regulators of Nlrp3-inflammasome-
mediated IL-1β activation and subsequent renal endothelial inflammation, podocyte injury, renal 
fibrosis and development of nephropathy. IL-1β was also shown to downregulate nephrin and 
increase proinflammatory cytokines in diabetic kidney, while Nlrp3 ablation or IL-1β antagonism 
prevented renal injuries and development of diabetic nephropathy (74). Thus, similar to TNF-α, 
IL-1β is also a key cytokine in tissue injury of hepatic, renal and cardiac tissue during obesity, 
diabetes and hypertension and IL-1β blockage by various means has cytoprotective benefits (62-
65,72,74,77). 
 
1.1.5.3 Interleukin 6 (IL-6) and mechanism of tissue injury 
IL-6 is a pleotropic cytokine that participates in several conditions of tissue injury and 
metabolic regulation during obesity, diabetes, and hypertension (5,47,48,78,79). In healthy 
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conditions, approximately one third of circulatory IL-6 is secreted by adipose tissue (80), however, 
during obesity, the stromal vascular fraction of visceral adipose tissue consisting of  macrophages 
and endothelial cells secrete a large amount of IL-6 (81). It is reported that during inflammatory 
conditions of obesity, diabetes, and hypertension, the IL-6 level is highly elevated in both the 
circulation and in inflamed tissues and is considered a predictive marker of inflammation, tissue 
injury and dysregulated metabolism (47,78,82,83). Interestingly, in obese patients, a close relation 
of increasing serum IL-6 and other adipokines (TNF-α and leptin) with enhancement of C-reactive 
proteins is documented that suggests an important role of IL-6 in inflammation initiation (48). 
Similarly, in experimental rodent models of obesity, diabetes (T1D, T2D) and hypertension, 
increasing IL-6 expression along with other proinflammatory cytokines such as TNF-α and IL1-β 
are associated with inflammation-induced deterioration of liver, kidney and heart and dysregulated 
glucose metabolism (5,10,14,15,17,47,79).  
IL-6-induced lipotoxicity through enhanced production of hepatic triglycerides and 
activation of downstream IL-1β and TNF-α are the major mechanisms of IL-6-associated 
inflammation and tissue injury (57,84).  In response to a high fat diet, IL-6 has been shown to 
promote inflammation through enhanced lipid accumulation in liver and activation of 
proinflammatory STAT3, Erk, and JNK molecules associated with steatohepatitis and liver cancer 
development (57), while IL-6 deficiency was shown to be associated with reduced inflammatory 
monocyte infiltration and reduced activation of proinflammatory mediators in the livers of high 
fat diet rodents. In the obese rodents, enhanced production of proinflammatory STAT3 and 
elevated levels of IL-6 has been shown to be associated with fibrotic liver injury through enhanced 
production of the destructive acute phase protein fibrinogen in the liver (85). IL-6 deficiency has 
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been shown to ameliorate this activation state of hepatic STAT3 and adipose tissue fibrinogen 
molecules.  
Despite destructive proinflammatory roles, an increasing number of scientific reports 
suggested the anti-inflammatory and metabolism regulatory roles of IL-6 in various conditions of 
metabolic alteration (86-97). During obesity, IL-6 protects against endotoxin-induced 
inflammation through enhanced expression of the anti-inflammatory CD206 expression via 
STAT3-dependent activation of interleukin-4R expression in macrophages and secretion of the 
anti-inflammatory cytokine IL-10. In contrast, blockage of IL-6 signaling is shown to enhance 
inflammation through augmentation of proinflammatory M1 cytokines (TNF-α, IL-1β, IL-6, IL-
12p35) and oxidative stress mediators (iNOS2 and JNK) in liver and skeletal muscle (88). 
Similarly, disruption of IL-6 signaling enhances the production of TNF-α, and phosphorylation of 
inhibitor of NF-κB (IκB-α) in the liver (89). In obese rodents, IL-6 deficiency is associated with 
development of obesity, hepatosteatosis, liver inflammation and insulin resistance due to 
suppression of mitochondrial metabolism through reduction of important metabolic enzymes in 
the liver (87). Interestingly, exercise-induced IL-6 in skeletal muscle was shown to plays an anti-
inflammatory role during various conditions of metabolic diseases, reviewed by Pedersen et al. 
(97). 
From all this evidence, it is suggested that the IL-6 cytokine can be both proinflammatory 
and anti-inflammatory and is associated with metabolic regulation. The mechanism of this dual 
behavior of IL-6 is not clearly understood and it is believed that intrinsic crosstalk of different 
factors in a given cellular environment determine the anti-inflammatory and proinflammatory role 
of IL-6 in metabolic disease (5,10,14,15,17,47,79,86-97). 
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1.1.6 Role of proinflammatory chemokines in tissue injury 
1.1.6.1 Monocyte chemotactic protein-1 (MCP-1)  
Monocyte-chemoattractant-protein-1 (MCP-1) is a member of the chemokine-β family of 
cytokines that plays a major role in chemotaxis and activation of inflammatory macrophages (98).  
In both obese, diabetic rodents and humans, MCP-1 is reported as an intermediate link of adipose 
tissue inflammation-induced injury and adipose tissue dysfunctions (5,7,99,100). During obesity, 
T2D and hypertension, the elevation of MCP-1 levels is the first step in inflammation initiation 
where MCP-1 is shown to enhance ED1 macrophages infiltration and TNF-α production in adipose 
tissue (30,99,101). In addition, MCP-1 is also considered as a significant regulator of liver and 
skeletal muscle inflammation-induced injury during obesity and T2D and hypertension 
(11,99,100,102).  
In high fat diet-induced obesity and T2D, propagermanium-induced MCP-1 inhibition, 
supressed the lipotoxicity, monocyte accumulation and hepatic steatosis development (99,100). In 
skeletal muscle, palmitate-induced MCP-1 was shown to increase skeletal muscle injury through 
an enhancement of a proinflammatory environment (102). For example; enhanced accumulation 
of ED1 macrophage, proinflammatory cytokine production (TNF-α and IL-1β), reduction of anti-
inflammatory chemokine (C-X3-C motif) ligand 1 (CX3CL1), CX3C chemokine receptor 1 
(CX3CR1) and interleukin-10 (IL-10) (102).  
Similarly, in T2D-induced nephropathy and hypertension, MCP-1 upregulation was 
associated with several features of renal deterioration and abnormal glucose metabolism, such as 
increased monocyte infiltration, podocyte apoptosis, renal atrophy, albuminuria and insulin 
resistance (30,101). However, pharmaceutical inhibition of MCP-1 significantly reduced the renal 
pathologies (30,101).  
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Elevated levels of MCP-1 were also shown to induce vascular inflammation and 
remodelling (aortic wall thickening and fibrosis, arterial scaring) and development of atheroma 
during hypertension (103,104). In contrast, MCP-1 deficiency was shown to blunt hypertension-
induced vascular tissue injury (103).  
Increasing levels of MCP-1 is strongly correlated with inflammation-induced insulin 
resistance and altered glucose metabolism during obesity, diabetes and hypertension in several 
tissues (adipose tissue, liver and skeletal muscle) (7,30,99,100,102) and suggested that MCP-1-
induced development of insulin resistance is principally governed through increased 
gluconeogenesis, lipotoxicity and production of proinflammatory cytokines TNF-α, IL-6 and IL-
1β (7,30,99,100,102). In contrast, MCP-1 inhibition by various means, supressed lipotoxicity, 
gluconeogenesis and hyperglycemia while it improved insulin sensitivity and glucose metabolism 
(7,30,99,100,102).  
Recently in two clinical trials, pharmaceutical inhibition of MCP-1 was shown to be 
associated with improved tissue health and metabolic functions (105,106).  In T2D patients, 5 mg 
once a day of a MCP-1 inhibitor (CCX140-B) significantly lowered albuminuria and proteinuria 
without any toxic side-effects (105). Furthermore, MCP-1 blockade through JNJ-41443532 is 
associated with improved β-cell function and improvement in glycemia in obese-T2D patients 
(106).  Collectively, these studies suggested that, MCP-1 is not only a crucial regulator of 
inflammation-induced injury during metabolic syndrome but also severely alters the insulin 
sensitivity and glucose metabolism through development of insulin resistance. Thus, MCP-1 
inhibition has a beneficial impact on both tissue injury and metabolism. However, some studies in 
transgenic high fat-fed MCP-1 knockouts failed to show the MCP-1 induced macrophage 
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infiltration in adipose tissue and suggested the presence of an alternative pathway and tissue 
specific roles of MCP-1 in rodents (107,108). 
 
1.1.6.2 Macrophage-inflammatory-protein-1 alpha (MIP-1α) 
Macrophage-inflammatory-protein-1 alpha (MIP-1α) is the other chemokine that is 
associated with metabolic syndrome-induced tissue injury (5,7). It is reported that similar to MCP-
1, MIP-1α is also associated with chemotaxis and facilitates the accumulation of macrophages in 
injured tissue  (5,7). An elevated level of MIP-1α is documented in obesity and T2D and 
hypertensive conditions (5,7,10,11,13,14,17,19,65,71). In addition, inflammatory cytokines such 
as TNF-α are also shown to induce MIP-1α during tissue injury (7). 
During both genetic and diet-induced obesity, MIP-1α is produced with MCP-1 and 
participates in adipose tissue inflammation initiation and adipose tissue injury through production 
of proinflammatory cytokines (5,7). Similarly, in diabetes and hypertensive conditions, MIP-1α 
production was associated with inflammatory injuries in heart, liver and kidney through 
augmentation of monocyte infiltration (10,11,13,14,17,19,65,71). Thus, MIP-1α is an important 
mediator of inflammation-induced tissue injury in metabolic and vascular conditions. (Refer to 
chapter-2 and chapter-3; Am J Hypertens. 2013; 26(9):1123-31 and Oxid Med Cell Longev. 2013; 
2013:253657 for more details on MCP-1 and MIP-1α). 
 
1.2 Oxidative stress and tissue injury during obesity, diabetes and hypertension 
1.2.1 Oxidative stress in obesity, diabetes and hypertension 
Increasing oxidative stress is a major contributor of tissue injuries and metabolic 
dysfunction in obesity, diabetes, and hypertension (8,13,14,109-114). During obesity and diabetes, 
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elevated lipid and hyperglycemia are the two major contributors that are associated with the 
production of several reactive oxygen species during these conditions (8,13,14,109-114). 
Hypertension that is the condition of dysregulated blood pressure, renin angiotensin aldosterone 
system (RAAS) and dysregulated lipid metabolism are the major producers of oxidative stress and 
associated injuries (19,113,114). In addition, metabolic by-products of non-enzymatic glycation 
of carbohydrate and lipid-peroxidation also produce significance levels of oxidative stress 
(8,13,14,109-114).  
It is observed that during obesity and diabetes, mitochondria overactivation and increasing 
NADPH-oxidase enzyme activity are the key mechanism through which these reactive species are 
elevated (109-112,115,116). In addition, tissue infiltrating monocytes and lymphocytes are the 
major ROS producing cellular entities  (5,7,115-118). Both these mechanisms collectively alter 
the tissue architecture and metabolic functions.  
During both obesity and T2D, increased lipotoxicity is one of the significant contributors 
of insulin resistance development through activation of oxidative JNK stress signalling pathways 
(56,91,111,115,119,120). Amelioration of oxidative stress through genetic ablation of JNK or 
overexpression of antioxidant genes in mitochondria such as catalase was shown to improve 
insulin sensitivity and glucose metabolism (56,91,111,115,119,120).  It is also shown that during 
increasing adiposity, generation of reactive oxygen species (ROS) is the first event in inflammation 
initiation that is regulated through NADPH-oxidase activation (121). The increased NADPH-
oxidase and elevated ROS further activate the inflammatory molecules MCP-1 and 
proinflammatory cytokines (TNF-α, IL-6) through activation of NF-kB and participate in 
development of insulin resistance (5,115,121,122). Thus, elevated levels of oxidative stress are the 
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other major regulator of tissue injury and metabolic dysfunction in liver, kidney, heart and 
pancreas (8,10,115,123-126).   
 
1.2.2 Oxidative stress, tissue injuries and dysfunctional metabolism 
1.2.2.1 Oxidative stress and liver injury 
Lipogenic oxidative stress is a significant risk factor for development of hepatic non-
alcoholic fatty liver disease in obese and diabetic subjects, that is characterised by enhanced 
hepatic accumulation of fat and presence of histopathological lesions (steatosis, ballooning, 
fibrosis) along with elevation of functional hepatic alanine transaminase, aspartate transaminase 
and alkaline phosphatase markers and inflammation (127). A similar trend of histopathological 
disturbance has been observed in both T2D patients and diet-induced obese and diabetic animals 
(128-130).  
In addition, in T2D patients and animals it is shown that the presence of hyperglycemia 
acerbates the hepatic injury during non-alcoholic fatty liver disease through further stimulation of 
fibrotic mediators and a number of lipid associated parameters and production of inflammatory 
mediators (131,132). These observations collectively suggest that the combined conditions of 
obesity and T2D will have more potent effects on the severity and progression of hepatic injury 
(131,132). In this situation, dietary interventions such as restricted dietary fat and cholesterol 
intake were shown to be associated with amelioration of lipotoxicity-induced hepatic pathologies 
and improvement in insulin functions (133). (Refer to chapter-2 and chapter-4 for more details on 
hepatic injuries; PLoS One. 2013; 8(11): e79270 and Am J Hypertens. 2013; 26(9):1123-31). 
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1.2.2.2 Oxidative stress and cardiac injury 
Oxidative stress is also detrimental for cardiac tissue during increasing adiposity since 
increasing levels of oxidative mediators such as malondialdehyde, protein carbonyl and decreased 
activity of  glutathione S-transferase, glutathione peroxidase, and paraoxonase1 were observed in 
cardiac tissue (134). In addition, obesity-induced oxidative stress negatively regulates cardiac 
health and metabolism through enhancement of several pathological features of cardiac tissue 
injury such as cardiac hypertrophy, fibrotic injury, cardiac stiffness, while it increased systolic 
blood pressure, endothelial dysfunction and impaired repolarization in the left ventricle (135). 
It is reported in diet induced obesity that increased caloric intake-induced oxidative stress is 
associated with mitochondrial dysfunction, cardiac apoptotic injuries and impaired contractibility 
(136). In addition, in these animals a significant decreased expression of   antioxidant enzymes 
manganese superoxide dismutase (MnSOD) and glutathione peroxidase 1 (GPx1) is documented 
(136). High-fat diet is also a potent cause of mitochondrial dysfunction and this abnormality is 
closely associated with elevated production of oxidative mediators that severely distort cardiac 
morphology and produced left ventricular hypertrophy and diastolic dysfunction (137). In contrast, 
catalase overexpression was shown to ameliorate the oxidative stress-mediated effects in the heart 
(137).  Even in pre-diabetic rodents, increasing cardiac oxidative stress was associated with 
enhanced cardiac lipid-accumulation, ventricular hypertrophy, and diastolic dysfunction 
suggestive of early cardiac injuries (138).  
Clinical studies also confirmed that excessive lipid-accumulation in cardiac tissue is a 
potent cause of increasing oxidative stress and inflammation. These factors equally participate in 
development of cardiac steatosis, cardiac dysfunction and cardiac insulin resistance (139).  
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Similarly, in obese animals,  lipid peroxidation-induced oxidative stress in the myocardium 
was shown to acerbate cardiac morphology and the antioxidant defence system (140). 
Interestingly,  even in the metabolic healthy obese condition,  obesity-induced oxidative and 
endoplasmic reticulum-induced stress significantly deteriorate the cardiac architecture through 
enhanced fibrosis while reducing  the antioxidant defense and accelerating the development of 
cardiomyopathy (141). These results suggest that during metabolic healthy obese conditions, 
oxidative stress and endoplasmic reticulum-induced stress are the major players of cardiac tissue 
injury while inflammation has a minor role at this early condition of metabolic dysfunction. 
Collectively this evidence suggests that similar to inflammation, elevated oxidative stress is a 
major cause of increasing cardiac injury and dysfunction during obesity, diabetes and 
hypertension. (Refer to chapter-3 for more details on cardiac injuries; Oxid Med Cell Longev. 
2013; 2013:253657). 
 
1.2.2.3 Oxidative stress and renal injury 
Obesity is predominantly associated with development of glomerulopathy characterised by 
enhanced renal pathological features such as glomerular volume, foot-process width and  
proteinuria with decreased podocyte density (142). The most acceptable cause for these renal 
injuries are the increasing lipotoxicity (142). During obesity, lipid-induced oxidative stress 
functions at earlier stages and is a major contributor to development of renal pathologies (143,144). 
In a normotensive and hyperlipidemic obese (fa/fa) model of rats it is observed that induction of 
oxidative stress at an earlier stage is associated with increased levels of triglycerides and 
cholesterol and elevated levels of lipid peroxidation components (thiobarbituric acid relative 
substance) in kidney. These kidneys showed a progressive focal segmentary glomerular 
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hyalinosis and associated renal pathologies such as tubular injury, interstitial fibrosis and 
proteinuria. This suggests that increasing lipid-induced oxidative stress is associated with renal 
tissue destruction in obesity (143). Similarly, in obese-hypertensive and diabetic animals, obesity-
induced early oxidative stress is the major cause of renal injury while hypertensive conditions 
further acerbates the pre-existing renal injuries (144).  
Furthermore, in diabetic patients, it is reported that altered triglyceride and cholesterol 
metabolism is an effect of dysregulated lipid metabolism and is associated with enhanced 
accumulation of lipid in renal tissue and development of severe glomerulosclerosis, podocyte 
dysfunction and inflammation. Studies in both human and mouse models suggest that abnormal 
lipid oxidation is also a major reason for enhanced lipid deposition and fibrotic responses in renal 
tissue (145). The similar trend of lipid abnormality and renal injuries is further reported in diabetic 
patients suggesting that during diabetes, the functions of triglyceride regulating effectors such as 
PPAR-alpha, carnitine palmitoyltransferase 1, acyl-CoA oxidase, renal lipoprotein lipase is 
drastically supressed (146). In contrast, the diabetic condition upregulates the expression of 
cholesterol uptake receptors, LDL receptors, oxidized LDL receptors, and acetylated LDL 
receptors (146). Thus, abnormal lipid regulation is the major mechanism responsible for enhanced 
renal injuries during diabetes. 
In a non-obese spontaneous model of T2D, an increased expression of oxidative stress 
mediators (NADPH p22 phox, and NADPH p47) and nitrosative stress mediators (eNOS, 
nitrotyrosin, nitrate and nitric oxide metabolite) were associated with renal pathologies such as 
increasing glomerular hypertrophy and expansion of the mesangial proliferation, increased 
creatinine clearance and urinary albumin (147). Collectively, these observations suggest that, 
development of renal injuries in diabetes is a collective  effect of both oxidative and nitrosative 
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stress that drastically affect the renal architecture and functions (147). (Refer to chapter-5 for more 
details on renal pathologies during obesity and diabetes; (PLoS One. 2014; 9(1): e87936). 
 
1.2.3 8-isoprostane  
8-isoprostane is a marker of lipid peroxidation widely used to determine oxidative stress in 
metabolic studies. 8-isoprotane is a by-product of lipid peroxidation formed by arachidonic acid 
peroxidation by reactive oxygens species (8,71,148,149). Chemically, it is very stable and less 
reactive then other less stable by-products of lipid peroxidation such as aldehydes and 
lipoperoxides that makes it suitable to evaluate oxidative stress (8,71,148,149). To determine the 
oxidative state at a systemic level, 8-isoprostane is measured in biological fluids (urine and plasma) 
while to determine tissue specific oxidative stress, 8-isoprostane is measured in tissue extracts  
(8,71,148,149).  An enhanced level of 8-isoprostane is observed in metabolic altered conditions 
like obesity, diabetes (T1D, T2D) and hypertension (8,16,17,19,144,150-153) and correlated with 
oxidative stress-mediated tissue injury and metabolic dysfunction in various tissues.  
In new-onset T1D patients and STZ-rats, increased lipid peroxidation was shown to be associated 
with enhanced generation of 8-isoprostane levels as a predictor of an oxidative stress environment 
and deviated glucose metabolism (8,151). In essential hypertensive patients, increasing plasma 8-
isoprostane is associated with oxidative stress-mediated increasing salt sensitivity in hypertension 
(150). Similarly, in rodents, combined conditions of genetic obesity, diabetes and hypertension, 
enhanced 8-isoprostane was associated with oxidative renal injury evident by enhanced collagen-
IV and albuminuria (144). In our previously published reports, enhanced 8-isoprostane levels were 
associated with enhanced oxidative fibrotic renal injury and renal hypertrophy in both obese-T2D 
diabetic and hypertensive rats (16,17,19).  In non-alcoholic fatty liver disease patients, elevated 
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levels of oxidative markers such as nitric oxide 2-derived peptide and 8-isoprostane are suggestive 
of enhanced oxidative hepatic deterioration (153). During obesity,  elevated,  8-isoprostane along 
with other oxidative stress markers such as 4-hydroxy-2-nonenal and  protein carbonyls was 
suggestive of oxidative skeletal muscle injury and skeletal muscle insulin resistance while exercise 
significantly reduced the levels of oxidative markers and improved insulin sensitivity (152). 
Elevated 8-isoprostane levels along with endothelin-1 (ET-1) were also documented in injured 
fibrotic cardiac and renal tissues of obese diabetic and hypertensive rats (13,15,17,71). In these 
metabolic altered conditions, antioxidant treatment was shown to counteract against oxidative 
stress and improved dysregulated parameters (154,155).  
Thus, increasing oxidative stress is a crucial factor in tissue degeneration during the 
metabolic dysfunctional states of obesity, diabetes, and hypertension. In these conditions, early 
detection through measurement of 8-isoprostane and use of antioxidants will help to counteract 
oxidative stress and associated tissue injury and dysfunction. 
 
1.2.4 Antioxidant capacity in T1D 
In normal physiology, several antioxidant enzymes regulate the elevated levels of oxidative 
stress and constitutes the antioxidant capacity of a given organ system (156-159). It is well known 
that T1D is an altered condition of oxidative stress tissue injury and dysregulated metabolism 
(8,10). During T1D, hyperglycemia generates a significant amount of reactive oxygen species and 
severely affect the pancreas and other organs (8,10). However, the pancreas is primarily affected 
due to intrinsic lower antioxidant capacity (160,161) which makes it more vulnerable against 
elevated oxidative stress-induced injuries. Similarly, in T1D patients, an abnormal response of 
antioxidant genes such as those for catalase, copper/zinc superoxide dismutase (Cu/Zn SOD), and 
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glutathione peroxidase (GSH-px) mRNA was observed with increased hyperglycemia (156).  In 
this condition, approaches to enhance defense against oxidative stress will be quite beneficial to 
reduce T1D-associated injuries in the pancreas and other organs. 
 In rodents, enhanced β-cell specific expression of Cu/Zn SOD enzymes prevented 
oxidative stress-induced diabetogenesis (162). Similarly, catalase and manganese/zinc superoxide 
dismutase (Mn-SOD) overexpressing rodents have shown improved β-cell survival and reduced 
NF-B activation in chemically-induced diabetes (163). In cultured insulin producing cells, 
overexpression of glutathione peroxidase, Cu/Zn SOD and catalase protects synergistically against 
both oxidative and nitrosative stress (157). In addition, enhanced expression of these antioxidant 
enzymes were also subjected to confer protection against proinflammatory cytokines-induced 
cytotoxicity (157).  
Treatment done using non-enzymatic antioxidants such as β-carotene, α-tocopherol and 
ascorbic acid were also shown to reduce oxidative stress and pro-inflammatory cytokines in T1D 
patients in a dose dependent manner. Moreover, these non-enzymatic antioxidants also enhanced 
the expression of antioxidant enzymes including SOD and catalase (158). In STZ-induced diabetic 
rats, treatment with vitamin K1 attenuated the oxidative-stress-induced injury in pancreatic islets 
through significant reduction of NF-B activation and inducible nitric oxide synthase (iNOS) 
expression and reduction in aldose reductase while increasing antioxidant enzymes (159). Thus, 
enhancing antioxidant capacity of the pancreatic compartment has a lifesaving benefits in T1D. 
 
1.3 Insulin signaling in obesity, diabetes, and hypertension 
1.3.1 Insulin signal transduction pathway and components 
In normal physiology, the insulin signaling pathway is the major pathway responsible for 
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the maintenance of glucose homeostasis. The regulatory insulin signaling cascade is composed of 
several factors and proteins that collectively orchestrate glucose homeostasis (164). Insulin is a 
major activator of the insulin signaling machinery that initiate the proximal phase of the insulin 
signaling process through its binding to surface anchored insulin receptors in metabolically active 
tissues such as liver and muscle (164). Based on structure and functions, insulin receptors belong 
to the tyrosine kinase subfamily of proteins and consist of two segments, the insulin like growth 
factor-1 (IGF-1) receptor and the insulin receptor-related receptor (164,165). Moreover, the insulin 
receptor is a heterotetrameric complex that is composed of two distinct  and two β subunits. 
Between these subunits, insulin binds to the extracellular domain of the  subunit and this binding 
results in activation of a tyrosine kinase site on the β subunit which is located at an intracellular 
location (164,165). The activation of the β subunit is a result of insulin-induced depression of the 
β-subunit tyrosine kinase domain and is governed by a series of trans-phosphorylation and 
conformational change events that finally lead to increased kinase activity (164,165).  
Recent evidence suggested that, although, the insulin receptor is the major binding site for 
insulin in pancreatic β-cells during high glucose levels, insulin is also shown to bind and activate 
IGF-1 or insulin receptor-IGF-1 conjugated or hybrid receptors (165). The insulin-induced 
activation of insulin receptor, IGF-1 or insulin receptor-IGF-1-conjugated, further activates the 
adaptor family of proteins popularly known as the insulin receptor substrate (IRS) through a series 
of binding and tyrosine phosphorylation. IRS proteins, which exists in multiple forms (IRS-1 to 
IRS-6) function as a connective adaptor molecule between proximal insulin signaling initiation 
and activation of downstream effector signaling pathways such as phosphatidylinositide-3-kinases/ 
protein kinase B (PI3K/Akt) and mitogen-activated protein kinase (MAPK) pathways (164,165). 
Insulin-mediated activation of the PI3K/Akt pathway further initiates the glucose translocation 
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process via glucose transporter molecules such as glucose transporter 4 (GLUT4) (165,166).  
 
1.3.2 Dysfunctional insulin signaling in obesity, diabetes, and hypertension 
1.3.2.1 TNF-α and dysfunctional insulin signalling and glucose metabolism 
Evidence suggested that TNF-α is actively involved in development of abnormal glucose 
homeostasis during obesity, diabetes, and hypertension (6,7,49,167-169). TNF-α-induced 
inflammation is a crucial factor for development of insulin resistance in insulin target organs like 
liver, skeletal muscle and heart (6,7,49,167-169), thus, TNF-α is considered as a link between 
inflammation and insulin resistance.  
Reduction of the tyrosine kinase activity of the insulin receptor (IR) and abnormal serine 
phosphorylation of IRS-1 are the major mechanisms through which TNF-α participates in the 
development of insulin resistance (6,168,169). The abnormal phosphorylation at the serine 
residues of IRS-1 further inhibits their tyrosine-phosphorylation-induced activation through the 
insulin receptor (IR) and in this condition, the insulin-induced activation of insulin signaling 
cascade is interrupted (6,168,169).  In addition, TNF-α also suppresses GLUT4 expression and 
associated glucose uptake in skeletal muscle (6,167-169). 
 Scientific reports further suggested that TNF-α-mediated activation of downstream Iκκβ-
NF-κB and JNK-stress-kinase pathways play a major role in development of insulin resistance 
during obesity and T2D (54-56,91,120). TNF-α-associated increased expression of JNK1 and 
JNK2 and altered phosphorylation of IRS-1 at the Ser312 residue and subsequent reduction of 
GLUT4-induced glucose uptake was also documented in human visceral adipocytes. However, 
either, JNK1/2 silencing or liver-X-receptor agonists-mediated inhibition of TNF-α, completely 
reverse insulin resistance while enhancing GLUT4-induced glucose uptake (120). Thus, in this 
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condition of reduced insulin sensitivity, TNF-α inhibition improved insulin sensitivity and glucose 
uptake in both genetic and diet-induced obesity (6,57,167). 
It has become increasingly clear that TNF-α induced lipolysis is the other mechanism of 
development of inflammation and subsequent development of insulin resistance during obesity 
(55,170-172). TNF-α is shown to stimulate lipolysis of excessive fat in adipose tissue and, as a 
result, this free fat enters into the systemic circulation and participates in inflammation and insulin 
resistance in liver and skeletal muscle (55,170-172).  An in vitro experiment suggested that TNF-
α-mediated lipolysis is dependent on mitogen-activated protein kinase (MAPK) and NF-κB 
activation, that collectively, downregulate the lipid droplet-associated protein perilipin and 
enhance lipolysis (170), while NF-κB inhibition via a cell permeable peptide, inhibit the TNF-α-
induce lipolysis (170). In vitro and in vivo observations in rodents suggested that TNF-α and its 
receptor TNFR both are negative regulators of adenosine monophosphate-activated protein kinase 
(AMPK) in skeletal muscle and TNF-α-mediated reduction of AMPK is regulated via TNF-α 
induced protein phosphatase 2C in skeletal muscle. The suppression of AMPK signaling reduces 
the fat oxidation while increases its accumulation in skeletal muscle (172). Deficiency of 
TNFR1/TNFR2 or TNF-α neutralization were shown to improve AMPK signaling and ameliorate 
the lipid-induced insulin resistance (172). Moreover, TNF-α upregulates adipose triglyceride 
lipase, while silencing of adipose triglyceride lipase in adipocytes completely abolish the TNF-α-
induced fatty acid release (171). Thus, TNF-α-induced lipolysis plays a significant role in insulin 
resistance development in metabolic tissues. 
Although, the above evidence in rodents collectively proposed a straightforward 
application of TNF-α blockage to overcome insulin resistance and tissue injury, the beneficial 
effects of TNF-α neutralization in humans was not very successful (173-175). In healthy obese 
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male subjects with insulin resistance, chronic TNF-α blockage with infliximab therapy showed 
abating effects only on inflammatory biomarkers such as C-reactive protein and fibrinogen but 
failed to improve insulin sensitivity and endothelial or vascular functions (173). Similarly, 
administration of the TNF-α blocker etanercept in obese T2D patients and patients with metabolic 
syndrome showed similar improvement in systemic inflammatory events through reduction of 
inflammatory mediators (C-reactive protein, IL-6, and fibrinogen) and increased total adiponectin 
but etanercept did not improve insulin resistance and vascular functions (174,175). These clinical 
studies collectively suggested that TNF-α neutralization may be effective in overcoming 
inflammation and insulin resistance in experimental rodents, however, in humans, the regulation 
of insulin resistance might involve some other effectors.   
 
1.3.2.2 IL-1β and dysfunctional insulin signalling and glucose metabolism 
Despite its crucial role in metabolic tissue injury, IL-1β also negatively affects glucose 
homeostasis (5,61,68,73,75,77,176-178). Both adipose tissue derived and macrophage derived IL-
1β negatively affect insulin sensitivity, glucose metabolism and participates in development of 
insulin resistance during obesity (5,61,73). IL-1β suppresses the insulin signalling mechanism 
through inhibited expression and activation of insulin signalling components such as IRS-1, PI3K, 
GLUT4 and protein kinase B (PKB) in obese rodents (73). Similar observations are also 
documented in both human and murine adipocytes in vitro, where IL-1β treatment decreases 
insulin sensitivity through marked suppression of IRS-1 and GLUT4-induced glucose uptake (73). 
IL-1β also inhibits the insulin-induced tyrosine phosphorylation-mediated activation of IRS-1 and 
insulin-induced activation of PKB and Erk1/2 (61,176). In contrast, IL-1β blockage is associated 
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with improvement in the insulin signalling mechanism (73). Thus, during conditions of adiposity, 
IL-1β negatively regulates the insulin signalling mechanism.  
In obese rodents, it is further reported that, IL-1β associated suppression of insulin 
signalling and development of insulin resistance is principally governed through monocytic Nlrp3-
inflammasome activation (177). During obesity, enhanced lipotoxicity is the major activator of 
Nlrp3-inflammasome and subsequent activation of autophagy, ROS, and AMPK signaling 
pathways. The lipotoxicity-induced activation of these pathways resulted in enhanced production 
of IL-1β and development of insulin resistance (177). It is further explained that insulin resistance 
development through activation of Nlrp3-IL-1β axis is executed by two distinct direct and indirect 
mechanisms. The first inhibitory mechanism involves the direct suppression of insulin signalling 
through alteration in serine phosphorylation of IRS-1 and devoid of TNF-α requirement. The other 
indirect mechanism is dependent on IL-1β-mediated TNF-α production and subsequent inhibition 
of IRS-1. Thus, in IL-1β-associated development of insulin resistance, Nlrp3 activation is a major 
requirement (177). These observations were further confirmed in obese animals where adipose 
tissue showed a higher expression of the inflammasome component caspase-1, that is known to 
participate in activation of mature IL-1β through cleavage of pro-IL-1β (75,77,178). Interestingly, 
in murine adipose tissue, elevated levels of caspase-1 itself had reasonable capabilities to 
selectively modulate adipocyte differentiation and forced them to acquire an insulin resistant 
phenotype. In contrast, ablation of caspace-1 or Nlrp3-deficiency is shown to be associated with 
more metabolically active and insulin sensitive fat cells that showed enhanced GLUT4, 
adiponectin and fat-oxidation levels (178).  
In T2D diabetic rats, elevated IL-1β is shown to stimulate hepatic gluconeogenesis through 
activation of the gluconeogenetic enzyme phosphoenolpyruvate carboxykinase. IL-1β-induced 
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gluconeogenesis is one reason for altered glycemic levels in T2D (65). Like TNF-α, IL-1β also 
induces lipotoxicity through increased lipolysis and suppression of lipid regulatory peroxisome 
proliferating-activated receptor γ and CCAAT/enhancer-binding protein-α (61,68). IL-1β-induced 
abnormal lipid regulation and subsequent elevated lipids in the systemic circulation collectively 
participate in development of insulin resistance during obesity and diabetes (61,68). IL-1β 
antagonism reduced lipotoxicity associated parameters (free fatty acids, cholesterol and 
triglyceride) while protecting from the insulin resistance development and hyperglycemia (61,68). 
Thus, detrimental functions of IL-1β enhance both tissue injury and metabolic dysregulation 
during diabetes and obesity. 
 
1.3.2.3 IL-6 and dysfunctional insulin signalling and glucose metabolism 
IL-6 plays important roles in deterioration of insulin sensitivity in metabolic organs such 
as liver and skeletal muscle during obesity and T2D and is associated with development of obesity 
and diabetes (54,57,85,120,179-181). The IL-6 associated reduction of adiponectin and  
dysregulation of carbohydrate and fat metabolism is a major cause of insulin resistance 
development during T2D and obesity (181). In contrast, IL-6 deficiency reverses these  conditions 
while improving the lipid and carbohydrate metabolism through enhanced adiponectin secretion 
(181). Interestingly, studies in obese and diabetic humans and rodents indicated that compared to 
TNF-α and other mediators (CRP and leptin),  IL-6 is more closely associated with several 
parameters of insulin resistance and abnormal glucose metabolism (179). In contrast, weight loss 
or caloric restriction significantly reduce IL-6 levels and improve glucose metabolism at both 
tissue and systemic levels (179).  
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During obesity, elevated levels of hepatic fat also stimulate the production of IL-6 and 
other proinflammatory cytokines (TNF-α, IL-1β) through activation of the Iκκβ-NF-κB axis and 
subsequent development of low insulin sensitivity, glucose intolerance and insulin resistance in 
both liver and skeletal muscle (54). IL-6 associated STAT3, Erk, and JNK activation and 
subsequent abnormal phosphorylation of IRS-1 at Ser312 are the other mechanisms of insulin 
resistance and abnormal glucose metabolism in liver while IL-6 ablation was shown to improve 
insulin sensitivity (57,120). In vivo and in vitro experiments further suggested that IL-6 was also 
a major reason for enhanced hepatic glucose production and reduced insulin-dependent insulin 
receptor autophosphorylation and activation of Akt molecules resulting in development of insulin 
resistance (85). In addition, IL-6 also inhibit insulin-induced glucose lowering effects via 
inhibition of the IRS-PI3K axis. However, the above inhibiting effect of IL-6 on IRS-PI3K is 
differentially regulated and tissue specific. In liver IL-6 inhibits IRS-1 and PI3K while in skeletal 
muscle it is executed through IRS-2 and PI3K inhibition (180). Moreover, in skeletal muscle IL-6 
stimulate fat accumulation through activation of lipid stimulatory fatty acyl-CoA enzyme. Thus, 
IL-6-induced lipotoxicity and altered insulin signalling are major reasons of skeletal muscle insulin 
insensitivity and glucose intolerance during inflammation (180). However, IL-6 inhibition 
ameliorates the negative consequence of abnormal or supressed insulin signalling (85). 
Collectively these observations suggested a close association of IL-6 in the development of insulin 
resistance during metabolic syndrome conditions. 
Although, collectively the above evidence suggested a potent role of IL-6 in development 
of insulin resistance, many studies reported that IL-6-mediated positive modulation of insulin 
signalling and glucose metabolism during obesity and diabetes. 
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In obese liver IL-6 and STAT-3 are shown to inhibit gluconeogenesis through activation 
of hepatic glucose-6 phosphatase at transcriptional level (86,89). IL-6 inhibition resulted in 
gluconeogenesis and development of glucose intolerance and insulin resistance in liver, adipose 
tissue and skeletal muscle of obese animals (88). IL-6 was also shown to increase insulin secretion 
through stimulation of pancreatic α-cell and intestinal L cells and reduce hyperglycemia in obese 
diabetic animals while IL-6 blockage ameliorates these beneficial effects of IL-6 on hyperglycemia 
(96). Similarly, in human skeletal muscle, IL-6 improves insulin sensitivity through enhancement 
of glucose regulating processes (glucose transportation, glycogen conversion and glucose 
disposal) (92,93). The IL-6 associated reduction of muscle insulin resistance is governed by 
increased phosphorylation-mediated activation of   STAT3, AMPK and p38 mitogen-activated 
protein kinase (92,93). It is further shown that IL-6-induced AMPK activation is regulated through 
increased cyclic adenosine monophosphate and adenosine monophosphate vs adenosine 
triphosphate ratio that results in increased skeletal muscle energy expenditure (94). Recently, in 
obese and diabetic mice, a glucose regulatory drug, protectin-DX was shown to act as an IL-6 
secretagogue in skeletal muscle and ameliorates the hepatic glucose production via STAT3-
mediated transcriptional suppression of gluconeogenesis. Thus, it is suggested that stimulation of 
skeletal muscle IL-6 and the liver glucose regulatory axis through protectin-DX will be highly 
valuable to reduce insulin resistance during obesity (95). Interestingly, in a comprehensive study, 
it is reported that depot specific expression of IL-6 is a critical factor in execution of its beneficial 
or destructive role during obesity and metabolic syndrome conditions (90,91). For example, during 
obesity, adipose derived IL-6 is mainly associated with development of insulin resistance through 
suppression of IRS-1. In contrast, in the hepatic compartment, Kupffer cells derived IL-6 causes 
improvement in insulin resistance through enhanced expression of IRS-2, which suggests the 
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tissue-specific dependence in IL-6 associated functions during obesity (90,91). Thus, the dual 
functionality of IL-6 is still not completely understood and is a matter of intensive research. 
 
1.3.3 T1D and dysregulated glucose metabolism 
Like obesity, T2D and hypertension, insulin insufficiency, increasing inflammation, 
oxidative stress and hyperglycemia severely alter the insulin signaling mechanism in T1D, as 
evident by suppressed expression and functions of insulin signaling components such as IRS-1, 
IRS-2, GLUT4, PI3K and PKB in metabolically active tissues (8,182-195).  In experimental 
animal models, any alteration or absence of these components results in abnormal glucose 
homeostasis through dysfunctional insulin signaling (8,182-195). Thus, optimal function of insulin 
signaling components are the essential requirements for maintenance of glucose homeostasis. 
 
1.4 Pancreatic tissue injury and Type-1 diabetes (T1D) 
1.4.1 Prevalence of T1D  
T1D is a chronic condition of inflammation and increasing β-cell death that is increasing 
at a very fast pace around the globe (1). Global health reports ranked it as one of the leading causes 
of mortality due to its close association with cardiovascular and renal disorders (1). The clinical 
management of diabetes mellitus is onerous and expensive (1). Despite, astonishing growth in the 
field of pharmaceutical research for anti-diabetic medications, only limited options are available 
for its treatment such as insulin therapy and oral medications, which are inadequate and produce 
the danger of unwanted side effects (196,197). In addition, in terminal T1D patients, islet 
transplantation is a lifesaving clinical intervention, however, there are numerous hurdles associated 
with islet transplantation procedures such as immune-mediated allograft rejection, low efficacy of 
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transplanted -cells, inflammatory reactions, graft survival and less availability of cadaveric 
donors. These factors drastically decrease the efficacy and feasibility of islet transplantation 
process in T1D patients (198). 
 
1.4.2 T1D and pancreatic tissue injury 
Regarding the pancreatic injury mechanism, T1D is an autoimmune form of diabetes where 
T-lymphocyte-(T-cell)-mediated -cell destruction, produces a condition of insulin inadequacy 
and hyperglycaemia (199,200). The T-cell-mediated autoimmune mechanism of T1D is unique 
and begins with the inflammatory process known as insulitis (199,200). During the insulitis 
process, many T-cells and macrophages invade pancreatic tissue and initiate the vicious cycle of 
inflammation and activation of several β-cell death pathways including granzymes or perforin-
mediated -cell death, Fas/FasL and TNF-α/TNF-R-induced -cell killing, proinflammatory 
cytokine-induced -cell death, and oxidative stress-induced -cell death  (201-204). Thus, during 
T1D, final -cell death involves several different mechanisms and effector molecules that makes 
its pathogenesis quite difficult. In this abnormal condition, reduction of inflammatory and 
oxidative stress, replenishment and enhanced survival and functions of β-cells are the necessary 
requirement in T1D management. 
A plethora of scientific studies suggested that the pancreas has a reasonable degree of 
plasticity through which pancreatic cells can regenerate and fulfill the required cell number or 
repair the injured (205-220) tissue. Observational studies in pancreatic injury models including 
pancreatectomy, partial duct-ligation and toxin-induced pancreatic injury documented the 
regeneration of both the endocrine and exocrine pancreas (205-220), however, the mechanism of 
pancreatic repair or regeneration was quit variable, which may be due to differences in animal 
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strains and experimental procedures and type of injury. 
 
1.4.3 Mechanisms of pancreatic repair and /or regeneration  
1.4.3.1 β-cell replication and pancreatic regeneration 
There are two distinct mechanisms of pancreatic regeneration, replication (221,222) or 
neogenesis (223). Replication of β-cells is one of the physiological mechanisms in the pancreas 
that is responsible for increasing β-cell number and subsequent increase in β-cell mass. In the 
process of replication, a pre-existing β-cell generates a new daughter β-cell through cellular 
division. The newly generated nascent daughter β-cell further enters into a maturation phase and 
differentiates into a functional mature β-cell (221,222). The scientific literature suggested that the 
process of replication is differentially governed by several epigenetic factors and cell cycle 
regulators at both the neonatal and adult stages (221,222). In addition, various systemic regulators 
such as nutritional and growth components and hormones are the other essential factors that 
participate in regulation of β-cell generation and functional maturation (221,222). Thus, regulation 
of β-cell generation through replication is quite variable at both the neonatal and adult stage and 
involves several effector molecules reviewed in (221,222).  
Studies utilizing genetic linage tracing experiments in pancreatic injury models suggested 
that β-cell replication is the only method of generation of new β-cells during the adult stage and 
almost all β-cells of the adult pancreas have replicative capabilities (205-208), thus, refuting the 
concept of neogenesis during the adult stage.  
In contrast, observations in rodents contradicted this concept and suggested that during the 
post-natal stage or adult stage, the process of β-cell replication and production of new β-cells is 
very slow and cannot fulfill the requirement for β-cells (221,224,225). Additionally, aging was a 
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significant contributor towards the slower rate of β-cell turnover in adults (224,226). 5-bromo-2-
deoxyuridine labelling experiments further confirmed these observations in mice and suggested 
that proliferation and replication of the β-cell is a very slow process and decreased with age 
(221,224,225).  Similar observations have been documented in rodent and human pancreas 
(227,228) and suggested that β-cell regeneration from replication of pre-existing β-cells follows 
slow kinetics and mostly occurred at the post-natal stage and declined with time and age (227,228). 
Furthermore, studies in rodents explained that during the adult stage, the presence of a replication 
refractory period in pancreatic islets slowed down the replication of pre-existing β-cells (207,229). 
Moreover, various metabolic stress conditions such as hyperglycemia, toxic injury and insulin 
resistance are also partially capable of activating β-cell replication and proliferation and insulin 
secretion (224,230-233), However, regardless of this partial activation, replication has less 
importance in replenishment of β-cells in the injured pancreas at the adult stage. Thus, in the adult, 
β-cell turnover through replication is a very slow process that declines with age and time and 
cannot sufficiently fulfill β-cell requirements. 
 
1.4.3.2 β-cell neogenesis and pancreatic regeneration 
Neogenesis is another mechanism of pancreatic regeneration by which the injured pancreas 
replenishes the cell number and regains essential functions. Pancreatic neogenesis is also known 
as  process of de novo formation of  both exocrine and endocrine pancreatic cells from either stem 
cell progenitors or from cells of different lineages (223). It is suggested that neogenesis is 
particularly important in T1D-induced pancreatic injury conditions, since it provides a starting 
population of pancreatic cells including β-cells. Neogenesis derived pancreatic cells further 
proliferate and replace the lost and injured pancreatic cells and participate in both tissue repair and 
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restoration of pancreatic functions, for example replenishment of β-cells and insulin production 
(223). 
Studies in rodents revealed that pancreatic neogenesis frequently occurs at the neonatal 
stage and after this period the occurrence of this regenerative process progressively declines with 
age (234-238). However, at the neonatal stage, the percentage of neogenesis derived islets cells 
was lower than the number of cells derived from replication (234,235), suggesting that β-cells 
neogenesis and replication both participate in maintenance of β-cell mass during the neonatal 
period.  
In contrast, at the post-natal stage, there was a significant decrease in frequency of 
replication of pancreatic cells through an apoptosis-mediated remodeling mechanism that shifts 
the regenerative process toward neogenesis (226), suggesting that the neogenesis-mediated 
pancreatic regeneration mechanism dominants over replication during the post-natal period. 
Moreover, experimental studies using carbonic anhydrase II as a marker of the post-gestation 
period suggested that at the post-natal stage both exocrine and endocrine pancreatic cells may be 
derived from the neogenesis process (235). Observations in rodents and autopsied donor human 
pancreas also documented neogenesis in the adult pancreas (209-220).  
 
1.4.3.3 Pancreatic regeneration and controversies 
Although, these observations strongly supported the occurrence of neogenesis during the 
adult life span, various other scientific reports suggested that there is either an absence of 
neogenesis or very restricted regeneration occurring in the adult pancreas (205,207,226,234-
237,239-244).  
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In mice, Solar and colleagues reported that exocrine ductal precursor Hnf1b+ cells 
participate in neogenesis and differentiate into β-cells. However, this neogenic conversion of 
ductal to β-cells only occur in the embryonic period after which these cells lose their ability to 
enter into the neogenic phase. These observations were further confirmed by ductal ligation and 
toxin-mediated ablation of ductal or β-cells, where no conversion of ductal to β-cells was observed 
(239). Lineage tracing studies also refuted the concept of injury-induced activation of pancreatic 
progenitors that participate in β-cell regeneration post injury. In adult rodents, pancreatic duct 
ligation studies failed to document the occurrence of a β-cell regenerating neogenic process and 
expansion of β-cell mass (242). A study using InsCremTmG transgenic mice suggested that even 
during pregnancy or after pancreatic tissue injury (partial pancreatectomy or partial ductal ligation) 
there was an absence of neogenic β-cell regeneration in adult rodents where β-cell regeneration 
through neogenesis is a rare event during adulthood (244). Similarly, in humans, the generation of 
β-cells  after  partial pancreatectomy was not observed, and suggested that this may be the reason 
for  development of diabetes in patients after pancreatic resection surgery (240). Lineage tracing 
studies using mucin gene Muc1 in rodents also argued against neogenesis in the adult stage (241). 
This study showed that exocrine cells, such as ductal cells only give rise to islet cells during the 
developmental period but at adulthood they are confined to the exocrine pancreas and do not 
transdifferentiate into endocrine islet cells (241).  
Similarly, after complete ablation of β-cells after a high dose of STZ followed by ductal 
ligation, only regeneration of exocrine acini cell was reported. There was a complete absence of 
β-cell regeneration from any exocrine source or progenitors (243). A study in rodents also failed 
to see neogenic conversion of acinar to β-cell, however, new acinar cells may develop from pre-
existing acinar cells (245).  
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Using a DNA analog-based lineage-tracing technique, it is further reported that at the adult stage, 
slow replication is the only method for β-cell replenishment throughout life and there was no 
involvement of any kind of specific progenitors in β-cell growth and regeneration (207,224). Dor 
and colleagues also reported that during the adult stage, β-cells only arise from pre-existing β-cells 
and do not involve stem cell progenitors (205).  
Collectively, this evidence refuted the existence of β-cell regeneration from progenitors or 
through transdifferentiation of exocrine cells. Despite the huge number of supporting and 
contradicting reports, pancreatic regeneration in adults is still a controversial issue. Moreover, 
differences in animal strain, and variability in experimental procedures also incorporated a 
significant heterogenicity in these studies and warrant further investigations.  
 
1.5 Marker implicated in pancreatic repair and/or regeneration 
1.5.1 Tyrosine-protein kinase protein (c-Kit) 
c-Kit is an important transmembrane glycoprotein protein that defines pluripotency, 
differentiation and longevity of embryonic stem cells and hematopoietic cells (246). c-Kit is 
activated through its ligand stem cell factor that is necessary for its biological functions (246).  
The expression of c-Kit is documented in both developing exocrine and endocrine pancreas (247). 
c-Kit expressing cells showed an enhanced Pdx1 and insulin gene, proliferation and survival and 
were shown to participated in both islet neogenesis and pancreatic development during the fetal 
stage (247). In the murine model, -cell specific c-Kit expression  was shown to enhance -cell 
proliferation and functional maturity and insulin secretion and counteracted against high fat 
induced detrimental features (248).  Studies in rodent injury models suggested that c-Kit is a 
characteristic marker of the resident progenitor population of the pancreas that participates in 
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pancreatic neogenesis (249-251). In the STZ-induced pancreatic injury model, a prolonged 
increased expression of c-Kit in response to endocrine injuries is suggestive of involvement of c-
Kit in -cell regeneration (249). Similarly, in a cerulein-induced pancreatic injury model of adult 
rats, presence of c-Kit expressing cells are considered as islet progenitors and are involved in islet 
repair and regeneration during injury (251). Furthermore, in the STZ-induced pancreatic injury 
model, bone marrow derived c-Kit expressing transplanted cells were shown to reduce 
hyperglycemia through proliferation and increased insulin content. The study further suggested 
that these c-Kit positive cells promote endogenous pancreatic regeneration and proliferation of 
preexisting -cells (252). All these studies collectively suggested the involvement of c-Kit 
expressing cells in pancreatic regeneration. Thus, c-Kit is an important marker for the progenitor 
phenotype of pancreatic cells and can be a candidate molecule in isolation and characterization of 
pancreatic stem cells in regenerative cell based therapies for diabetes treatment in the future. 
  
1.5.2 Stem cell antigen-1 (Sca-1) 
Sca-1 is a glycosyl-phosphatidylinositol-anchored cell surface protein that is involved in 
cell differentiation, growth and renewal and maintenance of hematopoietic stem cells (253-259). 
Several studies documented the Sca-1 expression in rodent pancreas and suggested that Sca-1 
participate in pancreatic regeneration, repair and maintenance (253-260). Sca-1 deficiency is 
shown to be associated with defective hematopoietic cells and progenitor development in Sca-1 
null mutants (Sca-1/Ly-6A) that hamper the self-renewal  and functions of hematopoietic cells and 
the development of specific progenitor populations (260). 
Using Sca-1 expression as an identification marker, a number of pancreatic progenitors 
have been isolated and characterized in the murine pancreas at both the post-natal and adult stage 
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from peri-ductal, peri-islet, centroacinar, and terminal ductal region (253,254). These Sca-1 
expressing progenitor cells are highly proliferative and able to develop into multiple lineages of 
pancreatic cells including endocrine and exocrine lineages upon pancreatic injury (253,254). 
Additionally, Sca-1 positive progenitors express several transcription factors associated with both 
endocrine and exocrine pancreas growth, differentiation and functions and are responsive towards 
glucose-induced insulin secretion (253,254).  
Sca-1 is considered to be an important regulating factor in pancreatic growth, development 
and regeneration during various conditions of pancreatic tissue injury including diabetes (261-
263). During STZ-induced pancreatic injury in adult NOD mice a large number of IgG-positive 
cells at the periductal region were observed which are capable of forming multiple layers of cells 
in the pancreas. Moreover, these cells expresses a number of markers of hematopoietic stem cells 
such as Sca-1, c-Kit,  suggesting that these IgG positive cells originated from hematopoietic stem 
cells (261). Cellular analysis through flow cytometry in NOD mice and pre-diabetic mice revealed 
that during diabetes, Sca-1, c-Kit and CD31 expressing endothelial progenitor cells migrated from 
bone marrow to peripheral blood in response to pancreatic injury signals and participate in 
pancreatic repair (262). Similarly NOD mice derived Sca-1 and c-Kit expressing hematopoietic 
stem cells have been transduced with lentivirus encoding pro-insulin II and transplantation of these  
cells in NOD mice were shown to reduce pancreatic insulitis and diabetes progression (263). 
Collectively, this evidence suggested the role for Sca-1 expressing progenitors in pancreatic repair 
Furthermore, Sca-1 expressing pluripotent very small embryonic like stem cells (VSELs) were 
identified in experimental models of rodents and suggested that deviated functions of these cells 
with age is a major cause of development of diabetes and cancer (256-259).  
During, STZ-induced pancreatic injury, Sca-1 expressing bone marrow derived VSELs 
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were shown to express several pancreatic differentiation markers (Nkx6.1, Pdx1, and pancreas 
tissue factor-1), and temporarily improved hyperglycemia in STZ-induced diabetes. The study 
further explains that in response to pancreatic damage, these VSELs cells migrated from bone 
marrow to peripheral blood and further entered into the injured pancreas and participated in 
pancreatic repair and regeneration (256). Similarly, Sca-1 and CXCR4 positive VSELs cells 
expressed Oct3/4 and stage specific embryonic antigen-1 and developed into multiple lineages of 
cells including -cells. Upon administration into an STZ-diabetic mice, these VSELs migrated to 
the injured pancreas and reduced hyperglycemia (257). Moreover, in a pancreatectomy model of 
mice, Sca-1 expressing VSELs were present in the adult mouse pancreas and were capable of 
differentiating into Pdx1 and Oct3/4 expressing progenitors which possibly regenerate into both 
exocrine and endocrine cells (258). These results collectively suggested that Sca-1 expressing 
VSELs have an important role in pancreatic repair and regeneration and may be used as a cellular 
tool for pancreatic repair during pancreatic injury. 
 
1.5.3 Insulin gene enhancer protein-1 (Islet-1) 
Islet-1 is a transcriptional factor which plays an important role in pancreas development 
and regeneration (264,265). Islet-1 is a stimulating factor for several genes associated with insulin 
secretion, protein trafficking, metabolism and differentiation in the pancreas suggesting it plays an  
important regulatory role in-cells growth, functions and maintenance of glucose homeostasis 
(264). These observations were further confirmed in STZ, Akita, Db/Db models, where Islet-1 
overexpression was associated with enhanced β-cell proliferation and colony formation through 
activation of c-Myc and cyclinD1 growth regulating genes (265). It is reported that Isl-1 along 
with its co-activator Lim-domain-binding protein-1 (Ldb1) participates in both endocrine 
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development and insulin promoter activation. In contrast, Ldb1 deficiency resulted in massive 
reduction in number of α-cells, β-cells and δ-cells and development of hyperglycemia suggesting 
a crucial role of Ldb1/Islet-1 axis in pancreatic development and function. (266).  
Moreover, Islet-1 is essential for endocrine growth-associated processes and functions in 
the pancreas (267,268). In contrast, Islet-1 deficiency altered endocrine development through 
reduced proliferation and survival of endocrine progenitors Pax6 positive cells and downregulation 
of transcriptional factor Maf-A resulting in supressed expression of both insulin and glucagon 
hormones and hyperglycemia and impaired glucose tolerance (267,268).  
Studies in rodents further extended the important role of Islet-1 in exocrine pancreatic 
development at the embryonic stage (269). Studies in mice revealed that Islet-1 is required for the 
generation of both the exocrine and endocrine pancreas, which is differentially regulated in a site-
specific manner Islet-1 expression in the dorsal mesenchyme is required for exocrine pancreas 
development while islet expression in endodermal cells regulates endocrine pancreatic 
development. Thus, Islet-1 regulates the development of both the endocrine and exocrine pancreas 
independently (269).  
 
 
1.5.4 Beta-catenin (-catenin) 
 
-catenin is a major component of the Wnt signaling pathway that governs the various 
stages of organogenesis of both the exocrine and endocrine pancreas (270-273). It is observed that 
at the embryonic stage -catenin is highly expressed with other Wnt factors and then decreased 
with time and is undetectable during the adult stage due to regulation of its inhibitor adenomatous 
polyposis coli gene (272). In vitro and in vivo studies in rodents showed that Wnt/-catenin 
signalling governs -cell growth, proliferation and expansion via enhancement of cyclin D2, Pdx1, 
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GLUT2, and Nkx6.1 and improves insulin release and glucose disposal while reducing 
hyperglycemia (273). Interestingly, -catenin activation participates in pancreatic regeneration in 
rodents through enhancement of both -cell replication and neogenesis (270). In contrast, Wnt/-
catenin blockage was associated with decreased pancreatic -cell proliferation and islet or -cell 
mass and regeneration, insulin secretory functions and development of impaired glucose tolerance 
(270,273).  
Although, the above studies acknowledged the potential role of -catenin in regulation of 
endocrine development and functions, it is also required for exocrine pancreas development and 
functions (271,274,275).  In mice, -catenin is shown to be essential for exocrine acinar cell 
lineage growth and specification (271,274), and its deficiency is associated with abnormal 
pancreatic development (271,274). In contrast, β-catenin deletion did not affect the islet endocrine 
cell mass or functions (271,274). Studies further explained that -catenin-mediated functions were 
essential prior to E16.5 days of development and loss of -catenin prior to E16.5 resulted in a 
decrease in the number of recognizable nascent acini and the pancreatic cellular mass (274). The 
reason for this exocrine developmental specificity is explained in β-catenin stabilization studies in 
rodents (275). This study suggested that β-catenin stabilization has dual opposing roles in 
pancreatic function and development at different stages of life. At the early period β-catenin 
stabilization was associated with loss of Pdx1 expression in early pancreatic progenitor cells and 
prevents differentiation and expansion of early pancreatic progenitor cells. In contrast, at a later 
stage, β-catenin activation was associated with increased  proliferation  and enlargement of the 
exocrine pancreas (275). Collectively this evidence supported the important role of β-catenin in 
exocrine pancreatic development. Despite these controversial reports, a clear majority of published 
scientific reports supported a regulatory role for β-catenin in the endocrine pancreas, and suggested 
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that β-catenin signaling regulates several processes including β-cell growth, proliferation, and 
insulin secretion. Thus, activation of Wnt/β-catenin has a positive impact on -cell growth and 
developmental functions in both the embryonic and adult stage. 
 
1.5.5 Octamer-binding transcription factor-3/4 (Oct3/4) 
 
The Oct3/4 is a member of the POU (Pit-Oct-Unc) domain transcription factor family that 
is involved in regulation of pluripotency and self-renewal of embryonic stem cells (276). Both in 
vitro and histological analysis in humans further suggested that Oct3/4 expressing pluripotent stem 
cells participate in regeneration of both the endocrine and exocrine pancreas (277,278). In the 
murine species, the pluripotent Oct3/4 expressing VSELs population is considered as a resident 
tissue progenitor and is shown to participate in tissue regeneration of the pancreas (258). Partial 
pancreatectomy studies (70%) studies in adult mice further reported that Oct3/4 expressing VESLs 
are involved in pancreatic regeneration during pancreatic injury (258). Interestingly, 
transplantation of human placenta derived Oct3/4 expressing multipotent progenitor cells restored 
the blood glucose levels through increased insulin production in diabetic  animals (279) that is 
suggestive of their role in endocrine pancreas regeneration. Studies further suggested that the 
pancreatic transcriptional factor Maf-A is a regulator of differentiation of Oct3/4 positive 
multipotent stem cells into islet-like and insulin positive cells (280), since, Maf-A overexpression 
in these cells enhances a number of genes associated with pancreatic development and secretory 
functions. Furthermore, transplantation of these Maf-A overexpressing Oct3/4 cells in diabetic 
animals have been shown to restore blood glucose levels through increased insulin production 
(280). Thus, collectively the above evidence suggests an important role of Oct3/4 in regulation of 
endocrine pancreatic regeneration and differentiation processes in both humans and rodents. 
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However, since Oct3/4 is usually expressed with other pancreatic markers during regeneration, its 
individual role in pancreatic regeneration requires more specific studies. 
 
1.5.6 Paired homeodomain transcription factor Pax2 
Pax2 is a member of the paired homeodomain transcription factor family that is involved 
in embryonic development, differentiation and maintenance of pluripotency of stem cells (281). 
Among the several members of Pax-transcription factors, Pax4 and Pax6 actively participate in 
pancreatic development and functions (282,283). Pax4 is required for development of insulin 
producing cells while Pax6 plays a major role in pancreatic α-cell differentiation (282,283). 
However, a limited number of studies up until now have evaluated the functions of Pax2 in the 
pancreas. Pax2 expression is documented in both insulin and glucagon producing cell lines (284-
286). However, RT-PCR analysis in rodents showed that Pax2 was only expressed during early 
embryonic pancreatic development and decreased with the time and determine the relative 
proportion of endocrine and exocrine tissues (284). 
Although, in vitro studies showed the role of Pax2 in activation of pro-glucagon hormone 
promoter (285), studies in adult Pax2-deficient mice contradicted this observation and suggested 
that Pax2 is not an essential factor for the formation, growth and maturation of proglucagon 
producing islets, since Pax2-deficient mice were shown to have normal development of islet α-
cells (285). Thus, short-term expression of Pax2 is required only at the early phase of pancreatic 
proglucagon promoter activity. Pax2 expression is also reported in both pancreatic insulin and 
glucagon producing cells and adult rodent islets (286). In rodent islets, two isoforms of Pax2 have 
been detected i.e., Pax2A and Pax2B, while in cell lines, in addition to Pax2A and Pax2B, a distinct 
third isoform, Pax2D2 is also detected (286). Functional assays suggested that both Pax2 isoforms 
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(Pax2A and Pax2B) are only involved in glucagon gene expression through their binding to the 
glucagon promoter at different sites while devoid of any effect on insulin gene expression (286). 
These observations collectively, suggested that Pax2 functions are more related to glucagon 
hormone transcription not the endocrine insulin transcription (286). Thus, it can be inferred that 
Pax2 only regulates the exocrine development at both embryonic and post-natal stages, however, 
its role in endocrine pancreatic development and function is not clear and requires further research. 
      
1.5.7 Homeobox protein-Nkx6.1(Nkx6.1) 
Nkx6.1 is a homeobox protein that was initially described by Rudnick et al., in rodent β-
cells and α-cells in vitro (287). Immunostaining and expression analysis further confirm its 
expression during early pancreatic developmental stages, where it co-express with the important 
endocrine transcription factor Pdx1 and suggested that Nkx6.1 and Pdx1 co-express in early 
pancreatic development and are essential for pancreatic development and maturation of  β-cells at 
the adult stage (288).  Nkx6.1 is also shown to govern the survival and proliferation of 
transdifferentiating β-cell progenitors with other transcriptional factors and participates in the β-
cell developmental process (289,290),  since Nkx6.1 deletion in rodents was subjected to a 
dramatic loss of β-cell precursors and  blockage of β-cell neogenesis (290). 
Nkx6.1 expression is also documented in the adult pancreas (291-293). It is reported that, 
during the adult stage, it regulates the survival, maturation and insulin secreting functions of β-
cells since Nkx6.1 ablation induces increasing β-cell death in rodents (290,291,293,294). During 
the adult stage, Nkx6.1 expression was shown to be restricted to insulin producing β-cells 
(291,294). and requires Pdx1 and GLUT-2 to execute its function (291,295). Conversely, Nkx6.1 
also governs the GLUT2 and glucagon-1 like peptide expression that are essential for β-cell 
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functions. Studies further suggested that both Nkx6.1 and it paralog Nkx6.2 are important in 
endocrine β-cell fate determination (296). However,  in Nkx6.1 null mutants it is reveled that 
Nkx6.2 has a limited capacity to compensate for Nkx6.1 functions (294). In addition, in vitro 
studies in modified primary human β-cells showed that Nkx6.1 co-express with several factors 
associated with β-cell growth and secretory function (Islet-1, Pdx1, Pax6, prohormone convertases 
1/3 and 2, and secretory granule proteins) (292). These cells contain glucose-induced insulin 
secretory capacity and upon transplantation facilitated improved glucose regulation in diabetic 
mice. Thus, Nkx6.1 functions were dependent on other pancreatic transcriptional factors, which 
collectively orchestrate β-cell growth and function (292).    
Nkx6.1 was also shown to regulate the glucagon producing α-cell (296) and control 
glucagon hormone production at the transcriptional level (293,297). This regulation is primary 
achieved by inhibition of glucagon gene transcription at transcriptional levels (293,297) In 
contrast, Nkx6.1 blockage resulted in a decrease in glucose stimulated insulin release while 
doubling of glucagon mRNA.  Thus, Nkx6.1 plays an essential role in functional β-cell maturation 
and insulin secretory functions in the pancreas while it inhibits glucagon hormone transcription in 
β-cells (293).  
 
1.5.8 Glucose transporter-2 (GLUT2) 
 
 GLUT2 is considered as a maturation marker for -cells that are mainly responsible for 
initiation of the glucose-stimulated insulin release function (298,299). Analysis of GLUT2-
deficient islets showed that GLUT2 deficiency negatively effects glucose utilization, insulin 
secretion and its biosynthesis. Moreover, in the absence of GLUT2, there is no compensatory 
expression of other glucose transporters such as GLUT1 or GLUT3, which collectively showed 
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the crucial requirement of GLUT2 in -cell functions (298).  
Comparative analysis of GLUT2 in neonatal and post-natal stages in mice, showed that at 
the neonatal stage, GLUT2 resides at a cytoplasmic location and confers limited glucose sensing 
capacity to -cells while at the time of birth GLUT2 is expressed on the plasma-membrane and 
performs better glucose sensing. Thus, the cellular location of GLUT2 plays an important role in 
glucose sensing in the mature adult -cells (299,300).  
In rodents, GLUT2 deficiency was associated with hyperglycemia, hyperinsulinemia and 
reduced survival, and these rodents showed elevated levels of plasma free fatty acids, glucagon 
hormone and impaired glucose tolerance (301,302). Similarly, -cell specific inhibition of GLUT2  
through antisense RNA resulted in elevated levels of glucose as well as  impaired levels of insulin 
secretion (303). In contrast, transgenic GLUT2 expression was associated with increased survival, 
and glucose-induced insulin secretion, suggesting the importance of GLUT2 transporter in both 
survival and glucose metabolism  (301,302).  
Experimental studies in rodents further revealed that during diabetes (T1D and T2D), 
GLUT2 expression is either absent or suppressed and absence of GLUT2 is considered as an 
important hallmark of -cell dysfunction (302,304-306). In addition, GLUT2 deficiency or 
suppression was associated with development of diabetic symptoms and impaired pancreatic 
development (302-304). In contrast, GLUT2 overexpression facilitates normal glucose utilization 
and insulin secretory capacity of islets (298,305,307). Thus, GLUT2 is an important regulator of 
-cell growth and maturation and insulin secretory functions during normal physiology. However, 
conditions like diabetes severely affect both the expression and function of GLUT2 that 
collectively results in aberrant -cell growth and functions.  
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1.6 Heme oxygenase (HO) system  
(This section is adapted and modified from my published article. Refer to the Appendix A for 
comprehensive details of heme oxygenase system and its regulation.  Mishra et al., Curr Pharm 
Des. 2014; 20(9):1370-91). 
 
1.6.1 Overview of the HO system 
The heme oxygenase system (HO) is a group of microsomal enzymes which catabolize the   
oxidative breakdown of heme. (Fig. 1-2) (308). The increasing accumulation of heme is toxic for 
cells; thus, the HO system regulates its level through its breakdown into carbon monoxide (CO), 
iron (Fe+2) and biliverdin (BV). The catabolic heme degradation through HO-enzymes is a 
multistep process and requires molecular oxygen and nicotinamide adenine dinucleotide phosphate 
(NADPH). The iron and biliverdin produced through heme degradation is further transformed to 
ferritin and bilirubin that function as antioxidants (Fig. 1-2)(308). 
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Figure 1-2:  Cytoprotective role of the heme oxygenase system. HO-1 catalyzes oxidative 
degradation of cellular heme to produce carbon monoxide, iron and biliverdin. Adapted and 
modified from my published article, Ref. (308), Mishra et al., Curr Pharm Des. 2014; 
20(9):1370-91. Refer to Appendix A for more details. 
Upregulation of HO-1 and its end-products by a variety of stimuli or by a pharmacological inducer 
exerts cellular protection against different pathological conditions via activation of distinct 
signaling pathways. (adapted and modified from ref. (308)). Abbreviations used; Carbon 
monoxide (CO), Biliverdin (BV); Bilirubin (BR); Iron (Fe+2); Heavy chain ferritin (FHC); Cyclic 
guanosine monophosphate(cGMP); Soluble guanylate cyclase (sGC); Oxidative stress (OS); Ultra 
violet rays (UV); Nicotinamide adenine dinucleotide phosphate (NADPH); Oxygen (O2-) 
 
1.6.2 Isoforms of the HO system 
The HO system is composed of three different enzyme molecules HO-1, HO-2 and HO-3 
(309-311). Among these three forms, the first isoform HO-1, is inducible and initially described 
as heat shock protein (310,311). In normal conditions, heme works as a substrate for HO-1 
induction while a number of other factors and physiological situations are able to induce a 
significant level of HO-1, for example, ultra-violet rays and hydrogen peroxide, heavy metals, 
nitric oxide, hypoxia, heat shock, endotoxin and conditions of stress like oxidative stress (Fig. 1-
2) (308). In addition, various biological, pharmaceutical and chemical compounds are able to 
induce and potentiate HO-1 expression in biological systems (308). Thus, safe induction of HO-1 
through various pharmaceutical inducers is possible in the living system, which provides an 
opportunity to explore its functions in various cellular compartments. 
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The second isoform HO-2, is constitutively expressed in almost all organs and shares the 
major responsibility of heme metabolism with HO-1 in the mammalian system (Fig. 1-2) 
(308,310,311). The third HO-3 is a less studied isoform of the HO system and is thought to be a 
pseudogene which has no defined functions (Fig. 1-2) (309). 
Genetically, the enzymes HO-1 and HO-2 are products of two different  genes Homox-1 
and Homox-2 and share a sequence homology of 43% (312). Interestingly, the HO-1 promoter 
contains various binding sites for NF-B, activating protein-1 , activating protein-2 and IL-6 (313-
315), while HO-2 shows a glucocorticoid response element in their promoter region (316). A 
striking difference between human HO-1 and HO-2 promoter is the presence of (GT)n dinucleotide 
length polymorphism and G(-1135)A and T(-413)A, single nucleotide polymorphisms, in the 
Hmox-1 gene of human which is completely absent from the Hmox-2 gene. Studies have further 
shown that the HO-1 promoter polymorphism is associated with susceptibility and outcome of 
various diseases, like pulmonary, cardiovascular, renal transplantation, neurological disease and 
diabetes (317-319). 
 
1.6.3 Cytoprotective roles of HO system  
HO system and its metabolites have a vast array of cytoprotective and regulating roles in 
several conditions of obesity, diabetes, and hypertension (Fig. 1-2)(308). The  HO system has been 
shown to protect several tissues (heart, kidney, skeletal muscle, liver and pancreas) from oxidative 
and inflammatory tissue injury during metabolic diseases (308). In addition, pharmaceutical or 
genetic upregulation of the HO system was shown to be associated with improved metabolic 
regulation during obesity, diabetes, and hypertension (For a detailed view of HO system and its 
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cytoprotective roles in metabolic disease, refer to the Appendix A that is my first author 
publication.  Mishra et al., Curr Pharm Des. 2014; 20(9):1370-91)  
  
1.7 Nuclear factor-(erythroid-derived 2)-like 2 factor (Nrf2) and HO-1 regulation 
Nrf2 is a member of the Cap ‘n’ collar transcription factors family that modulates several 
important cellular signaling processes related to human disease and metabolism (320,321). Nrf2 is 
regarded as a sensor for increasing oxidative stress that can induce a number of cytoprotective 
pathways to combat against increasing oxidative stress (320,321).  
 
1.7.1 Nrf2-mediated transcriptional regulation of HO-1 
The scientific literature suggests a close interaction between Nrf2 activation and the HO 
system during various conditions of stress in mammals.  Moreover, it has been observed that HO-
1 transcription initiation is executed in an Nrf2 dependent manner (320,321). Moreover, the HO-
1 promoter contains a stress responsive element which activates HO-1 transcription in multiple 
conditions of stress, and confers cytoprotection against cellular stress (320,321). Studies have 
further shown that Nrf2 transcriptional factors respond to oxidative stress by binding to the 
antioxidant response element in the promoter of HO-1 genes coding for antioxidant enzymes which 
leads to coordinate enhanced expression of genes coding for cytoprotective proteins. Thus, during 
oxidative stress conditions, HO-1 upregulation is transcriptionally controlled by Nrf2 
transcriptional factors (320,321). The Nrf2/HO-1 axis has been shown to confer protective effects 
in various conditions of inflammatory and oxidative tissue injury and in various conditions of 
abnormal tissue homeostasis associated with diabetes (322-332). (For further, details on Nrf2/HO 
axis please refer to recent published article from our lab (320). (Ndisang et al.,Curr Pharm Des. 
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2017;23(10):1465-1470). 
 
1.7.2 HO-1-mediated upregulation of Nrf2 
Although, a large majority of evidence collectively proposed HO-1 regulation through Nrf2 
signalling, HO-1 also regulates Nrf2 and its functions in cellular systems. A close modulating 
interaction between HO-1 and Nrf2 is observed in a number of studies that is shown to be 
cytoprotective (322-333). 
Both in vitro and in vivo studies in rodents showed that during elevated oxidative stress, 
nuclear HO-1 actively participates in Nrf2 activation and stabilization and protects from 
proteolytic degradation (333). This HO-1-mediated increase in Nrf2 half-life further potentiates 
the antioxidant defence through augmentation of phase II oxidants and glucose regulating enzymes 
(333).  
CO which is a metabolic by-product of HO-1 is also shown to activate Nrf2 (334-336). In 
endothelial cells, CO-associated cytoprotective effects against increasing endoplasmic reticulum 
stress was regulated through Nrf2 activation (334,335). In addition, in mice, the HO/CO axis is 
shown to regulate mitochondrial biogenesis through activation of the Nrf2 transcription factor and 
protect from inflammatory lethal sepsis (336).  
A number of HO-inducers such as hemin, cobalt protoporphyrin (CoPP) are also shown to 
exert HO-mediated cytoprotective effects through activation of Nrf2 factor (337,338). HO-1 
inducers such as hemin and CoPP both induce HO-1 via Nrf2 activation in a dose dependent 
manner in the glomerulus (337). This study further suggested a regulating mechanism of HO-1 
through which HO-1 reduces it sustained expression and prevent the renal cells (337). Similarly, 
in the rodent lung transplantation model, hemin-mediated activation of HO-1 is governed through 
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Nrf2 activation and confers protection against lung injuries through potentiation of antioxidant 
defence while reducing inflammation. In contrast, hemin-induced effects were abrogated by an 
HO-1 inhibitor (338). Studies further showed that HO-induced Nrf2 activation and subsequent 
cytoprotection is governed through Erk1/2 and PI3K/Akt pathway activation (339,340). The 
involvement of Erk1/2 and PI3K/Akt pathway in HO-mediated regulation of metabolism and 
tissue protection was also confirmed in an in vivo model where HO-1 is induced by hemin 
(15,341). From this evidence, it is suggested that a close cross talk between HO system and Nrf2 
is one reason for the modulatory roles of HO system in various conditions of dysregulated 
metabolism and tissue injury.  
 
1.7.3 Cytoprotective role of Nrf2 in diabetes  
A large number of studies have shown important cytoprotective advantages of Nrf2 
transcriptional factor activation during the diabetic condition (322-332).  Additionally, Nrf2 is 
considered as one of the regulating factors against increasing oxidative stress and disturbed 
antioxidant defenses during diabetes (322-327). In rodents, genetic activation of Nrf2 is also shown 
to associate with suppression of development and progression of diabetes through improvement of 
insulin secretion and insulin signaling mechanisms (327). Moreover, Nrf2-induced cytoprotective 
mechanisms also protected from development of high-caloric diet-induced hyperglycemia and 
diabetes in db/db mice (327). Moreover, Nrf2 activation was also shown to associate with 
increased expression of antioxidant enzymes such as NADPH: quinone-acceptor-oxidoreductase-
1, Hmox1, glutathione peroxidase-2, and glutathione peroxidase-4, not only in pancreatic islets 
but also in liver, while Nrf2 null mutants have shown abrogated expression of these antioxidant 
enzymes. Similarly, genetic knockdown of Nrf2 has been shown to exacerbate the diabetic 
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condition as evident by elevated levels of hyperglycemia through increased gluconeogenesis and 
reduced glycolysis (331). In contrast, Nrf2 induction through its inducer, also mimicked diabetes 
counteracting effects in rodents (327), Similarly, in skeletal muscles and liver, Nrf2 activation 
participated in maintenance of physiological glucose levels through improved peripheral glucose 
consumption and increased insulin sensitivity (327,332).  In addition, Nrf2 plays an important role 
in the diabetic cutaneous wound healing process (322,323). It is observed that during diabetes, 
hyperglycemia induced oxidative stress severely reduces the antioxidant defence through 
activation of Keap1 (a negative regulator of Nrf2) and suppression of nuclear translocation of Nrf2 
and subsequent production of antioxidant enzymes (322). This reduction in antioxidant defense 
collectively results in impaired cutaneous wound healing. However, Keap1 inhibition through 
topical siKeap1 therapy or siRNA restored this weakened antioxidant system and improved wound 
healing through enhanced regeneration in diabetes animals (322). In addition, Nrf2 null mutants 
showed a reduced wound healing through reduced expression of antioxidant enzymes, TGF-β 
expression with higher expression of the matrix degrading enzyme matrix metalloproteinase 9, 
compared to Nrf2+/+ mice (323). The similar mechanism of impaired wound healing is documented 
in human skin samples. In contrast sulforaphane and cinnamaldehyde (Nrf2 activator) ameliorates 
the above conditions of impaired wound healing (323). Thus, in diabetes, suppression of Nrf2-
mediated enhancement of antioxidant defense is one of the major reasons for delayed wound 
healing and regeneration. 
Nrf2 also participates in repair and/or regeneration of renal, skeletal and liver injuries (324-
326). In the acute renal injury model, transplantation of Nrf2 overexpressing mesenchymal cells  
improved the renal functions and renal repair markers such as AQP1 and CK-18 (324).  In contrast 
renal injury markers such as Kim-1 and cystatin-C were reduced (324). Similarly, studies in a 
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skeletal muscle injury model reported that Nrf2 deficiency is closely related to enhanced skeletal 
muscle injury and suppressed stem-cell associated muscle regeneration (325). Both in vivo and in 
vitro studies in rodents and human liver cells suggest that, the hepatic regeneration element is a 
major target of the Nrf2/antioxidant response element (ARE) and participates in hepatic repair. 
However, during Nrf2 deficiency or increasing oxidative stress the Nrf2/ ARE-mediated regulation 
of hepatic regeneration element is suppressed and results in exacerbation of hepatic injury and 
reduced the hepatic regeneration or repair  (326). This evidence collectively proposed the 
functional requirement of Nrf2 in repair and regeneration of renal, skeletal muscle and liver.  
Evidence further suggested that the Nrf2-induced cytoprotective effects were advantageous 
for β- cell survival and functions in the pancreas (328-330). Studies utilizing transgenic animals 
revealed that Nrf2 activation conferred protection against oxidative and nitrosative stress-induced 
β-cell death while it improved insulin secretory functions (328). Similarly, in human islets, Nrf2 
activation through its synthetic-inducer (Dh404) increased the expression of NADPH-
dehydrogenase-[quinone]-1, HO-1, glutamate cysteine ligase and phase II antioxidant genes. In 
addition, Nrf2 activation through Dh404 was shown to associate with significant reduction in 
oxidative/inflammatory damage of pancreatic islets through suppression of ROS and 
proinflammatory cytokines such as IL-1β, IL-6, IFN-γ and MCP-1 (329). Interestingly, Nrf2 has 
been shown to regulate the levels of unfolded and misfolded proteins in β-cells, through ubiquitin-
proteasome-induced degradation and supressed their accumulation which may be cytotoxic for β-
cell longevity (330). In contrast, genetic silencing of Nrf2 abolished the Nrf2-mediated 
cytoprotective advantages against increasing endoplasmic-reticulum-induced stress in β-cells 
(330). Thus, activation of Nrf2 has a cytoprotective benefit in the diabetic system not only in the 
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pancreatic compartment but also in other major organs of glucose homeostasis such as liver and 
skeletal muscle.  
 
1.8 Summary 
 
Enhanced tissue injury and dysfunctional metabolism are the characteristic features of 
obesity, diabetes, and hypertension that actively participate in development of tissue pathologies 
such as fatty liver disease, cardiomyopathy and nephropathy and pancreatic injuries.   
As governing factors, elevated inflammation and oxidative stress are the major players behind 
these undesirable conditions of altered tissue homeostasis. In response to increasing adiposity 
during obesity and T2D, enhanced accumulation of inflammatory M1-macrophages in metabolic 
tissues (liver, heart, kidney) are the initial event during inflammation that are principally governed 
by the chemokine molecules (MCP-1 and MIP-1α). Tissue accumulated macrophages produce 
higher levels of proinflammatory cytokines (TNF-α, IL-1β, IL-6) and reactive oxygen species in 
the local tissue environment and activates the major inflammatory NF-κB and JNK-stress 
signalling pathways and initiates a vicious cycle of inflammatory and oxidative stress in metabolic 
tissues.  
Activation of these pathways further augment the production of these proinflammatory 
cytokines and oxidative mediators that leads to development of systemic inflammatory/oxidative 
conditions and associated tissue injury and dysfunctional glucose metabolism. Additionally, these 
proinflammatory cytokines are also responsible for elevated levels of free fatty acid in both the 
local and systemic circulation due to lipolysis and induction of lipotoxicity-mediated tissue injuries 
in several vital organs such as liver, skeletal muscle and cardiac tissue.   
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Increasing levels of proinflammatory and oxidative mediators are also known to induce 
fibrotic tissue injury via activation profibrotic mediators such as TGF-β, collagen and fibronectin 
in hepatic, cardiac and renal tissues that collectively leads to development of pathological 
conditions of liver cirrhosis, cardiomyopathy and nephropathy and organ failure if not managed. 
Moreover, hypertension which is primarily a condition of dysregulated blood pressure is also 
shown to be associated with increased tissue injury and metabolic dysfunction both in vascular 
and metabolic tissue (heart kidney, liver and skeletal muscle) through lipid, RAAS-induced 
inflammation and oxidative stress. 
Due to their tissue destructive role, inflammatory and oxidative mediators are responsible 
factors for development of metabolic dysfunctional states such as insulin resistance, glucose 
intolerance in liver, skeletal muscle and cardiac tissues. Elevated levels of proinflammatory 
cytokines and oxidative mediators negatively affect the insulin signaling mechanism via inhibiting 
the expression and activation of major insulin signalling components (IRS-1, IRS-2, PI3K, 
GLUT4) while reducing the insulin-induced glucose uptake in liver, heart and skeletal muscle. 
Furthermore, T1D that is governed by autoimmunity-associated mechanisms also severely 
injure pancreatic tissue through T-cell-induced insulitis and subsequent enhanced β-cell apoptosis 
via various mechanisms which results in pancreatic injuries.  In addition, during T1D, 
hyperglycemia-induced inflammation and oxidative stress further contributes to tissue injury and 
metabolic alteration in peripheral organs. Thus, obesity, diabetes (T1D, T2D), and hypertension 
are associated with increasing tissue injury and abnormal glucose metabolism and require an 
efficient management tool.  
In these conditions, the cytoprotective and metabolism regulatory capabilities of the HO 
system and its metabolites (CO, BV and iron) can be used as an alternative tool. Moreover, a close 
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cross talk between the HO system and Nrf2 can regulate inflammatory and metabolic signalling at 
transcriptional levels, thus, exploration of the regulatory role of the Nrf2/HO axis may be 
advantageous during tissue injury and dysfunctional glucose metabolism. Due to inducible 
features, the HO system provides a great opportunity for safe induction by various pharmaceutical 
inducers in cellular systems that make it a reasonable choice for use as a therapeutic agent in 
several metabolic diseases. Although, HO is cytoprotective, its effect on hepatic, cardiac, renal 
and pancreatic injury and associated metabolic dysfunction is not well understood. Thus, the 
present study is designed to evaluate the role of the HO system on hepatic, cardiac, renal and 
pancreatic injury and dysfunction during obesity, diabetes (T1D, T2D) and hypertension. 
 
1.9 Rationale 
Increasing conditions of tissue injury and metabolic alteration in obesity, diabetes and 
hypertension present a great risk to human life and a daunting task to manage (1). During this 
metabolic dysfunctional state, elevated levels of proinflammatory cytokines (TNF-α, IL-1β, IL-6) 
chemokines (MCP-1, MIP-1α), oxidative mediators and increased macrophage accumulation in 
the tissue compartment are major reasons for enhanced tissue injury, dysfunctional metabolic 
responses and organ failure (8,16,71,342-344).  
Locally produced inflammatory and oxidative responses are further augmented through 
activation of the central NF-κB-JNK inflammatory-oxidative axis and systemically injure almost 
every organ of the body (8,343,345). If these unfavourable conditions of tissue injury persist, it 
further progresses into fibrotic organ injury through activation of profibrotic and extracellular 
matrix deposition (TGF-β, fibronectin, collagen) (129) and development of pathological 
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conditions of hepatosteatosis, cardiomyopathy,  nephropathy and pancreatic lesions (8,16,71,342-
344).  
Additionally, inflammatory and oxidative stress are considered as major destructive forces 
for the insulin signalling mechanism and glucose metabolism through development of insulin 
resistance and altered glucose tolerance. Thus, in these comorbid conditions of tissue injury and 
metabolic dysfunction, therapeutic approaches directed to reduce tissue injury and improvement 
of metabolic alteration is warranted.  
An upregulated HO system through its pharmaceutical inducer hemin can be used as an 
alternative approach to counteract these tissue injuries and metabolic alterations. Although, reports 
from our lab and many others have shown the cytoprotective metabolic regulatory efficacy of the 
HO system in abnormal metabolic homeostasis in obesity, hypertension, diabetes (T1D and T2D) 
(8,10,15,19,341,346), the underlying mechanisms are not clearly understood. Thus, the present 
study is designed to understand the multifaceted mechanism of HO-mediated cytoprotective 
effects on tissue injury and metabolism. 
 
1.10 General hypothesis 
 
Based on the above scientific information, it is hypothesized that upregulation of the HO 
system by hemin would counterect the liver, heart, kidney and pancreatic tissue injury while 
improving insulin signaling in models of obese ZF, ZDF, SHR and STZ rats. 
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1.11 Thesis objectives   
The major objectives of my thesis are as follows; 
1) To determine the effect of hemin on HO-1 induction in the liver, heart, kidney and pancreas 
of SHR, ZDF, ZF and STZ rats. 
2) To investigate the effects of hemin therapy on inflammatory cytokines and chemokines of 
liver, heart, kidney of SHR, ZDF, ZF rats 
3) To investigate the effect of hemin therapy on proinflammatory M1 and anti-inflammatory 
M2 macrophage markers in liver, heart, kidney and pancreas of SHR, ZDF, ZF and STZ 
rats. 
4) To assess whether hemin therapy suppresses oxidative stress in SHR, ZDF, ZF and STZ 
rats. 
5) To assess the effect of hemin therapy on profibrotic and extracellular matrix mediators in 
the liver, heart and kidney of ZDF, ZF rats 
6) To access the role of hemin therapy on major components of the insulin signal transduction 
pathway in SHR, ZDF, ZF and STZ rats 
7) To investigate the effects of hemin therapy on glucose intolerance and insulin resistance in 
ZF rats.  
8) To access the role of hemin treatment on ANP and adiponectin in heart and kidney of ZF 
and ZDF rats. 
9) To assess the effects of hemin therapy on hepatic, cardiac, and renal lesions and functions 
in ZF and ZDF rats. 
10) To study the effects of hemin therapy on markers of pancreatic repair and/or regeneration 
in STZ rats. 
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CHAPTER 2 
The heme oxygenase system selectively suppresses the proinflammatory 
macrophage M1 phenotype and potentiates insulin signaling in spontaneously 
hypertensive rats 
 
Joseph Fomusi Ndisang and Manish Mishra 
 
This chapter has been published as a paper in  
American Journal of Hypertension, September 2013; 26(9): 1123-31 
Contribution: This article Am J Hypertens. 2013; Sep;26(9):1123-31 was co-authored with my 
supervisor Joseph Fomusi Ndisang. This chapter reports the beneficial effects of the hemin-
induced HO system on hepatic injuries and dysregulated glucose metabolism in a rat model of 
hypertension (SHR) and suggests that increasing inflammation and dysregulated insulin signalling 
mechanisms during hypertension is a major cause of hepatic injuries and impaired glucose 
metabolism. As co-author, I contributed to the western immunoblotting experiments, statistical 
analysis and data interpretation. My supervisor Joseph Fomusi Ndisang participated in research 
design, wrote the manuscript and performed data analysis. This study was financially supported 
by a grant from the Heart and Stroke Foundation of Saskatchewan, Canada to Dr. Ndisang. 
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2.1 Abstract  
Background 
The mechanisms by which heme oxygenase (HO) improves glucose metabolism in essential 
hypertension are not completely understood. Because dysfunctional insulin signaling is associated 
with elevated inflammation and high cholesterol and triglycerides, we investigated the effects of 
HO on the proinflammatory macrophage M1-phenotype and the anti-inflammatory macrophage 
M2-phenotype in spontaneously hypertensive rats (SHRs). SHRs are a model of human essential 
hypertension with features of metabolic syndrome, including impaired glucose metabolism. 
Methods 
Spectrophotometric analysis, enzyme immunoassay, enzyme-linked immunosorbent assay, and 
Western immunoblotting were used. HO was enhanced with hemin or inhibited with chromium-
mesoporphyrin (CrMP). 
Results 
Hemin suppressed inflammation by abating proinflammatory macrophage M1-phenotype (ED1) 
and chemokines such as macrophage-chemoattractant-protein-1 (MCP-1) and macrophage-
inflammatory-protein-1 alpha (MIP-1α) while enhancing anti-inflammatory macrophage M2-
phenotype by potentiating ED2, CD206, and CD14. Similarly, hemin improved insulin signaling 
by enhancing insulin receptor substrate 1 (IRS-1), IRS-2, phosphatidylinositol 3 kinase (PI3K), 
and glucose transporter 4 (GLUT4) but reduced total cholesterol and triglycerides. These effects 
were accompanied by increased HO-1, HO activity, and cyclic guanosine monophosphate 
(cGMP), whereas the HO inhibitor CrMP nullified the hemin effects. Importantly, the effects of 
the HO system on ED1, ED2, CD206, and CD14 in SHRs are novel. 
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Conclusions 
Hemin abated inflammation in SHRs by selectively enhancing the anti-inflammatory macrophage 
M2-phenotype that dampens inflammation while suppressing the proinflammatory macrophage 
M1-phenotype and related chemokines such as MCP-1 and MIP-1α. Importantly, the reduction of 
inflammation, total cholesterol, and triglycerides was accompanied by the enhancement of 
important proteins implicated in insulin signaling, including IRS-1, IRS-2, PI3K, and GLUT4. 
Thus, the concomitant reduction of inflammation, total cholesterol and triglycerides and the 
corresponding potentiation of insulin signaling are among the multifaceted mechanisms by which 
the HO system improves glucose metabolism in essential hypertension. 
 
2.2 Introduction 
Impaired glucose metabolism is linked to insulin resistance and considered the major 
contributor to the development of metabolic syndrome (1). Similarly, glucose metabolism is 
deregulated in patients with essential hypertension (2).  
Many studies have underscored the role of inflammatory-insults in insulin resistance (3). 
Moreover, macrophage infiltration plays a major pathophysiological role in dysfunctional insulin 
signaling and impaired glucose metabolism (4, 5). Similarly, elevated inflammatory activity 
triggered by macrophage infiltration is a cardinal pathophysiological feature in spontaneously 
hypertensive rats (SHRs), a model of human essential hypertension (6, 7).  
Generally, macrophages express distinct patterns of surface receptors when responding to 
different stimuli (3, 8). To date, two different polarization states of macrophages have been 
described. These include “classical,” or M1-phenotype, and “alternative,” or M2-phenotype (3, 8). 
The M1-phenotype triggers inflammation, whereas the M2-phenotype counteracts inflammation 
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(3, 8). Therefore, novel therapeutic modalities that selectively suppress the proinflammatory 
macrophage M1-phenotype and lower blood pressure but enhance the macrophage M2-phenotype 
that counteracts inflammation would be needed for patients comorbid with essential hypertension 
and impaired glucose metabolism. The heme oxygenase (HO) system may be explored in this 
regard. HO is a microsomal enzyme with inducible (HO-1) and constitutive (HO-2) isoforms (9) 
that break down the heme-moiety to yield cytoprotective products, including bilirubin, ferritin, and 
carbon monoxide (9). Bilirubin and ferritin suppress oxidative stress and inflammation, whereas 
carbon monoxide induces vasorelaxation, lowers blood pressure, and enhances insulin release (9, 
10).  
Although, we recently reported the antidiabetic effect of the HO system in different models, 
including SHRs (11), uninephrectomized deoxycorticosterone acetate hypertension (12), Zucker 
diabetic fatty rats (13) and Goto-Kakizaki rats (14, 15) to date, the effects of the HO system on 
macrophage polarization in SHRs have not been reported. Given that inflammation due to 
macrophage infiltration is a causative factor of impaired insulin signaling (4,16), this study was 
designed to investigate the effects of upregulating the HO system on the expressions of M1 and 
M2 macrophage phenotypes in SHRs, a model with impaired glucose metabolism (17, 18). In 
addition, the effect of the HO system on chemokines implicated in macrophage infiltration, such 
as macrophage-chemoattractant-protein-1 (MCP-1) (19) and macrophage-inflammatory-protein 1 
alpha (MIP-1α) (20) were also assessed. Moreover, the effect of the HO system on MIP-1α has 
not been reported. Therefore, the major objective of this study was to investigate whether hemin 
therapy would selectively enhance the anti-inflammatory macrophage M2-phenotype that 
alleviates inflammation while concomitantly abating the proinflammatory M1-phenotype and 
chemokines that stimulate macrophage infiltration. Because elevated inflammation is known to 
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impair insulin signaling (4, 16, 21), we also investigated whether the suppression of inflammation 
by hemin would be accompanied by the potentiation of proteins of insulin signaling such as insulin 
receptor substrate 1 (IRS-1), IRS-2, phosphatidylinositol 3 kinase (PI3K), and glucose transporter 
4 (GLUT4).  
Given that macrophage infiltration is implicated in impaired insulin signaling (4, 16, 21), 
we hypothesized that hemin therapy would abate inflammation and potentiate insulin signaling by 
selectively enhancing the macrophage M2-phenotype that dampens inflammation while 
concomitantly suppressing the proinflammatory M1-phenotype in SHRs. 
 
2.3 Methods 
2.3.1 Animal treatment and biochemical assays 
Our experimental protocol was approved by the University of Saskatchewan Standing 
Committee on Animal Care, which is in conformity with the Guide for Care and Use of Laboratory 
Animals stipulated by the Canadian Council on Animal Care and the National Institutes of Health. 
Eight-week-old male SHRs and age-matched Wistar-Kyoto (WKY) rats were purchased from 
Charles River Laboratories (Willington, MA), housed at 21°C with 12-hour light/dark cycles, fed 
with standard laboratory chow, and given access to drinking water ad libitum. Our study design 
included the following groups (n = 6 per group): (i) controls (WKY rats and SHRs), (ii) hemin-
treated SHRs, (iii) hemin-treated WKY rats, and (iv) SHRs treated with hemin and the HO 
inhibitor chromium-mesoporphyrin (CrMP). Hemin was administered at a dose of 15 mg/kg by 
intra peritoneal injection, whereas CrMP was injected at a dose of 4 μmol/kg intraperitoneally, as 
previously described (22).  
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Systolic blood pressure was measured weekly in conscious animals by standard tail-cuff 
non-invasive method (Harvard Apparatus, Montreal, Canada), whereas fasting glucose was 
determined with a diagnostic autoanalyzer (BD, Franklin Lakes, NJ) after 6 hours of fasting, as 
previously reported (11, 14, 15, 22). At the end of the 4-week treatment, the animals were weighed, 
anesthetized with pentobarbital sodium (50 mg/kg intraperitoneally), and killed, and the liver, 
soleus muscle, and blood were collected. From the plasma, total cholesterol and triglycerides were 
routinely measured by Saskatoon Royal University Hospital in Canada, as previously reported 
(11). Other biochemical parameters including cyclic guanosine monophosphate (cGMP) were 
measured by enzyme immunoassay (Cayman Chemical, Ann Arbor, MI), whereas MCP-1 and 
MIP-1α were measured by enzyme-linked immunosorbent assay kits (OmniKine Assay; 
Biotechnology, Sunnyvale, CA) following the manufacturer’s instructions. 
 
2.3.2 Determination of HO-1 concentration and HO activity 
HO activity in the liver and soleus muscle was measured as bilirubin production using our 
established method (22). The amount of bilirubin in each sample was quantified using extinction 
coefficient for bilirubin of 40 mM/cm, and expressed as nanomoles per milligram protein per hour. 
The protein content was measured using Bradford assay. As a positive control, spleen tissue was 
used. Liver and soleus muscle HO-1 concentration was determined by enzyme-linked 
immunosorbent assay (Stressgen-Assay Design, Ann Arbor, MI), as previously reported (22). 
 
2.3.3 Western immunoblotting 
The liver was homogenized and centrifuged as previously described (22). Primary 
antibodies (Santa Crutz Biotechnology, Santa Cruz, CA) targeting ED1 (CD68) (sc-59103), ED2 
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(CD163) (sc-58956), CD14 (sc-9150), CD206 (sc-48758)), PI3K (sc67306), IRS-1 (sc-559), IRS-
2 (sc-8299), and GLUT4 (Abcam, Cambridge, MA) were used. Densitometric analysis was done 
with UN-SCAN-IT software (Silk Scientific, Orem, Utah). Beta-actin (Sigma, St. Louis, MO) was 
used as a control to ascertain equivalent loading. 
 
2.3.4 Statistical analysis 
All data were expressed as means SEM from at least 4 independent experiments unless 
otherwise stated. Statistical analyses were done using Student t-test and 2-way analysis of variance 
by means of Statistical Analysis System (SAS) software version 9.3 (SAS Institute, Cary, NC). 
Group differences at the level of p<0.05 were considered statistically significant. 
 
2.4 Results 
2.4.1 Hemin therapy enhanced HO-1, HO activity, and cGMP in the liver and soleus muscles 
Our results indicate that SHRs had normal glucose levels. Although, SHRs were 
normoglycemic (Table 2-1), hemin administration slightly but significantly lowered glucose 
levels, whereas the HO inhibitor CrMP abolished the hemin-induced glucose-lowering effect. On 
the other hand, hemin and CrMP affected body weight. In hemin and CrMP-treated animals, a 
slight body-weight loss (<9%) was observed (Table 2-1). Although, loss of body weight can cause 
reduction of glycemia, this was not the case in our study because we observed a slight decrease of 
glycemia in hemin-treated animals but a slight increase in CrMP treated animals, suggesting that 
the HO system may have an intrinsic antidiabetic effect. Hemin also lowered blood pressure in 
SHRs and WKY rats, although, the hemin effect was greater in SHRs (Table 2-1).  
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To investigate the role of the HO system on insulin signaling, we determined the effects of 
hemin therapy on important components of the HO signal transduction pathway, including HO-1, 
HO activity, and cGMP in the liver and soleus muscle. The liver and skeletal muscles, including 
the soleus muscles, are important for glucose metabolism (15, 23). In liver tissue obtained from 
untreated SHRs (control), the basal levels of HO-1, HO activity, and cGMP, a secondary 
messenger through which endogenously produced carbon monoxide by the HO system acts (9), 
were significantly reduced by 2.7-, 1.8-, and 2.1-fold, respectively, as compared with age-matched 
WKY control rats. Interestingly, the administration of hemin greatly increased the depressed basal 
HO-1, HO activity and cGMP levels in SHRs by 8.5-, 9.8-, and 7.8-fold, respectively (Fig. 2-1a-
c). On the other hand, co-administering the HO-inducer hemin and the HO inhibitor CrMP resulted 
in the annulment of the hemin-induced increase of HO-1, HO activity, and cGMP. Similarly, 
treatment with CrMP alone caused further depletion of the depressed basal levels of HO-1, HO 
activity, and cGMP in SHRs (Fig. 2-1a-c). Hemin therapy also enhanced HO-1 and HO activity in 
WKY rats, although, the magnitude was smaller than in hemin-treated SHRs.  
Because glucose uptake by skeletal muscles is an important physiological process for 
glucose disposal and metabolism, we assessed the effects of hemin therapy on HO-1, HO activity, 
and cGMP in the soleus muscles (15). In control SHRs (untreated), the basal levels of HO-1 and 
HO activity were slightly higher than those in WKY rats. Treatment with hemin increased HO-1 
and HO activity in SHRs by 3.2- and 3-fold, respectively (Fig. 2-1d, e). The enhanced HO activity 
would increase endogenous carbon monoxide, which would in turn stimulate cGMP (22). Both 
cGMP and carbon monoxide are known to enhance glucose metabolism (24, 25). Consistently, we 
detected a 3.2-fold increase of cGMP in hemin-treated SHRs (Fig. 2-1f). Contrarily, the co-
administration of the HO inducer hemin and the HO blocker reversed the hemin-dependent 
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increase of HO-1 and HO activity, with annulment of the hemin-induced increase of cGMP. 
Although, the basal HO activity in SHRs was higher than the control, it did not cause an increase 
in cGMP (Fig. 2-1e, f), suggesting that the transient increase in HO activity might have occurred 
with a magnitude below the threshold necessary to trigger an increase in cGMP. A similar 
observation has been previously reported (11). Hemin therapy also enhanced HO-1, HO activity, 
and cGMP in normotensive WKY control rats, although a greater increment was observed in 
hemin-treated SHRs (Fig. 2-1). 
 
2.4.2 Hemin therapy abated total cholesterol and triglycerides in SHRs 
Given that elevated cholesterol and high triglycerides levels are common denominators of 
impaired insulin signaling and deregulated glucose metabolism (26), we determined the effect of 
hemin total cholesterol and triglycerides. In control SHRs, the levels of total cholesterol and 
triglycerides were significantly elevated by 1.96- and 1.92-fold, respectively, as compared with 
WKY control rats (Fig. 2-2a, b). However, the administration of hemin significantly abated the 
elevated levels of total cholesterol in SHRs by 49.8%, reinstating comparable levels as observed 
in WKY rats. Similarly, hemin therapy markedly reduced triglyceride levels in SHRs by 33.1%, 
suggesting that hemin therapy is more effective in abating total cholesterol than triglycerides 
(although, the levels in WKY control rats were not attained). On the other hand, the cotreatment 
with the HO inducer hemin and the HO inhibitor CrMP abolished the effects of hemin on total 
cholesterol and triglycerides, suggesting a role of the HO system in the regulation of total 
cholesterol and triglycerides. Hemin also lowered total cholesterol and triglycerides in WKY rats, 
although, the hemin effect was greater in SHRs (Fig. 2-2a, b). 
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2.4.3 Hemin therapy suppressed proinflammatory chemokines that stimulate macrophage 
infiltration in SHRs 
Because MIP-1α and MCP-1 are chemokines that stimulate macrophage infiltration (19, 20), 
we investigated the effects of hemin on these chemokines. In control SHRs, the basal levels of 
plasma and liver MCP-1 were significantly elevated by 3.5- and 4.1-fold, respectively, as 
compared with WKY rats (Fig. 2-3a, b). Interestingly, the administration of hemin to SHRs greatly 
reduced the elevated levels of plasma MCP-1 to comparable levels as observed in WKY rats. 
Similarly, hemin therapy significantly abated the high liver levels of MCP-1 in SHRs by 2.6-fold, 
although, it did not reinstate similar levels as in the WKY control rats (Fig. 2-3b). On the other 
hand, the co-administration of the HO inducer hemin and the HO inhibitor CrMP abolished the 
hemin effects and reinstated the elevated levels of plasma and liver MCP-1 (Fig. 2-3a, b).  
Because MIP-1α is a potent chemokine implicated in macrophage infiltration and the effect 
of the HO system on MIP-1α in SHRs has not been reported, we also evaluated control SHRs, the 
basal levels of MIP-1α in the liver were markedly elevated by 3.3-fold as compared with WKY 
rats (Fig. 2-3c). Interestingly, the application of hemin to SHRs greatly attenuated the elevated 
MIP-1α levels by 3.3-fold, whereas the co-application of hemin together with the HO inhibitor 
CrMP abolished the effects of hemin (Fig. 2-3c). Hemin therapy was also effective against MCP-
1 and MIP-1α in WKY rats, although, the effect was less intense compared with the untreated and 
unhealthy SHR controls (Fig. 2-3a-c). In WKY rats, hemin treatment reduced plasma and liver 
MCP-1 by 37.2% and 32.2%, respectively, compared with reductions of 72.6% and 62.2% in 
SHRs. Similarly, hemin therapy attenuated liver MIP-1α in WKY rats by 37.3%, whereas a greater 
magnitude of 69.2% was observed in SHRs (Fig. 2-3a-c), suggesting that hemin therapy may have 
greater selectivity for SHRs with unhealthy status. 
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2.4.4 Hemin therapy selectively abated inflammatory proteins that deregulate insulin 
signalling 
Given that macrophage infiltration is implicated in dysfunctional glucose metabolism (3,8), 
we used ED1 to quantify the expression of proinflammatory macrophage M1-phenotype (27-30). 
Our Western immunoblotting and relative densitometric analyses indicated that the basal protein 
expression of ED1 in SHRs was markedly elevated compared with that in WKY rats (Figure 4a). 
However, the administration of hemin significantly attenuated the elevated basal expression of the 
proinflammatory M1-phenotype marker ED1 in SHRs by 2.9-fold.  
To examine whether the hemin-induced suppression of macrophage M1-phenotype will be 
accompanied by changes in the anti-inflammatory macrophage M2-phenotype, we also examined 
the effects of hemin therapy on the M2-phenotype using several selective markers for M2, 
including ED2, CD206, and CD14 (27-30). Our results indicate that the basal expressions of ED2, 
CD206, and CD14 in SHRs were markedly reduced by 4.6-, 2.5-, and 7.2-fold, respectively, 
compared with that in WKY rats (Fig. 2-4b-d). Interestingly, hemin therapy significantly enhanced 
the depressed basal expressions of ED2, CD206, and CD14 by 3.1-, 1.4-, and 3.7-fold, 
respectively, suggesting that hemin may selectively modulate the polarization of macrophages in 
SHRs toward the M2-phenotype that counteracts inflammatory insults. Importantly, the effects of 
the HO system on ED1, ED2, CD206, and CD14 in SHRs are novel finding that have not been 
previously reported.  
 
2.4.5 Hemin therapy potentiated insulin signal transduction pathway 
Because the suppression of macrophage infiltration is accompanied by the potentiation of 
insulin signaling (21) and we observed that hemin therapy abated the proinflammatory 
macrophage M1-phenotype, we investigated whether the attenuation of macrophage-induced 
76 
 
inflammation in SHRs will be accompanied by the corresponding potentiation of proteins of the 
insulin signal transduction pathway, such as IRS-1, IRS-2, PI3K, and GLUT4 (3).  
Our Western immunoblotting and relative densitometric analyses of the expressed proteins 
revealed that the basal protein expressions of IRS-1, IRS-2, PI3K, and GLUT4 in SHRs were 
significantly lower by 3.5-, 8.8-, 10.9, and 8.6-fold, respectively, than that in WKY rats (Fig. 2-
5a-d), suggesting reduced insulin signaling in SHRs. Interestingly, hemin therapy robustly 
enhanced the expressions of IRS-1, IRS-2, PI3K, and GLUT4 in SHRs by 1.7-, 3.9-, 9.3-, and 4.2-
fold, respectively (Fig. 2-5a-d), suggesting that a novel mechanism by which hemin potentiates 
insulin signaling and improve glucose metabolism in SHRs is concomitantly abating the 
proinflammatory macrophage M1-phenotype while enhancing the anti-inflammatory M2-
phenotype. 
 
2.5 Discussion 
Our study unveils novel mechanisms by which the HO system abates inflammation and 
potentiates insulin signaling to improve glucose metabolism in SHRs, a genetic rat model of 
essential hypertension with characteristics of the human metabolic syndrome, including insulin 
resistance and impaired glucose metabolism (17,18). In untreated SHRs, the levels of the 
proinflammatory macrophage M1-phenotype, total cholesterol, and triglycerides were markedly 
elevated. These factors may have contributed to impaired insulin signaling, given that macrophage 
infiltration, elevated cholesterol, and high triglycerides are known to deregulate glucose 
metabolism (3, 8, 26). Interestingly, hemin therapy abated inflammation due to macrophages, 
reduced cholesterol/triglycerides, and improved glucose metabolism in SHRs. Importantly, the 
selective enhancement of the anti-inflammatory macrophage M2-phenotype and corresponding 
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reduction of the proinflammatory M1-phenotype by hemin is a novel mechanism by which hemin 
therapy suppresses inflammation in essential hypertension. Moreover, this selective effect of 
hemin may be indicative of a modulatory role of the HO system that favors the polarization of 
macrophages toward the anti-inflammatory macrophage M2-phenotype. However, further 
investigations are needed to fully characterize the effects of upregulating the HO system on 
macrophage polarization. Importantly, the effects of the HO system on the pro inflammatory M1-
phenotype marker ED1 and the anti-inflammatory M2-phenotype markers ED2, CD206, and CD14 
in SHRs are novel findings that have not been previously reported. An important revelation from 
our study is that the hemin dependent suppression of the proinflammatory macrophage M1-
phenotype was associated with a parallel reduction of chemokines such as MIP-1α and MCP-1, 
which stimulate macrophage infiltration (19,20), whereas the co-administration of the HO inducer 
hemin together with the HO inhibitor CrMP nullified the hemin effects, suggesting a role of the 
HO system in the regulation of these chemokines. Moreover, the effect of the HO system on MIP-
1α in SHRs is a novel observation reported here for the first time.  
Another interesting observation from our study is the potentiation of insulin signaling 
following the suppression of inflammation. In hemin-treated animals, important components of 
the insulin signal transduction pathway, including IRS-1, IRS-2, PI3K, and GLUT4, were 
significantly enhanced. Given that patients with essential hypertension eventually develop diabetes 
(31) and SHRs are a model of essential hypertension, this study suggest that although SHRs are 
normoglycemic, impaired insulin signaling may be a forerunner to overt hyperglycemia in 
essential hypertension. Therefore, the reduced levels of IRS-1, IRS-2, PI3K, and GLUT4 are a 
signature to the defective insulin signaling in SHRs, which interestingly was corrected by hemin. 
Because our study also indicates that hemin therapy lowers blood pressure in SHRs, it could be 
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argued that the improved insulin signaling is due to the blood pressure–lowering effect. However, 
we recently reported the antidiabetic effects of hemin therapy in different normotensive diabetic 
models, including Goto-Kakizaki rats, Zucker diabetic fatty rats, and streptozotocin-induced 
diabetes (13-15, 22). Consistently, other investigators have also reported the insulin-sensitizing 
effects of HO inducers in normotensive animals (32, 33).  Therefore, evidence from this study and 
other reports strongly suggest that the HO system is also endowed with an intrinsic insulin-
sensitizing effect. Hemin therapy also enhanced the HO system with reduction of total cholesterol 
and triglycerides, MCP-1, and MIP-1α in WKY rats, although, the magnitude was smaller than 
that in SHRs. The reasons for this selective effect of the HO system are not fully understood. 
Importantly, the selectivity of the HO system in diseased conditions such as essential hypertension 
and deregulated insulin signaling as observed in SHRs could be explored against the comorbidity 
of hypertension and impaired glucose metabolism.  
Although, we previously reported the effects of the HO system in the gastrocnemius muscle 
of SHRs (11), tissue-specific response is a well-known phenomenon in the pathophysiology of 
impaired insulin signaling and deregulated glucose metabolism. Emerging evidence indicates that 
different tissues may respond distinctly to the same stimuli, indicating that a physiological 
response in one tissue may not necessarily be the same in another tissue (34, 35). Whether the 
reported effects were unique for the gastrocnemius muscle or universal for other tissues in SHRs 
is critical for understanding the role of hemin in insulin signaling and glucose metabolism in 
essential hypertension.  
Collectively, these results suggest that the selective potentiation of the macrophage M2 
phenotype that dampens inflammation, with the corresponding decline of the proinflammatory 
macrophage M1-phenotype and related chemokines such as MCP-1 and MIP-1α are responsible 
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for the suppression of inflammation in hemin-treated SHRs. Importantly, the concomitant 
reduction of inflammation and cholesterol/triglycerides and associated potentiation of insulin 
signaling are the multifaceted mechanisms by which the HO system improves glucose metabolism 
in essential hypertension. 
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Table 2-1: Effects of hemin and chromium mesoporphyrin (CrMP) on physiological and 
biochemical variables 
Parameter Animals and treatment groups 
WKY 
control 
SHR  
control 
WKY + 
hemin 
SHR + hemin SHR + CrMP + 
hemin 
Body 
weight 
(grams) 
 
513 ± 10.3 
 
409 ± 9.7 
 
495 ± 12.6* 
 
393 ± 8.4* 
 
378 ± 9.1* 
Fasting 
glucose 
(mmol/L) 
 
7.0 ± 0.3 
 
7.2±0.4 
 
6.3 ± 0.3* 
 
6.1 ± 0.2* 
 
7.5 ± 0.5** 
Systolic 
blood 
pressure 
(mm Hg) 
 
120.8 ± 5.6 
 
185.9 ± 12.3*** 
 
112.9 ± 4.8 
 
123.6 ± 5.5**** 
 
191.9 ± 10.3*** 
 
*p<0.05 vs. respective control; **p<0.05 vs. SHR + hemin; ***p<0.01 vs. all groups; ****p<0.01 
vs. SHR Control; n = 6 per group 
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Figure 2-1: Effects of the heme oxygenase (HO) inducer hemin and the HO inhibitor chromium 
mesoporphyrin (CrMP) on liver and soleus muscle HO-1 concentration, HO activity, and cyclic 
guanosine monophosphate (cGMP) levels. The basal HO-1 (a), HO-activity (b), and cGMP (c) 
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levels in hepatic tissue from spontaneously hypertensive rats (SHRs) were reduced compared with 
the normotensive Wistar-Kyoto (WKY) control rats but were robustly increased by hemin therapy, 
whereas cotreating the SHRs with hemin and the HO blocker CrMP reversed the hemin effects, 
whereas treatment with CrMP alone resulted in further reduction of the basal HO-1, HO activity, 
and cGMP in the liver of SHRs. Hemin also increased HO-1 and HO activity in WKY rats, 
although, less intensely than in SHRs. (d) The basal HO-1 concentration in SHRs was slightly 
elevated compared with that in normotensive WKY control rats. Treatment with hemin enhanced 
HO-1 levels, whereas the co-administration of the HO inducer hemin and the HO blocker CrMP 
nullified the effects of hemin. Hemin also increased HO-1 levels in WKY rats, although, less 
intensely than in SHRs. (e) The basal HO activity in SHRs was slightly elevated compared with 
that in normotensive WKY control rats. The administration of hemin increased HO activity in 
SHRs, whereas the cotreatment with hemin and the HO blocker CrMP reversed the effects of 
hemin. Hemin therapy also enhanced HO activity in WKY rats but to a lesser magnitude than in 
SHRs. (f) Hemin treatment enhanced cGMP levels in SHRs, whereas cotreatment of hemin and 
CrMP abolished the hemin effect. Hemin therapy also enhanced cGMP levels in WKY rats. Bars 
represent means ± SEM. n = 6 rats per group. *p<0.01 vs. all groups; **p<0.05 vs. all groups; 
***p<0.05 vs. SHRs + hemin. 
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Figure 2-2: Effects of the heme oxygenase (HO) inducer hemin and the HO inhibitor chromium 
mesoporphyrin (CrMP) on total cholesterol and triglycerides. (a) The basal levels of total 
cholesterol in spontaneously hypertensive rats (SHRs) were markedly elevated compared with 
those in the Wistar-Kyoto (WKY) control rats. Treatment with hemin abated the elevated levels 
of total cholesterol, whereas the co-application of the HO inducer hemin and the HO blocker CrMP 
nullified the effects of hemin. Hemin also suppressed total cholesterol levels in WKY rats, 
although, less intensely than in SHR rats. (b) The basal levels of triglycerides in SHRs were greatly 
elevated compared with those in WKYs. Treatment with hemin reduced the levels of triglycerides 
in SHRs, whereas the co-administration of hemin and the HO blocker CrMP reversed the effects 
of hemin. Hemin therapy also attenuated triglycerides in WKYs but to a lesser magnitude than in 
SHRs. Bars represent means ± SEM. n = 6 rats per group. *p<0.01 vs. SHR controls or SHRs + 
hemin + CrMP; **p<0.01 vs. all groups; ***p<0.05 vs. WKY control rats. 
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Figure 2-3: Effects of the heme oxygenase (HO) inducer hemin and the HO inhibitor chromium 
mesoporphyrin (CrMP) on plasma and liver macrophage-chemoattractant-protein-1 (MCP-1) and 
macrophage-inflammatory-protein-1 alpha (MIP-1α) in spontaneously hypertensive rats (SHRs) 
and Wistar-Kyoto (WKY) rats. The basal levels of plasma MCP-1 (a), liver MCP-1 (b), and liver 
MIP-1α (c) in SHRs were markedly elevated compared with the levels in WKY control rats, but 
hemin administration greatly reduced the elevated levels of MCP-1 and MIP-1α, whereas the HO 
inhibitor CrMP reversed the effects of hemin MCP-1 and MIP-1α. Hemin therapy also attenuated 
MCP-1 and MIP-1α in WKY rats but to a lesser magnitude than in SHRs. Bars represent means ± 
SEM. n = 6 rats per group. *p<0.01 vs. SHR controls or SHRs + hemin + CrMP; **p<0.01 vs. all 
groups; ***p<0.05 vs. WKY control rats. 
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Figure 2-4: Effect of hemin therapy on the proinflammatory macrophage M1-phenotype marker 
ED1 and the anti-inflammatory macrophage M2-phenotype markers ED2, CD206, and CD14. 
Representative Western immunoblots and relative densitometric analyses revealed that treatment 
with hemin suppressed ED1 but enhanced ED2 (b), CD206 (c), and CD14 (d) in spontaneously 
hypertensive rats (SHRs). Bars represent means ± SEM, n = 4 rats per group. *p<0.05 vs. Wistar-
Kyoto (WKY) rats; **p<0.05 vs. SHRs; ***p<0.01 vs. all groups; ****p<0.05 vs. all groups. 
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Figure 2-5: Effect of hemin on proteins of the insulin signal transduction pathway such as insulin 
receptor substrate 1 (IRS-1), IRS-2, phosphatidylinositol 3 kinase (PI3K), and glucose transporter 
4 (GLUT4). Representative Western immunoblots and relative densitometry indicates that hemin 
therapy markedly increased the depressed expressions of IRS-1 (a), IRS-2 (b), PI3K (c), and 
GLUT4 (d) in spontaneously hypertensive rats (SHRs). Bars represent means ± SEM. n = 4 rats 
per group. *p<0.05 vs. all groups; **p<0.01 vs. all groups. Abbreviation: WKY, Wistar-Kyoto. 
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CHAPTER 3 
The risk of heart failure and cardiometabolic complications in obesity may be 
masked by an apparent healthy status of normal blood glucose 
 
Shuchita Tiwari, Manish Mishra, Ashok Jadhav, Courtney Gerger, Paul Lee, 
Lynn Weber and Joseph Fomusi Ndisang 
 
This chapter has been published as a research paper in 
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Contribution: The article, Oxid Med Cell Longev. 2013; 253657, was co-authored with Shuchita 
Tiwari, Ashok Jadhav, Courtney Gerger, Paul Lee, Lynn Weber, and my supervisor Joseph Fomusi 
Ndisang. This chapter describes the role of an upregulated HO system on cardiac injuries in a rat 
model of obesity (ZF rats) and the mechanisms by which hemin therapy counteracts inflammation 
and oxidative stress while improving insulin signaling, glucose metabolism and cardiac functions.  
Moreover, this chapter suggests that altered insulin signaling and cardiac functions are the 
forerunners for development of overt hyperglycemia and heart failure in obesity. In this study, I 
participated in animal and biochemical experiments, collection of data, and statistical analyses and 
interpretation. The idea for the study was conceived by my supervisor Joseph Fomusi Ndisang and 
financial supported by the Heart and Stroke Foundation of Saskatchewan, Canada grant to Dr. 
Ndisang. 
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3.1 Abstract 
Although many obese individuals are normoglycemic and asymptomatic of cardiometabolic 
complications, this apparent healthy state may be a misnomer. Since heart failure is a major cause 
of mortality in obesity, we investigated the effects of heme-oxygenase (HO) on heart failure and 
cardiometabolic complications in obese normoglycemic Zucker-fatty rats (ZFs). Treatment with 
the HO-inducer, hemin, reduced markers of heart failure, such as osteopontin and osteoprotegerin, 
abated left-ventricular (LV) hypertrophy/fibrosis, extracellular matrix/profibrotic proteins 
including collagen-IV, fibronectin, TGF-β1, and reduced cardiac lesions. Furthermore, hemin 
suppressed inflammation by abating macrophage-chemoattractant-protein-1, macrophage-
inflammatory protein-1 alpha, TNF-α, IL-6, and IL-1β but enhanced adiponectin, atrial-natriuretic 
peptide (ANP), HO activity, insulin sensitivity, and glucose metabolism. Correspondingly, hemin 
improved several hemodynamic/echocardiographic parameters including LV diastolic wall 
thickness, LV-systolic wall thickness, mean-arterial pressure, arterial-systolic pressure, arterial-
diastolic pressure, LV developed pressure, +dp/dt, and cardiac output. Contrarily, the HO-
inhibitor, stannous mesoporphyrin nullified the hemin effect, exacerbating inflammatory/oxidative 
insults and aggravated insulin resistance (HOMA-index). We conclude that perturbations in insulin 
signaling and cardiac function may be forerunners to overt hyperglycemia and heart failure in 
obesity. Importantly, hemin improves cardiac function by suppressing markers of heart failure, LV 
hypertrophy, cardiac lesions, extracellular matrix/profibrotic proteins, and inflammatory/oxidative 
mediators, while concomitantly enhancing the HO-adiponectin-ANP axis. 
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3.2 Introduction 
The recent escalation of obesity in every segment of the population including children, 
adolescences, and adults poses a great health challenge of considerable socioeconomic burden (1, 
2). The impact on healthcare systems may become unsustainable given the numerous chronic 
diseases such as type-2 diabetes, dyslipidemia, hypertension, and other related cardiometabolic 
complications associated with obesity (1-3). Cardiac complications including heart failure are 
among the major causes of mortality in obese individuals. Obesity causes lipotoxicity and adipose 
tissue dysfunction with excessive production of adipokines like tumor necrosis factor-α (TNF-α) 
and interleukin 6 (IL-6) IL-1β, all of which are implicated in heart failure and related 
cardiometabolic complications (4, 5). However, obesity may not always translate into increased 
risk for these comorbidities (6). Some obese individuals dubbed “metabolically healthy” are 
protected against obesity related metabolic diseases. These “metabolically healthy” obese 
individuals are insulin sensitive with normal lipid metabolism and cardiac function similar to 
healthy lean individuals, which is in stark contrast to “metabolically unhealthy” obese individuals 
with high risk of developing cardiometabolic complications (6). However, the apparent state of 
good health in “metabolically healthy” obese sub-phenotype may be a misnomer because the 
development of several characteristics of metabolic syndrome is now being observed in many 
adults who previously manifested the healthy obese phenotype (7), suggesting that individuals 
with a healthy obese phenotype may not remain healthy for their entire lives. Several parameters 
including environmental and behavioral factors may modify obesity sub-phenotypes, and the 
transition from healthy to unhealthy. Whether healthy obese individuals can maintain insulin 
sensitivity during the entire life or whether healthy obesity simply represents delayed onset of 
obesity related cardiometabolic complications has to be clarified.  
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In obesity, excessive oxidative stress, intense inflammatory activity, insulin resistance, 
deregulated lipid metabolism, altered glucose metabolism, and impaired mitochondrial biogenesis 
are among the pathophysiological driving forces that precede the early stages of cardiac 
dysfunction. Many cardiac complications have the common denominator of elevated inflammation 
due to the infiltration of macrophage M1-phenotype (8). Generally, macrophages exhibit two 
different forms dubbed “classical” or M1-phenotype and “alternative” or M2-phenotype (8), and 
each phenotype expresses distinct patterns of surface receptors when responding to different 
stimuli. The M1-phenotype stimulates inflammation while the M2-phenotype blunts inflammation 
(8). During macrophage infiltration, the M1-phenotype is stimulated by different chemokines 
including macrophage-inflammatory-protein-1 alpha ((MIP-1α), chemokine (C-C motif) ligand-3 
(CCL3)) and macrophage-chemoattractant-protein-1 ((MCP-1) (9), chemokine (C-C motif ligand-
2 (CCL2)) (9). The activation of the macrophage M1-phenotype is generally associated with 
elevated levels of proinflammatory cytokines including TNF-α, IL-6, and IL-1β (10-12). 
Moreover, the levels of macrophage M1-phenotype, MCP-1, TNF-α, IL-6, and IL-1β are elevated 
in obesity and insulin resistance (9, 10, 13), and these factors play a major pathophysiological role 
in heart failure (4). In obesity, markers of heart failure such as osteopontin (14) and osteoprotegerin 
(15) are elevated (16, 17). Similarly, the levels of extracellular matrix/profibrotic proteins like 
transforming growth factor beta (TGF-β), collagen, and fibronectin are elevated in obesity (18). 
Therefore, in obesity elevated chemokines, cytokines and increased macrophage-M1 infiltration 
would act in concert with elevated extracellular matrix/profibrotic and heart-failure proteins to 
exacerbate cardiac tissue destruction and compromise heart function. Thus, novel strategies 
capable of selectively suppressing macrophages M1-phenotype, proinflammatory 
cytokines/chemokines, and extracellular matrix/profibrotic proteins are needed. 
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In many pathophysiological conditions, various stress response immune-regulatory 
proteins, including heme oxygenase (HO-1), are activated as an innate defense mechanism (19-
22). However, the pathophysiological activation of HO-1 may only result in a transient or marginal 
increase of HO activity that falls below the threshold necessary to activate the downstream 
signaling components through which the HO system elicits its cytoprotective effects, so a robust 
and surmountable increase of HO activity with HO inducers like hemin may be needed for 
cardioprotection (23-27). Generally, HO is composed of two main isoforms (HO-1 or inducible) 
and (HO-2 or constitutive), which are largely responsible for the antioxidant and anti-inflammatory 
effects of HO (28). We recently reported the cardioprotective effects of the HO system in Zucker 
diabetic fatty rats (ZDFs) (13), a model characterized by obesity, insulin resistance, and overt 
hyperglycemia. However, because ZDFs are hyperglycemic, their pathophysiological profile is not 
reflective of individuals dubbed “metabolically healthy,” a subtype of obesity characterized by 
normoglycemia (7). Given that the incidence of cardiometabolic complications is increasing in 
many adults who previously manifested the metabolically healthy obese phenotype (7), novel 
studies with animal models that closely mimic the pathophysiological profile of metabolically 
healthy obese subtype are needed. Therefore, this study will investigate the effects of the HO 
system on cardiometabolic complications in Zucker fatty rats (ZFs), an obese model with 
normoglycemia and cardiometabolic complications (29) that closely mimic the pathophysiological 
profile of metabolically healthy obese individuals with normoglycemia and an apparent state of 
good health. Although, the HO system is cytoprotective, its effects on cardiomyopathy in ZFs 
remain to be elucidated.  
Since dysfunctional insulin signaling, obesity, elevated inflammation, and cardiac 
hypertrophy are forerunners to heart failure, this study will also investigate the multifaceted 
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mechanisms by which the HO system preserves cardiac function in ZFs. Whether an upregulated 
HO system by hemin is capable of modulating macrophage polarization towards the M2-
phenotype that blunts inflammation, while suppressing the proinflammatory M1-phenotype, will 
be assessed. As macrophage infiltration is stimulated by chemokines like MIP-1α and MCP-1 (9), 
and the effects of the HO system on these chemokines in ZFs have not been reported, this study 
will also determine left-ventricular MIP-1α and MCP-1 and correlate changes of these chemokines 
to the expression of the proinflammatory macrophage M1-phenotype in the left ventricle of ZFs. 
Similarly, the effect of hemin therapy on important markers of heart failure such as osteopontin 
(13) and osteoprotegerin (14) will be investigated. Importantly, no study has reported the levels of 
expression of osteopontin and osteoprotegerin in myocardial tissue of ZFs. Therefore, this study 
will unveil the multifaceted mechanisms by which hemin therapy improves cardiac function and 
insulin signaling in obesity. 
 
3.3 Materials and methods 
3.3.1 Animals, treatment groups, and biochemical parameters 
Our experimental protocol was in conformity with the Guide for Care and Use of 
Laboratory Animals stipulated by the Canadian Council on Animal Care and the National Institutes 
of Health (NIH Publication no. 85-23, revised 1996) and was approved by University of 
Saskatchewan Animal Ethics Committee. Male ZFs (12 weeks old) and sex/age matched Zucker 
lean (ZL) rats were purchased from Charles River Laboratories (Willington, MA, USA). The 
animals were housed at 21°C with 12-hour light/dark cycles, fed with standard laboratory chow, 
and had access to drinking water ad libitum. The HO-inducer, hemin (30 mg/kg i.p., Sigma, St 
Louis, MO, USA), and HO-blocker stannous-mesoporphyrin ((SnMP) 2 mg/100 g body weight 
i.p.) were purchased from Porphyrin Products (Logan, UT, USA), and prepared as we previously 
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reported and administered biweekly for 8 weeks (13, 30, 31). At 16 weeks of age, the animals were 
randomly assigned to the following experimental groups (𝑛 = 6 per group): (A) controls (ZF and 
ZL), (B) hemin-treated ZF and ZL, (C) ZF + hemin + SnMP, and (D) ZF + vehicle dissolving 
hemin and SnMP.  
During the treatment period body weight and glucose were monitored on a weekly routine. 
Body weight was measured using a digital balance (Model Mettler PE1600, Mettler Instruments 
Corporation, Greifensee, Zurich, Switzerland). At the end of the 8-week treatment period, the 
animals were 24 weeks of age. A day prior to killing, the animals were fasted in metabolic cages 
for 24 hr urine collection and weighed. Systolic blood pressure was determined by non-invasive 
tail-cuff method (Model 29-SSP, Harvard Apparatus, Montreal, Canada), while a Millar Mikro-
Tip ultraminiature tip sensor pressure transducer catheter (Model SPR-407, Harvard Apparatus, 
Montreal, Canada) for invasive hemodynamic parameters. In addition, a Vevo 660 high frequency 
ultrasound machine (Visual Sonics, Markham, ON, Canada) equipped with B-mode imaging was 
used for echocardiographic measurements as we previously reported (13). After anaesthetizing the 
animals with pentobarbital sodium (50 mg/kg i.p.), blood was collected by cardiac puncture, and 
the heart was cleaned and weighed with an analytical balance (Precisa Instruments Ltd., Dietikon, 
Switzerland) as we previously reported (32). The atria were removed from the heart and the right 
ventricle free wall separated from the left ventricle including the septum as we previously reported 
(32).  
Left-ventricular HO activity was evaluated spectrophotometrically as we previously 
reported (30, 32). ELISA kits were used for HO-1 (Stressgen-Assay Design, Ann Arbor, MI, 
USA), adiponectin (Phenix Pharmaceuticals, Inc., Burlingame, CA, USA), TNF-α, IL-6, and IL-
1β (Immuno-Biological Laboratories Co Ltd., Gunma, Japan), MIP-1α, and MCP-1 (OmniKine, 
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Assay Biotechnology Company Inc., Sunnyvale, CA, USA) (33, 34), while EIA kits for 8-
isoprostane, ANP, ET-1, cGMP, and kits for cholesterol and triglyceride were purchased from 
Cayman (Cayman Chemical, Ann Arbor, MI, USA) following the manufacturers’ instructions as 
we reported (13, 30, 32). Intraperitoneal glucose tolerance test (IPGTT) and homeostasis model 
assessment of insulin resistance (HOMA-IR) were done as we previously reported (30). 
 
3.3.2 Histological, morphological, and immunohistochemical analyses of left ventricle 
Histological and morphometric analyses were done as we previously described (35). 
Sections of 5 𝜇m were cut and stained with hematoxylin and eosin for histological analysis. 
Masson’s Trichrome staining detected left-ventricular collagen deposition. Morphometrical 
evaluation of left-ventricular longitudinal myocyte thickness was done by randomly measuring 30 
cardiac muscle fibers from each experimental group by a blinded researcher using a microscope 
(Aperio Scan Scope Model CS, Aperio Technologies Inc., Vista, CA, USA) and analyzed using 
Aperio ImageScope V11.2.0.780 software (Aperio, e-Pathology Solution, Vista, CA, USA). 
Morphologic assessment of collagen deposition in left-ventricular sections was accessed using 
Aperio Image Scope (Aperio Technologies Inc., Vista, CA, USA). Each left-ventricular section 
was magnified at 200x, and 20 random snaps were taken per slide (20 × 6 = 120 images per group) 
subsequently scored semi-quantitatively by a blinded researcher as we previously reported (13, 
35).  
Immunohistochemistry was done as we previously reported (36). Sections of 5 𝜇m of left-
ventricular tissue were treated with bovine serum albumin in phosphate buffered saline to block 
nonspecific staining and incubated overnight with ED1 (1: 500 dilutions; sc-59103, Santa Cruz 
Biotechnology, CA, USA). The sections were later treated with goat anti-mouse IgG for 30 min 
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(1: 200 dilutions; Jackson Immuno-Research Laboratories, Inc., ME, USA). Immunohistochemical 
staining was done using the standard avidin-biotin complex method with the chromagen 3,3׳-
diaminobenzidine (DAB) at the final detection step. Sections of heart tissue were scanned using 
virtual microscope (Aperio Scan Scope Model CS, Aperio Technology Inc., Vista, CA, USA). 
Quantitative assessment of ED1 was done by a blinded researcher who randomly examined 20-22 
fields of each left ventricular section magnified at 200x. Macrophages which were positively 
stained with ED1 (brown from immune stained sections) were quantified by manually counting 
the ED1-stained cells around the blood vessels and interstitial spaces of myocardium. 
 
3.3.3 Western immunoblotting 
Left-ventricular tissue was homogenized as previously reported (13, 30-32, 35). Primary 
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA), ED1 (CD68) (sc-59103), ED2 
(CD163) (sc-58956), CD14 (sc-9150), CD206 (sc-48758), CD36 (sc-9154), osteopontin (sc-
21742), osteoprotegerin (sc-11383), PI3K (sc67306), IRS-1 (sc-559), collagen-IV (sc-11360), 
fibronectin (sc-18825), TGF-β1/2/3 (sc7892)) and GLUT4 (ab654, Abcam Inc., Cambridge, MA, 
USA) were used. Densitometric analysis was done with UN-SCAN-IT software (Silk Scientific 
Inc., Orem, UT, USA). G6PDH antibody (A9521, Sigma St. Louis, MO, USA) was used as a 
control to ascertain equivalent loading. 
 
 
3.3.4 Statistical analysis 
All data are expressed as means ± SEM from at least four independent experiments unless 
otherwise stated. Statistical analyses were done using two-way ANOVA, using Statistical Analysis 
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System (SAS), software Version 9.3 (SAS Institute Inc., Cary, NC, USA) and Student’s t-test. 
Group differences at the level of p<0.05 were considered statistically significant. 
 
3.4 Results 
3.4.1 Hemin therapy upregulates the HO System to improve cardiac function 
To investigate the mechanisms underlying the improvement of cardiac function in obese 
insulin resistant ZFs, we measured the concentration of HO-1 and HO activity. In ZF-control rats, 
the basal level of HO-1 concentration and HO activity was significantly lower than that of ZL 
control (Figures 3-1(a) and 3-1(b)). However, hemin administration increased HO-1 and HO 
activity in ZF by 8.4- and 11.3-fold, respectively. The enhanced HO activity would increase 
endogenous carbon monoxide that would in turn stimulate cGMP (30, 32). Both cGMP and carbon 
monoxide are known to enhance insulin signaling and glucose metabolism (37). Accordingly, we 
detected a 3.4-fold increase of cGMP in hemin-treated animals (Figure 3-1(c)). In contrast, the 
coadministration of the HO blocker, SnMP and the HO inducer, and hemin abolished the hemin-
induced increase of HO-1 and HO activity, with corresponding reduction of cGMP levels (Figure 
3-1(c)). Hemin therapy also enhanced HO-1, HO activity, and cGMP levels in ZL-control rats 
(Figures 3-1(a), 3-1(b), and 3-1(c)). In hemin-treated ZLs, HO-1, HO activity and cGMP were 
enhanced by 3.1-, 2.8-, and 2.4-fold, respectively, as compared to 8.4-, 11.3-, and 3.4-fold, 
respectively, in hemin-treated ZFs, suggesting greater selectivity of hemin to the HO system in 
unhealthy ZFs characterized obesity, insulin resistance, and cardiomyopathy (29).  
Since cardiac hypertrophy is amongst the forerunners to heart failure, we investigated the 
effects of hemin on cardiac hypertrophy. Our results indicate that hemin therapy significantly 
reduced cardiac hypertrophy in ZF, whereas the coadministration of hemin and SnMP nullified the 
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effect (Table 3-1). Echocardiography was used to further assess left ventricular hypertrophy. Our 
hemodynamic data obtained during catheterization of the left side of hearts from ZFs showed 
association between elevated myocardial hypertrophic response and obesity. A significant 2-fold 
increase in left-ventricular free wall thickness, an important index of cardiac hypertrophy (38), 
was observed during diastole and systole, and interestingly these were abated by hemin by 33.3% 
and 15.6%, respectively (Table 3-2). Other hemodynamic deficiencies in ZFs including 
abnormalities in left-ventricular end-diastolic volume, left-ventricular end systolic volume, stroke 
volume, and cardiac output which were reduced by 17.5%, 16%, 8.3%, and 7.7%, respectively 
(Table 3-2), were increased by hemin therapy by 15.2%, 27.3%, 13.6% and 12.4%, respectively. 
Hemin therapy also improved cardiac hemodynamics by lowering arterial-systolic pressure, 
arterial-diastolic pressure, mean-arterial pressure, and total peripheral resistance by 12.4%, 11.4% 
and 12.2%, 17.6%, respectively, with corresponding reduction of +dp/dt (the maximal rate of 
increase in left-ventricular pressure), left ventricular developed pressure, and heart rate.  
Treatment with hemin and SnMP caused loss of body weight in ZL controls and ZFs, which, 
however, did not exceed 9% (Table 3-1). The loss of weight may not be due to toxicity as we 
recently showed that several indices of toxicity including plasma gamma-glutamyl transferase, 
aspartate aminotransferase, and alanine aminotransferase were within normal range (30). 
Although, ZFs had normoglycemia, hemin and SnMP affected blood glucose. In hemin-treated 
animals, there was a slight but significant reduction of glycemia, whereas in SnMP-treated animals 
a slight increase was observed (Table 3-1). Similarly, hemin therapy slightly reduced glycemia in 
ZL controls. The vehicle dissolving hemin and SnMP had no effect on the measured parameters. 
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3.4.2 Hemin therapy abates MCP-1, MIP-1α, TNF-α, endothelin-1, and 8-isoprostane but 
enhanced ANP in ZFs 
Since 8-isoprostane stimulates ET-1 (39), and both ET-1 and 8-isoprostane are involved in 
the oxidative destruction of tissue, we measured ET-1 and 8-isoprostane. ET-1 in untreated ZFs 
was markedly elevated as compared to ZL controls (Figure 3-2(a)) but was significantly abated by 
hemin. In contrast, the coadministration of hemin and the HO blocker, SnMP, annulled the effect 
of hemin (Figure 3-2(a)). Because elevated oxidative stress is linked to impaired insulin signaling 
and cardiac dysfunction, we measured urinary 8-isoprostane, an important marker of oxidative 
stress (40). In ZFs, the basal levels of 8-isoprostane were significantly elevated (Figure 3-2(b)) but 
were reduced by hemin, whereas cotreatment of hemin with SnMP nullified the effects. Given that 
ET-1 and ANP are known to interact reciprocally (41), we investigated whether the hemin-
dependent suppression of ET-1 (Figure 3-2(a)) would be associated with a parallel potentiation of 
ANP. In ZFs, the basal ANP levels were markedly depressed by 1.7-fold (Figure 3-2(c)) but 
interestingly were robustly enhanced by hemin by 3.3-fold. In contrast, the coadministration of 
hemin with SnMP abolished the effects of hemin.  
We also investigated the effects of hemin on MIP-1α and MCP-1 since these chemokines 
trigger macrophage infiltration (9). In ZFs, the basal MCP-1 levels were significantly increased by 
4.6-fold (Figure 3-2(d)) but were attenuated by hemin by 2.8-fold, whereas the coadministration 
with SnMP nullified the effects of hemin (Figure 3-2(d)). Although, hemin therapy greatly 
attenuated MCP-1 by 64% in ZF, however comparable levels as observed in the ZL controls were 
not reinstated. Hemin therapy was also effective in suppressing MIP-1α (Figure 3-2(e)). In ZFs, 
the basal MIP-1α levels were significantly elevated by 4.9-fold but were reduced by hemin by 3.5-
fold, whereas the cotreatment of hemin with SnMP nullified the effects (Figure 3-2(e)). Since 
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TNF-α is implicated in macrophage infiltration (9), we also assessed the effects of hemin on TNF-
α. In ZFs, the basal levels of TNF-α were elevated by 3.5-fold but were significantly attenuated 
by hemin by 2.6-fold (Figure 3-2(f)), whereas cotreatment with SnMP abolished the effect of 
hemin. Hemin therapy also affected ET-1, 8-isoprostane, ANP, MCP-1, and MIP-1α in ZL controls 
although, the magnitude of effect was smaller than that in ZFs (Figure 3-2). 
 
3.4.3 Hemin selectively abated the proinflammatory macrophage M1 phenotype but 
enhanced the anti-inflammatory M2 phenotype in the left ventricle of ZFs  
After having observed the hemin-dependent reduction of cytokines/chemokines implicated 
in macrophage infiltration such as MIP-1α, MCP-1, and TNF-α, we investigated whether the 
suppression of these chemokines/cytokines in the left ventricle of ZFs would be accompanied by 
the selective attenuation of the proinflammatory macrophage M1-phenotype using a specific 
marker such as ED1 (42) to quantify the expression of the proinflammatory M1-phenotype in left-
ventricular tissue and other markers for the assessment of anti-inflammatory M2-phenotype 
including ED2 (42), CD14 (43, 44), CD206 (8), and CD36 (45, 46).  
Our Western immunoblotting and relative densitometry revealed that the basal expression 
of the proinflammatory macrophage M1-phenotype marker, ED1, in ZFs was markedly elevated 
by 4.8-fold as compared to ZL controls (Figure 3-3(a)) but was significantly reduced by hemin by 
3.5-fold although control levels were not attained. On the other hand, the basal expression of 
several markers of the anti-inflammatory macrophage M2-phenotype including ED2, CD206, 
CD36, and CD14 was significantly depressed in ZFs by 2.1-, 5.7-, 3.6-, and 2.9-fold, respectively, 
(Figures 3-3(b), 3-3(c), 3-3(d), and 3-3(e)). Interestingly, hemin therapy greatly enhanced the 
depressed ED2, CD206, CD36, and CD14 in ZFs by 3.8-, 4.1-, 2.3-, and 2.6-fold, respectively, 
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suggesting that a novel mechanism by which hemin therapy blunts inflammation is by selectively 
modulating the polarization of macrophage toward the M2-phenotype that dampens inflammation. 
 
3.4.4 Hemin therapy suppressed macrophage infiltration in the left ventricle of ZFs  
Following the observation from our Western blot experiment that hemin therapy reduced 
left-ventricular ED-1, a marker of macrophage infiltration, we use the ED-1 antibody to further 
confirm macrophage infiltration in the left ventricle by immunohistochemistry (Figure 3-4(a)). 
Our results reveal that left-ventricular sections from ZL-control rats were almost devoid of the 
dark brown ED1 positive staining. However, in untreated ZF control rats, a greater number of 
ED1-positively stained dark brown cells were observed, indicating increased macrophage 
infiltration. Interestingly, in hemin-treated ZFs, there was a marked reduction in the number of 
dark brown-stained macrophages, suggesting reduction of macrophage infiltration. 
Correspondingly, hemin therapy significantly reduced the quantitative ED1 score (Figure 3-4(b)). 
 
3.4.5 Hemin therapy enhanced insulin signaling but suppressed extracellular matrix and 
profibrotic proteins implicated in cardiac injury  
Since visceral adiposity and elevated inflammation impair insulin signaling (47), we 
investigated the effects of hemin therapy on the expression of important components of the insulin 
signal transduction pathway including IRS-1, PI3K, and GLUT4. In in ZFs, the basal expression 
of IRS-1, PI3K, and GLUT4 was significantly reduced by 11.2-, 2.5-, and 2.3-fold as compared to 
the ZL control (Figures 3-5(a), 3-5(b), and 3-5(c)) but was enhanced by hemin by 5.7-, 4.01-, and 
1.9-fold, respectively.  
To further confirm the antihypertrophic effect of hemin therapy, we measured collagen-
IV, an important protein implicated in cardiac hypertrophy and fibrosis (35). In ZFs, the basal 
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expression of left-ventricular collagen-IV was significantly elevated by 6.9-fold but was abated by 
hemin by 2.8-fold (Figure 3-5(d)). Given that excessive deposition of extracellular 
matrix/profibrotic proteins and inflammation due to macrophage infiltration are cardinal 
pathophysiological events implicated in cardiac insult (47, 48), while atrial natriuretic peptide 
(ANP) and adiponectin are known to suppress fibrosis caused by the deposition of extracellular 
matrix (49, 50), we investigated whether the concomitant potentiation of ANP, adiponectin, and 
the HO system by hemin would abate TGF-β. In ZFs, the basal expression of TGF-β was 
significantly elevated by 4.6-fold but was markedly attenuated by hemin by 3.4-fold (Figure 3-
5(e)). Since TGF-β mobilizes the extracellular matrix by stimulating fibronectin and collagen to 
cause fibrosis and cardiac injury (49, 51), we also measured the expression of fibronectin. In ZF 
rats, the basal expression of fibronectin was increased by 7.5-fold but was markedly attenuated by 
hemin therapy by 4.5-fold (Figure 3-5(f)). 
 
3.4.6 Hemin improved glucose tolerance, enhanced the insulin-sensitizing protein, 
adiponectin, but abated insulin resistance 
After having observed the hemin-induced potentiation of insulin signalling, to further 
confirm the role of hemin therapy on glucose metabolism, we assessed the effects of hemin on 
glucose tolerance, insulin resistance, and the insulin-sensitizing protein, adiponectin in ZFs, an 
obese model with elevated inflammation. Since inflammation due to macrophage infiltration is 
implicated in insulin resistance and cardiomyopathy (47, 48), and ZFs are characterized by insulin 
resistance (29), we investigated whether the hemin dependent suppression of macrophage 
infiltration would be accompanied by improved glucose metabolism. In untreated ZFs, IPGTT 
analysis showed marked increase in glycemia as compared to ZL controls and hemin-treated ZFs 
at all time points tested (Figure 3-6(a)), suggesting improved glucose tolerance in hemin-treated 
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ZFs. Although, ZFs were hyperinsulinemic with elevated basal glycemia, when challenged with a 
bolus injection of glucose, only to a meagre glucose stimulated insulin release was observed 
(Figure 3-6(b)), suggesting glucose intolerance. On the other hand, glucose challenge to ZL 
controls and hemin-treated ZFs greatly stimulated insulin release (Figure 3-6(b)), suggesting 
improved glucose tolerance. Hemin also reduced the elevated insulin resistance HOMA-IR in ZFs 
(Figure 3-6(c)), whereas coadministration with SnMP reversed the effects of hemin (Figure 3-
6(c)).  
We also investigated the effects of hemin therapy on adiponectin, an anti-inflammatory, 
insulin sensitizing and cardioprotective protein (52, 53). Interestingly, hemin therapy significantly 
enhanced the depressed basal adiponectin levels in ZFs, whereas treatment with SnMP abolished 
and further reduced the depressed levels of adiponectin (Figure 3-6(d)). Hemin therapy also 
reduced HOMA-IR index in ZL controls and enhanced adiponectin although, the effect was less 
intense as compared to ZFs. 
 
3.4.7 Hemin therapy suppressed left-ventricular fibrosis, cardiomyocyte hypertrophy, and 
longitudinal cardiac myofibril thickness in ZFs 
Histological and morphometric analyses Using Masson’s trichrome and hematoxylin and 
eosin staining were done to further confirm the cardioprotection by hemin. Cardiomyocytes 
appeared as dark reddish while extracellular matrix, such as collagen, stained blue (Figure 3-7(a)). 
Left ventricular sections from ZL controls appeared morphologically normal, with scanty 
interstitial collagen deposition. In contrast left-ventricular images from ZFs showed moderate to-
severe fibrosis, with scarring of cardiomyocytes, and interstitial and perivascular collagen 
depositions (Figure 3-7(a)). Interestingly, hemin therapy attenuated the severity of scarring and 
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intestinal and perivascular collagen deposition, evidenced by reduced extracellular and 
perivascular blue staining (Figure 3-7(a)). Correspondingly, semi-quantitative analysis showed 
that hemin therapy significantly abated the elevated collagen deposition and perivascular fibrosis 
in ZFs, reinstating comparable levels to ZL control (Figure 3-7(b)). Hemin therapy was also 
effective against cardiomyocyte hypertrophy (Figure 3-7(c)). In ZFs, cardiomyocytes were 
enlarged with increscent nuclei and the inner myofibril spaces were decreased, as compared to 
normal cardiomyocytes in ZL controls (Figure 3-7(c)). In ZFs, the longitudinal cardiac myofibril 
thickness was 37% higher than that of ZL controls (Figure 3-7(d)) but was reduced by 27% in 
hemin-treated ZFs. Although, ZL-control values were not reinstated, hemin increased 
intermyofibril spaces in ZFs close to the levels observed in ZL controls (Figure 3-7). 
 
3.4.8 Hemin therapy suppressed the elevated expression of markers of heart failure in the 
left ventricle of ZFs  
To further confirm the cardioprotective effects of an upregulated HO system, we 
investigated the effects of hemin therapy on important markers of heart failure such as osteopontin 
(13) and osteoprotegerin (14). Since left-ventricular hypertrophy is associated with heart failure 
(54), we determined whether the hemin-dependent suppression of left-ventricular hypertrophy in 
ZFs would be accompanied by the reduction of markers of heart failure. Our results indicate that, 
in ZFs, the basal expression levels of osteopontin and osteoprotegerin were significantly elevated 
by 4.6- and 7.1-fold, respectively, as compared to ZL controls (Figures 3-8(a) and 3-8(b)). 
Interestingly, treatment with hemin attenuated the expressions of osteopontin and osteoprotegerin 
by 3.5- and 3.3-fold, respectively, (Figures 3-8(a) and 3-8(b)). 
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3.5 Discussion 
The present study indicates that the multifaceted mechanisms by which hemin therapy 
improves cardiomyopathy in obesity include (i) the suppression of visceral adiposity, (ii) the 
reduction of macrophageM1 phenotype, (iii) the attenuation of markers of heart failure, (iv) the 
reduction of extracellular matrix/profibrotic proteins, and (v) the amelioration of insulin resistance, 
with corresponding enhancement of glucose metabolism. In ZFs, excessive visceral adiposity, 
increased macrophage infiltration and the elevated levels of 8-isoprostane, MIP-1α, MCP-1, TNF-
α, IL-6, IL-1β, and ET-1 proteins of heart failure, and extracellular-matrix deposition are among 
the complex molecular processes that characterize the intricate relationship between inflammation, 
oxidative stress, cardiac fibrosis, and the progressive development of insulin resistance and 
cardiomyopathy (5, 47-49, 55-57). Importantly, the present study unveils that hemin therapy 
selectively enhances the anti-inflammatory macrophage M2-phenotype in left-ventricular tissue of 
ZFs while concomitantly abating the proinflammatory M1-phenotype, suggesting that a novel 
mechanism by which hemin therapy suppresses cardiac inflammation in obesity is by selectively 
favoring the polarization of macrophage towards the M2-phenotype that ablates inflammation. 
Correspondingly, hemin therapy abated several chemokines and cytokines that promote 
macrophage infiltration including MIP-1α, MCP-1, TNF-α, IL-6, and IL-1β (9-11). Interestingly, 
the suppression of visceral adiposity and inflammation in hemin-treated ZFs was accompanied by 
reduced insulin resistance and improved glucose intolerance, and the potentiation of important 
components of the insulin signal transduction pathway including IRS-1, PI3K, and GLUT4, which 
in addition to the hemin-dependent enhancement of adiponectin, an anti-inflammatory, insulin 
sensitizing, and cardioprotective protein (52, 53) may account for improved glucose metabolism 
in obese conditions.  
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Hemin therapy also reduced LV hypertrophy, cardiac fibrosis, and cardiomyocyte 
longitudinal muscle-fiber thickness, a pathophysiological feature of cardiomyocyte hypertrophy 
(35), with a corresponding suppression of markers of heart failure such as osteopontin and 
osteoprotegerin (14, 15), as well as the reduction of extracellular matrix protein like TGF-β, 
fibronectin, and collagen which are implicated in cardiac hypertrophy and fibrosis (49, 57). Since 
TGF-β mobilizes the extracellular matrix by stimulating fibronectin and collagen causing tissue 
damage and hypertrophy (49, 57), the concomitant reduction of TGF-β, fibronectin, and collagen-
IV in ZFs may account for reduced cardiac lesions. Another mechanism by which the HO system 
suppresses extracellular matrix and profibrotic agents like TGF-β and ET-1 may be due to the HO-
dependent potentiation of ANP, a substance known to suppress extracellular matrix (41, 58). 
Generally, ANP and ET-1 have opposing effects (59). For example, ANP reduces fibrosis by 
inhibiting TGF-β1 and fibronectin (41), while ET-1 acts in conjunction with TGF-β1 to stimulate 
the synthesis of fibronectin (58). Similarly, ANP suppresses inflammation to reduce insulin 
resistance (59), while ET-1 stimulates inflammatory/oxidative insults causing insulin resistance 
(60). On the other hand, ANP stimulates the production of adiponectin (61), a protein with insulin-
sensitizing and anti-inflammatory effects (52). The effects of ANP are largely mediated by cGMP 
(62), and adiponectin is also known to enhance cGMP (63). Moreover, ANP and the HO system 
have mutual stimulatory effects. Accordingly, ANP enhances HO (64, 65), and similarly, the HO 
system has been shown to upregulate ANP and adiponectin (23, 66). Therefore, the synergistic 
potentiation of the HO-adiponectin-ANP axis and insulin signaling with corresponding ablation of 
extracellular matrix/heart failure proteins, the reduction of oxidative stress, and inflammation 
mediators such as macrophage M1-phenotype, MIP-1α and MCP-1, TNF-α, IL-6, IL-1β, ET-1, 
and 8-isoprostane are among the multifaceted mechanisms by which hemin therapy improved 
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cardiac function. Thus, novel strategies capable of potentiating the HO-adiponectin-ANP axis 
would improve cardiomyopathy and insulin signaling in obesity.  
Cardiomyocyte hypertrophy and myocardial fibrosis are early microscopic changes in heart 
failure. Subsequently, macroscopic alterations including increased left-ventricular wall thickness, 
diastolic/systolic dysfunction, and impaired cardiac hemodynamics become evident. Interestingly, 
hemin therapy modulated several hemodynamic and echocardiographic parameters to improve 
cardiac function (67). These include the reduction of left-ventricular diastolic wall thickness, left-
ventricular systolic wall thickness, mean-arterial pressure, arterial-systolic pressure, arterial-
diastolic pressure, left-ventricular developed pressure, +dp/dt, and total peripheral resistance, with 
corresponding enhancement of stroke volume and cardiac out, and thus improved cardiac function 
in hemin-treated ZFs. Hemin therapy also enhanced the HO system, cGMP, adiponectin, and ANP, 
abated 8-isoprostane, MCP-1, MIP-1α, TNF-α, IL-6, IL-1β, and ET-1 and lowered HOMA-IR 
index in ZL-control rats although, the magnitude was smaller as compared to ZFs with depressed 
HO activity. The reasons for this selective effect of HO are not fully understood. However, it is 
possible that as ZL controls are healthy animals with normal/functional insulin-signalling, the HO 
system may be more stable as compared to ZFs which have deregulated HO system with depressed 
HO-1 and HO activity. Importantly, the selectivity of the HO system in diseased conditions could 
be explored against the comorbidity of insulin-resistant diabetes and obesity.  
Although, we recently reported the cardioprotective effects of the HO system in ZDFs (13), 
a model characterized by obesity, insulin resistance, and overt hyperglycemia, pathophysiological 
profile of ZDF is not reflective of the metabolically healthy individuals who are characterized by 
obesity and normoglycemia (7). In contrast, ZFs closely mimic the pathophysiological profile of 
metabolically healthy obese individuals with normoglycemia, so our findings may be applicable 
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to this subtype of obese individuals. Moreover, with the rising incidence of cardiometabolic 
complications in many adults who previously manifested the metabolically healthy obese 
phenotype (7), novel studies with animal models that closely mimic the pathophysiological profile 
of metabolically healthy obese subtype are needed. Therefore, studying the effects of the HO 
system on ZFs may offer new perspective in the pathophysiology of cardiometabolic 
complications and especially the progressive deterioration of cardiac function which may 
eventually lead to heart failure given the elevated levels of proteins of heart failure detected in 
untreated ZFs.  
Collectively, our study unveils the beneficial effect of upregulating the HO system in the 
comorbidity of obesity and insulin resistance and suggests that the suppression of oxidative 
mediators, macrophage M1-phenotype infiltration and extracellular matrix/remodeling proteins 
are among the multifaceted mechanisms by which the HO system maintains and enhances insulin 
signaling and counteract diabetic cardiomyopathy. These data suggest that although, ZFs are 
normoglycemic, perturbations of insulin signaling, and cardiac function may be forerunners to 
overt hyperglycemia and heart failure in obesity. 
 
3.6 Conclusion 
The novelty of our study includes: (i) the hemin-induced selective enhancement of the anti-
inflammatory M2-phenotype in left-ventricular tissue of ZFs and parallel reduction of the 
proinflammatory macrophage M1-phenotype and MIP-1α, a chemokine implicated in macrophage 
infiltration; (ii) the hemin-dependent suppression of heart failure proteins such as osteopontin and 
osteoprotegerin; (iii) the suppression of inflammatory cytokines in ZFs; and (iv) the hemin-
induced reduction of insulin resistance and improvement of cardiac function in ZFs. Since we 
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recently reported that the HO system suppressed pericardial adiposity in a model characterized by 
obesity, insulin resistance, and overt hyperglycemia (13), and the present study indicates that 
hemin therapy abates cardiac inflammation in obesity, an interorgan crosstalk of inflammatory 
mediators between the myocardium and pericardial adipose tissue can be envisaged in the 
pathophysiology of diabetic cardiomyopathy. Importantly, the concomitant modulation of 
macrophage polarization in left ventricles towards the anti-inflammatory M2 phenotype alongside 
the parallel reduction of proinflammatory cytokines and chemokines implicated in macrophage 
infiltration and tissue destruction may be indicative of a putative interorgan crosstalk and the 
movement of inflammatory mediators from the pericardial fat to the myocardium or vice versa, 
and this may be particularly important in the progressive development of cardiomyopathy, insulin 
resistance, and related cardiometabolic complications. Although, this linkage has to be established, 
this study would set the stage for further exploration of the putative interorgan communication 
between pericardial fat and the heart. 
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Table 3-1: Effect of hemin and stannous mesoporphyrin (SnMP) on physiological and 
biochemical variables in Zucker fatty (ZF) and Zucker lean (ZL) rats 
Parameters Animal groups 
ZL  
control 
ZL + 
hemin 
ZF  
control 
ZF + 
hemin 
ZF + 
hemin + 
SnMP 
ZF + 
vehicle 
Body weight 
(g) 
 
472.9 ± 9.7 
 
445.5 ± 11.6† 
 
746.8 ± 21.5§ 
 
685.9 ± 14.7§ 
 
691.4 ± 15.2$ 
 
702.8 ± 24.6 
Fasting 
glucose 
(mmol/L) 
 
7.2 ± 0.6 
 
6.5 ± 0.3* 
 
8.2 ± 0.5§ 
 
6.9 ± 0.4* 
 
8.5 ± 0.4* 
 
8.1 ± 0.4 
Heart 
weight (g) 
 
1.5 ± 0.03 
 
1.1 ± 0.02† 
 
3.4 ± 0.06§ 
 
2.0 ± 0.04§ 
 
3.0 ± 0.03$ 
 
3.1 ± 0.04 
Cardiac 
hypertrophy 
(g/kg body 
weight) 
 
3.1 ± 0.07 
 
2.5 ± 0.06* 
 
4.6 ± 0.16§ 
 
2.9 ± 0.08* 
 
4.4 ± 0.17* 
 
4.4 ± 0.09 
 
†p<0.05 versus ZL; $p<0.05 versus ZF; §p<0.05 versus ZL control; *p<0.05 versus ZF-control or 
ZL-control. 
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Table 3-2: Effect of hemin therapy on hemodynamic and echocardiographic parameters 
Parameters                             Experimental groups P-value  
ZF ZL ZF + hemin ZF  
versus 
ZL 
ZF 
versus 
ZF + 
hemin 
Effect of 
hemin on 
ZF 
Arterial systolic pressure 
(mmHg) 
153 ± 5.2 124 ± 3.4# 134 ± 6.3* 0.001 0.018 Reduced by 
12.4% 
Arterial diastolic pressure 
(mmHg) 
109 ± 3.2 92 ± 2.5# 96 ± 4.7* 0.003 0.024 Reduced by 
11.9% 
Mean arterial pressure 
(mmHg) 
123 ± 3.8 102 ± 2.7# 109 ± 5.2* 0.002 0.022 Reduced by 
11.4% 
Total peripheral resistances 
(mmHg·min/mL) 
1.7 ± 0.1 1.4 ± 0.1 1.4 ± 0.1 
 
0.060 
 
0.080 
 
Reduced by 
17.6% 
LV developed pressure 
(mmHg) 
161 ± 4.1 136 ± 8.0# 140 ± 5.8* 0.012 0.030 Reduced by 
13.0% 
+dp/dt
(max)
 (mmHg/sec) 3634 ± 127 3050 ± 200# 3050 ± 169* 0.027 0.027 Reduced by 
16.1% 
Heart rate (beats/min) 328 ± 9.2 331 ± 7.2 289 ± 14.2* 0.814 0.020 Reduced by 
11.9% 
LV diastolic wall thickness 
(mm) 
2.7 ± 0.1 1.7 ± 0.1# 1.8 ± 0.1* 0.0001 0.0001 Reduced by 
33.3% 
LV systolic wall thickness 
(mm) 
3.2 ± 0.1 2.1 ± 0.1# 2.7 ± 0.1* 0.0001 0.007 Reduced by 
15.6% 
LV end diastolic volume 
(mL) 
0.33 ± 0.01 0.40 ± 0.04 0.38 ± 0.02 0.075 0.169 Increased by 
15.2% 
LV end systolic volume 
(mL) 
0.11 ± 0.01 0.16 ± 0.01# 0.14 ± 0.01 0.001 0.089 Increased by 
27.3% 
Stroke volume (mL) 0.22 ± 0.01 0.24 ± 0.02 0.25 ± 0.02 0.564 0.311 Increased by 
13.6% 
Cardiac output (mL/min) 72.8 ± 3.6 78.9 ± 9.0 81.8 ± 9.8 0.519 0.412 Increased by 
12.4% 
 
Values for each echocardiography and hemodynamic endpoint were averaged for each rat and the 
mean values used in statistical analyses, with 𝑛: number of rats. Differences among treatment 
groups were compared using one-way ANOVA followed by Fisher’s Least Square Difference 
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(LSD) posteriori tests. Differences of p<0.05 were considered statistically significant. Values are 
means ± SE; 𝑛 = 6 per group. *p<0.05 versus control ZF rats, #p<0.05 versus control ZL rats. LV: 
left ventricle; +dp/dt(max), maximal rate of increase in left ventricular pressure. 
 
Figure 3-1: Effects of the HO inducer, hemin, and the HO inhibitor, SnMP on HO-1, HO activity 
and cGMP in the left ventricle of ZLs and ZFs. (a) Hemin enhanced HO-1, whereas SnMP nullified 
the effects of hemin. (b) Hemin increased HO activity, while SnMP abolished the hemin effect. 
(a) 
(b) 
(c) 
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(c) Hemin enhanced cGMP, which, however, was abolished by SnMP. Bars represent means ± 
SEM; 𝑛 = 6 rats per group (*p<0.01 versus ZL control; †p<0.05 versus ZL control; @p<0.01 versus 
ZF + hemin + SnMP or ZF control). 
 
 
Figure 3-2: Effects of the HO inducer, hemin and the HO inhibitor, SnMP on endothelin-1, ANP, 
MCP-1, MIP-1α, and TNF-α in left-ventricular tissue from ZLs and ZFs. Hemin therapy: (a) 
reduced endothelin-1, (b) attenuated 8-isoprostane, (c) increased ANP, (d) suppressed MCP-1, 
(a) 
(c) 
(e) 
(b) 
(d) 
(f) 
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(e) abated MIP-1α, and (f) reduced TNF-α, whereas SnMP abolished the hemin effects. Bars 
represent means ± SEM; 𝑛 = 6 rats per group (*p<0.05, **p<0.01 versus ZL control; †p<0.05, 
††p<0.01 versus ZL control; @p<0.01 versus ZF + hemin + SnMP or ZF control). 
 
 
 
 
Figure 3-3: Effects of hemin on ED1, ED2, CD206, CD36, and CD14 in left-ventricular tissue 
from ZLs and ZFs. Hemin therapy (a) abated ED1, but (b) enhanced ED2, (c) increased CD206, 
(d) enhanced CD36, and (e) increased CD14 in ZFs. Bars represent means ± SEM; 𝑛 = 4 rats per 
group (*p<0.01 versus all groups; #p<0.01 versus all groups). 
 
 
(a) (b) (c) 
(d) (e) 
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Figure 3-4: (a) Representative photomicrographs of cross-sections of the left-ventricle showing 
macrophage infiltration (ED1-positive cells stained dark brown) (magnification ×200). (b) 
Quantitative analyses of macrophage infiltration per field indicating that in ZFs the number of 
ED1-positive dark-brown cells (macrophage infiltration) was markedly elevated as compared to 
ZL control but interestingly was significantly attenuated by hemin therapy. Bars represent means 
± SEM; 𝑛 = 6 rats per group (#p<0.01 versus all groups). 
    ZL 
Control 
      ZF 
Control 
ZF + Hemin 
Left ventricular ED1 (macrophage infiltration) 
(b) 
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Figure 3-5: Effects of hemin on the expression of important proteins of the insulin signal 
transduction pathway such as IRS-1, PI3K, GLUT4, and the expression of profibrotic/extracellular 
matrix proteins including collagen-IV, TGF-β, and fibronectin in left-ventricular tissue from ZLs 
and ZFs. Representative Western immunoblotting and relative densitometry of the expressed 
proteins normalized by G6PDH indicates that hemin therapy significantly (a) enhanced IRS-1, (b) 
increased PI3K, (c) upregulated GLUT4, but (d) abated collagen-IV, (e) reduced TGF-β, and (f) 
suppressed fibronectin in ZFs. Bars represent means ± SEM; 𝑛 = 4 rats per group (*p<0.01 versus 
all groups; #p<0.01 versus all groups). 
 
 
 
(a) (b) (c) 
(e) (f) (g) 
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Figure 3-6: Effects of hemin on glucose tolerance, insulin resistance (HOMA-IR index), and 
adiponectin. Hemin therapy (a) improved glucose tolerance (IPGTT), (b) increased glucose-
stimulated insulin release, (c) reduced insulin resistance, and (d) increased adiponectin. Bars 
represent means ± SEM; 𝑛 = 6 rats per group (*p<0.05, **p<0.01 versus ZL control; †p<0.01 
versus ZL control; @p<0.01 versus ZF + hemin + SnMP or ZF control). 
 
 
 
 
(a) (b) 
(d) (c) 
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(a) 
(b) 
(c) 
(d) 
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Figure 3-7: Effect of hemin on histological lesions in the left ventricle of ZLs and ZFs. (a) 
Representative Mason’s trichrome-stained images revealing severe cardiac muscle scaring and 
collagen deposition in ZFs. (b) Semi-quantitative evaluation showed that hemin therapy reduced 
collagen deposition in ZFs. (c) Representative hematoxylin and eosin-stained images revealing 
severe longitudinal muscle-fiber thickness in ZFs. (d) Quantitative evaluation showed that hemin 
reduced longitudinal muscle-fiber thickness. ± SEM; 𝑛 = 6 rats per group (*p<0.05, **p<0.01 
versus all groups). 
 
 
 
 
Figure 3-8: Effect of hemin on markers of heart failure such as osteopontin and osteoprotogerin 
in the left ventricle of ZLs and ZFs. Representative Western immunoblotting and relative 
densitometry of the expressed proteins normalized by G6PDH indicates that hemin therapy 
significantly (a) abated osteopontin and (b) reduced osteoprotogerin in ZFs. Bars represent means 
± SEM; 𝑛 = 4 rats per group (*p<0.01 versus all groups). 
 
 
 
 
 
 
 
(a) (b) 
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4.1 Abstract 
 
The prevalence of non-alcoholic fatty-liver disease (NAFLD) is increasing globally. NAFLD is a 
spectrum of related liver diseases that progressive from simple steatosis to serious complications 
like cirrhosis. The major pathophysiological driving of NAFLD includes elevated hepatic 
adiposity, increased hepatic triglycerides/cholesterol, excessive hepatic inflammation, and 
hepatocyte ballooning injury is a common histo-pathological denominator. Although, heme-
oxygenase (HO) is cytoprotective, its effects on hepatocyte ballooning injury have not been 
reported. We investigated the effects of upregulating HO with hemin or inhibiting it with stannous-
mesoporphyrin (SnMP) on hepatocyte ballooning injury, hepatic adiposity and inflammation in 
Zucker diabetic fatty rats (ZDFs), an obese type-2-diabetic model. Hemin administration to ZDFs 
abated hepatic/plasma triglycerides and cholesterol, and suppressed several pro-inflammatory 
cytokines and chemokines including, TNF-α, IL-6, IL-1β, macrophage-inflammatory-protein-1α 
(MIP-1α) and macrophage-chemoattractant-protein-1 (MCP-1), with corresponding reduction of 
the pro-inflammatory M1-phenotype marker, ED1 and hepatic macrophage infiltration. 
Correspondingly, hemin concomitantly potentiated the protein expression of several markers of 
the anti-inflammatory macrophage-M2-phenotype including ED2, IL-10 and CD206, alongside 
components of the HO-system including HO-1, HO-activity and cGMP, whereas the HO-inhibitor, 
SnMP abolished the effects. Furthermore, hemin attenuated liver histo-pathological lesions like 
hepatocyte ballooning injury and fibrosis, and reduced extracellular-matrix/profibrotic proteins 
implicated in liver injury such as osteopontin, TGF-β1, fibronectin and collagen-IV. We conclude 
that hemin restore hepatic morphology by abating hepatic adiposity, suppressing macrophage 
infiltration, inflammation and fibrosis. The selective enhancement of anti-inflammatory 
macrophage-M2-phenotype with parallel reduction of pro-inflammatory macrophage M1-
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phenotype and related chemokines/cytokines like TNF-α, IL-6, IL-1β, MIP-1α and MCP-1 are 
among the multifaceted mechanisms by which hemin restore hepatic morphology. 
 
4.2 Introduction 
Obesity is associated with many health complications including, type-2 diabetes, 
hyperlipidemia, dyslipidemia, hypertension and non-alcoholic fatty liver disease (NAFLD) (1-6). 
NAFLD is a wide spectrum of related liver diseases that progressive from simple a condition like 
steatosis to a more serious complication like cirrhosis, and elevated hepatic adiposity, high levels 
of hepatic triglycerides and hepatic cholesterol and hepatocyte ballooning injury are common 
denominators of NAFLD (1-5), (7-9). Besides hepatic adiposity, inflammation is crucial in the 
pathogenesis of NAFLD. Elevated levels of pro-inflammatory cytokines such as tumor necrosis 
factor (TNF-α), interleukin (IL)-6, IL-1β are amongst the pathophysiological driving force of 
NAFLD (10, 11). Similarly, pro-inflammatory chemokines such as macrophage-inflammatory-
protein-1 alpha (MIP-1α) and macrophage-chemoattractant-protein-1 (MCP-1) are known to 
trigger macrophage infiltration to accentuate hepatic inflammatory insults (12, 13) and 
compromise hepatic morphology and function. Generally, two common forms of macrophages 
have been described (14, 15). These include the pro-inflammatory macrophage M1-phenotype that 
is stimulated by cytokines and chemokines like TNF-α, IL-6, IL-1β, MIP-1α and MCP-1 (16, 17) 
and the anti-inflammatory M2-phenotype that is associated with IL-10 (18-20). Therefore, 
substances capable of selectively modulating the polarization of macrophages towards the anti-
inflammatory M2-phenotype and concomitantly reducing the pro-inflammatory M1-phenotype 
and its related secretagogues like TNF-α, IL-6, IL-1β, MIP-1α, MCP-1 and abates excessive 
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hepatic triglycerides and hepatic cholesterol may suppress and/or retard the progression of NAFLD 
to more severe conditions like hepatic cirrhosis.  
Fatty liver contributes significantly to obesity-related morbidity and mortality (21-23). 
Pharmacological agents that can rescue the liver from lipotoxicity by restoring adipose tissue 
insulin sensitivity or preventing activation of inflammatory and oxidative insults hold promise in 
the treatment and management of NAFLD, although, their long-term safety and efficacy remains 
to be clearly established (24). The soaring prevalence of NAFLD necessitates the development of 
new therapeutic modalities to improve and possibly reverse the clinical symptoms of NAFLD. An 
interesting physiological enzyme that could be explored in this regard is heme-oxygenase (HO). 
HO is a microsomal enzyme with two active isoforms HO-1 (inducible) and HO-2 (constitutive), 
while the third isoform, HO-3 is a pseudo-transcript of HO-2 without catalytic activity (14). The 
HO-system can be pharmacologically enhanced to modulate physiological functions and combat 
adversity in tissue (14), (25-27). Although, emerging evidence indicates that an upregulated HO-
system is capable of suppressing visceral adiposity (28-29), however, the effect of the HO-system 
on hepatic adiposity has not been reported. More-importantly, the role of the HO system on 
hepatocyte ballooning injury has not been reported. Similarly, the pathophysiology of hepatocyte 
ballooning injury in Zucker diabetic fatty rats (ZDFs), a model characterized by obesity and type-
2 diabetes, with aberrant hepatic response to insulin (30) and impaired hepatic lipid metabolism 
(31) remains largely unclear. Furthermore, the role of the HO-system on macrophage M1/M2-
phenotype in hepatic tissue from ZDFs has not been reported. Understanding the 
pathophysiological perturbations that accompanies hepatic impairment would have important 
implications for the prevention and treatment of diseases associated with fatty liver.  
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Therefore, this study will examine the effects of the HO-system on the pathophysiology of 
hepatocyte ballooning, macrophage M1/M2-phenotypes and related cytokines and chemokines 
such as TNF-α, IL-6, IL-1β, MIP-1α and MCP-1α, IL-10 in the liver of ZDFs. In addition, the 
effects of hemin therapy on extracellular-matrix/profibrotic proteins implicated in hepatic injury 
like osteopontin, transforming growth factor-beta (TGF-β1), fibronectin and collagen-IV (32-
36) were examined. 
4.3 Materials and methods 
 
4.3.1 Animals and treatment groups 
 
Our experimental protocol was approved by the Animal Care and Research Ethics 
Committee of University of Saskatchewan, which is in conformity with the Guide for Care and 
Use of Laboratory Animals by the Canadian Council on Animal Care and the National Institutes 
of Health (NIH Publication No. 85-23, revised 1996). Male ZDFs of twelve weeks and age/sex-
matched Zucker-lean (ZL) littermates were bought from Charles River (Willington, MA, USA), 
and housed at 21°C with 12-hour light/dark cycles, fed with Purina 5008 diet and had access to 
drinking water ad libitum. The animals were allowed to accommodate for two weeks. At 14 weeks 
of age, the animals were randomly assigned to the following experimental groups (n = 6 per 
group): (A) controls (ZDF and ZL), (B) hemin-treated ZDF and ZL, (C) ZDF + hemin + 
SnMP, (D) ZDF + SnMP, and (E) ZDF + vehicle dissolving hemin and SnMP. The HO-inducer, 
hemin (Sigma, St Louis, MO) was administered twice weekly for a duration of eight weeks at a 
dose of 30 mg/kg intraperitoneally, while the HO-inhibitor, stannous-mesoporphyrin (SnMP, 
Porphyrin Products, Logan, UT) was given at a dose of (2 mg/100 g body weight) by 
intraperitoneal injection twice weekly for 8 weeks as we previously reported (29). During the 
treatment period body weight and glucose levels were determined on a weekly routine after 6 hrs 
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of fasting in metabolic cages using glucose-meter (BD, Franklin Lakes, NJ, USA). The 
experiments were terminated at the end of the 8-week treatment period, and the age of the animals 
was 22 weeks. Before killing, the animals were weighed and anaesthetized with pentobarbital 
sodium (50 mg/kg i.p.), and when the animals were fully unconscious blood was obtained by 
cardiac puncture. Subsequently, an incision was made in the peritoneum and the liver was carefully 
isolated, cleaned in ice-cold phosphate-buffered saline and weighed using an analytical balance 
(Precisa Instruments Ltd, Switzerland) as previously reported (37-39). The liver and plasma were 
used for biochemical assays. 
 
4.3.2 Histological, morphological and immunohistochemical analysis of liver tissue 
Histological and morphometric studies were done as we previously reported (28). Liver 
sections of 5 µm were cut and treated with Masson’s trichrome staining to assess collagen 
deposition and hepatocyte ballooning injury using a microscope (Aperio Scan Scope, Model CS, 
Aperio Technology Inc, CA). Morphologic assessment of hepatocyte ballooning injury was done 
by a blinded researcher using a microscope (Aperio Scan Scope, Model CS, Aperio Technology 
Inc, CA), and analyzed using Aperio Image Scope V11.2.0.780 software (Aperio, e-Pathology 
Solution, CA). Liver sections were magnified at 200X, and 20 random snaps shots were taken per 
slide for each experimental group of 4-6 animals (80-120 images per group). The images were 
scored semi-quantitatively by a blinded researcher as we previously reported (28, 29). 
Immunohistochemistry was done as we previously reported (40). Sections of 5 µm of 
whole liver sections were treated with bovine serum albumin in phosphate buffered saline to block 
non-specific staining and incubated overnight with ED1 antibody (1∶500 dilution, Santa Cruz 
Biotechnology, CA). Subsequently, the liver sections were incubated with goat anti-mouse IgG 
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for 30 minutes (1∶200 dilution; Jackson ImmunoResearch Laboratories, Inc., ME, USA). 
Immunohistochemical staining was done using the standard avidin-biotin complex method with 
the chromagen 3,3′-diaminobenzidine (DAB) at the final detection step. The liver sections were 
scanned using a virtual microscope (Aperio Scan Scope, Model CS, Aperio Technology Inc, CA). 
Macrophages (brown from immune-stained sections) were quantified by a blinded researcher by 
manually counting the positively-stained ED1 cells under 200 X magnification in 15 randomized 
non-overlapping fields, and only distinct ED1-stained cells from all experimental groups were 
taken into consideration. 
 
4.3.3 Determination of HO activity and HO-1 concentration 
Liver HO activity was measured as bilirubin production using our established method (41-
43). The amount of bilirubin in each sample was determined spectrophotometrically (extinction 
coefficient for bilirubin 40 mM−1cm−1), and expressed as nmole/mg protein/hour. Hepatic HO-1 
concentration was determined using enzyme-linked immunosorbent assay (ELISA, Stressgen-
Assay Design, Ann Arbor, MI, USA) as we previously reported (41-43). 
 
4.3.4 Measurement of TNF-α, IL-6 and IL-1β 
The levels of TNF-α, IL-6 and IL-1β in the liver was assessed by using ELISA kits 
(Immuno-Biological Laboratories Co Ltd, Takasaki-shi, Gunma, Japan) following to the 
manufacturer’s instructions and read at 450 nm in a plate reader (SpectraMax 340PC, Molecular 
Device, CA, USA) as we previously reported (29). 
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4.3.5 Western immunoblotting 
The liver was homogenized (1∶10, w:v) in 10 mM Tris-buffered saline (20 mM Tris-HCl, 
pH 7.4, 0.25 M sucrose, and 1 mM EDTA) in the presence of a cocktail of protease inhibitors, 
centrifuged, and proteins extracted and quantified as we previously reported (44, 45). Aliquots of 
50 µg of proteins were loaded on SDS-polyacrylamide gel, and the fractionated proteins were 
electrophoretically transferred to nitrocellulose paper. Non-specific bindings were blocked with 
3% non-fat milk, and incubated overnight with primary antibodies against ED1, ED2, CD206, IL-
10, TGF-β1/2/3, collagen-IV, fibronectin and osteopontin (Santa Cruz Biotechnology, CA, USA). 
Anti-mouse Beta-actin (Sigma St Louis, MO, USA) was used as control to ascertain equivalent 
loading. After washing, blots were incubated with anti-rabbit IgG conjugated to horseradish 
peroxide (Bio-Rad, CA, USA), and the immuno-reactivity visualized using enhanced horseradish 
peroxide/luminol chemiluminescence reagent (Perkin Elmer Life Sciences, Boston, MA, USA). 
Densitometric analysis was done with UN-SCAN-IT software (Silk Scientific, Utah, USA). 
 
4.3.6 Determination of cGMP 
The concentration of cGMP in the liver determined using an enzyme-immunoassay kit 
(Cayman Chemical, Ann Arbor, MI, USA) as previously described (41, 42). Briefly, homogenized 
liver tissue was treated with 6% trichloroacetic acid at 4°C in the presence of 3′-isobutyl-1-
methylxanthine to inhibit phosphodiesterase activity. The samples were subsequently centrifuged 
at 2000 g for 15 minutes and the supernatant was recovered, washed with water-saturated diethyl 
ether and the upper ether layer aspired and discarded while the aqueous layer containing cGMP 
was recovered and lyophilized. The dry extract was dissolved in 1-ml assay buffer and the cGMP 
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was assessed according to the manufacturer’s instruction and expressed as picomol per mg of 
protein. 
 
4.3.7 Determination of MCP-1 and MIP-1α 
The concentrations of macrophage-inflammatory-protein-1-alpha (MIP-1α) and 
macrophage-chemoattractant-protein-1 (MCP-1) in the liver were determined using ELISA kits 
(OmniKine™, Assay Biotechnology Company Inc, Sunnyvale, CA). All samples were assayed in 
triplicates following the manufacturer’s instructions. 
 
4.3.8 Determination of triglycerides and total cholesterol 
Total-cholesterol and triglycerides were measured in liver homogenates and plasma using 
cholesterol and triglycerides assay kits (Cayman Chemical, Ann Arbor, MI, USA) following 
instructions from the manufacturer. 
 
4.3.9 Statistical analysis 
All data are expressed as means ± SEM from at least four independent experiments unless 
otherwise stated. Statistical analyses were done using two-way ANOVA, by means of Statistical 
Analysis System (SAS), software, version 9.3 (SAS Institute Inc., Cary, NC, USA) and Student’s t-
test. Group differences at the level of p<0.05 were considered statistically significant. 
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4.4 Results 
4.4.1 Hemin therapy potentiates the HO-system, normalized glycaemia and reduced liver 
hypertrophy 
The administration of the HO-inducer, hemin, to ZDFs normalized glycemia (26.3 ± 
2.5 vs 8.3 ± 1.4 mmol/L, p<0.01) and reduced liver-to-body weight ratio, an important index of 
liver hypertrophy (46) (54.8 ± 1.8 vs 40.7 ± 1.5 g/kg body weight, p<0.01) (Table 4-1). In contrast, 
co-administrating hemin and the HO-inhibitor, SnMP abolished the effect of hemin on liver 
hypertrophy (54.8 ± 1.8 vs 55.2 ± 2.3 g/kg body weight) and glycaemia (26.3 ± 2.5 vs 29.4 ± 3.7 
mmol/L). On the other hand, treatment with hemin together with SnMP resulted in a slight 
reduction of body-weight, which was less than 10% (Table 4-1). The body-weight loss may not be 
due to toxicity because we recently reported that important indices of toxicity such as gamma-
glutamyltransferase, plasma alanine aminotransferase and aspartate aminotransferase were within 
normal range (42). 
Although, body-weight loss may affect glucose levels, it is unlikely in this situation 
because the slight loss of body-weight in hemin-treated ZDFs and hemin + SnMP-treated ZDFs 
were accompanied by opposing glycemic effects (Table 4-1). Accordingly, in hemin-treated ZDFs 
there was reduction of hyperglycemia, whereas co-administering hemin and the HO-blocker, 
SnMP abolished the effects of hemin on glycaemia, suggesting that the HO system may have an 
intrinsic anti-diabetic effect. 
To further investigate the role of the HO system on hyperglycemia and liver hypertrophy, 
we measured important components of the HO system such as HO-1 and HO-activity in the liver. 
Our results indicate that in ZDF-control, the basal HO-1 and HO-activity were significantly 
depressed as compared to the ZL-controls (Figs. 4-1A and 4-1B). Interestingly, hemin 
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administration greatly enhanced the aberrant HO-1 and HO activity in ZDFs, whereas the co-
administration of hemin together with the HO inhibitor, SnMP nullified the effect of hemin. 
Since enhanced HO activity is accompanied by increased production of endogenous of 
carbon monoxide that would in turn enhance cGMP (42), we measured cGMP. Moreover, both 
cGMP and carbon monoxide are known to enhance glucose metabolism (47, 48). In ZDF-controls, 
the basal levels of cGMP were markedly reduced as compared to ZL-controls (Fig. 4-1C). 
However, treatment with hemin robustly enhanced cGMP in ZDFs (Fig. 4-1C), suggesting a role 
of the HO-cGMP axis in the normalization of hyperglycemia in hemin-treated ZDFs (Table 4-1). 
In contrast, co-administering hemin with SnMP reversed the effects of hemin. 
Hemin therapy also enhanced HO-1, HO-activity and cGMP levels in ZL-controls, although, 
the magnitude was smaller as compared to ZDFs, suggesting greater selectivity of hemin in 
diseased condition. The vehicle dissolving hemin and SnMP had no effect on any of the measured 
parameters. 
 
4.4.2 Hemin therapy abated the elevated basal levels of inflammatory cytokines in the liver 
of ZDFs 
Given that elevated inflammation due to TNF-α, IL-6 and IL-1β are amongst the causative 
factors of liver fibrosis and liver steatosis (10), and high levels of TNF-α, IL-6 and IL-1β are 
known to deregulate glucose metabolism (14, 49), we measured the levels of these cytokines in 
the liver. Our results indicate that the basal levels of TNF-α, IL-6 and IL-1β in ZDF-controls were 
significantly elevated as compared to the ZL-controls (Figs. 4-2A, 4-2B and 4-2C). Interestingly, 
the normalization of glycaemia in hemin-treated ZDFs was accompanied by the attenuation of 
TNF-α, IL-6 and IL-1β, whereas co-treatment of hemin and the HO-inhibitor, SnMP, reversed the 
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effects of hemin (Figs. 4-2A, 4-2B and 4-2C). Hemin therapy also attenuated TNF-α, IL-6 and IL-
1β in the ZL-controls, although to a lesser extent as compared to ZDFs. 
 
4.4.3 Treatment with hemin abated inflammatory chemokines such as MCP-1 and MIP-1α 
in hepatic tissue of ZDFs 
To further investigate the effects of hemin therapy on liver inflammation and hepatic 
lesions, we measured MIP-1α and MCP-1 since these chemokines trigger macrophage infiltration 
and cause hepatic injury (12, 13). In ZDF-controls, the basal levels of MCP-1 levels were markedly 
elevated as compared to ZL-controls (Fig. 4-3A), but were abated by hemin, whereas the co-
treatment of hemin with SnMP nullified the effects of hemin (Fig. 4-3A). Hemin therapy was also 
effective against MIP-1α in ZDFs (Fig. 4-3B). In ZDF-controls, the basal levels of MIP-1α were 
significantly enhanced as compared to ZL-controls but were reduced by hemin, whereas the co-
administration of hemin with SnMP abolished the effects of hemin (Fig. 4-3B). Hemin therapy 
also reduced MCP-1 and MIP-1α in ZL-controls, although, the effect in hemi-treated ZLs was 
smaller as compared to hemin-treated ZDFs. 
 
4.4.4 Hemin therapy abated plasma and hepatic triglycerides and cholesterol in ZDFs 
 
Since elevated hepatic triglycerides and high levels of hepatic cholesterol are common 
denominators of liver disease (7-9), we investigated the effects of hemin therapy on hepatic 
triglycerides and hepatic cholesterol. In ZDF-controls, the basal levels of liver triglycerides and 
liver cholesterol were significantly elevated as compared to ZL-controls (Figs. 4-4A and 4-4B). 
Similarly, the basal levels of plasma triglycerides and plasma cholesterol in ZDF-controls were 
markedly elevated (Figs. 4-4C and 4-4D). Interestingly, treatment with hemin greatly reduced the 
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elevated basal levels of liver triglycerides/cholesterol and plasma triglycerides/cholesterol (Fig. 4-
4). Hemin therapy also reduced triglycerides and cholesterol in ZL-controls, though to a lesser 
extent as compared to ZDFs. 
 
4.4.5 Hemin therapy abated the expression of markers for the pro-inflammatory M1-
macrophage, while enhancing markers for the anti-inflammatory M2-phenotype in hepatic 
tissue 
Given that macrophage infiltration is implicated in hepatic impairment (50-52), we used 
specific markers namely, ED1 to quantify the pro-inflammatory M1-phenotype, and ED2, CD206 
and IL-10 for the assessment of anti-inflammatory M2-phenotype (19, 53, 54). Moreover, IL-10 
is protective against fatty liver disease (18). Our Western immunoblotting and relative 
densitometry revealed that the basal expression of ED1 in the liver of ZDF-controls was 
significantly elevated as compared to the ZL-controls (Fig. 4-5A). Interestingly hemin therapy 
significantly attenuated the elevated expression of the pro-inflammatory M1-phenotype marker, 
ED1 (Fig. 4-5A). 
To further investigate the effects of hemin on inflammation, we also determined the 
expression of the M2-phenotype. Our results indicate that the basal expression levels of different 
anti-inflammatory M2-phenotype markers including ED2, CD206 and IL-10 were markedly 
reduced in ZDF-controls as compared to ZL-controls (Figs. 4-5B, 4-5C and 4-5D). Interestingly, 
hemin therapy robustly enhanced the depressed basal expression levels of ED2 (Fig. 4-5B), CD206 
(Fig. 4-5C) and IL-10 (Fig. 4-5D), suggesting that hemin therapy may selectively modulate the 
polarization of macrophage toward the M2-phenotype that dampens inflammation. 
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4.4.6 Hemin therapy suppressed macrophage infiltration in the liver 
Since our Western immunoblotting data indicated that hemin therapy abated the expression 
of  ED1 a marker of the pro-inflammatory macrophage M1-phenotype (Fig. 4-5A), we did 
immunohistochemistry to assess macrophage infiltration in hepatic tissue (Fig. 4-6A). Images of 
hepatic sections from ZL-controls were almost devoid of cells with the characteristic dark-brown 
ED1-positive staining. In contrast, liver sections from ZDF-controls showed marked increase of 
ED1-positive dark-brown cells as compared to ZL-controls, suggesting increased macrophage 
infiltration in ZDFs (Fig. 4-6A). Interestingly, hemin therapy greatly attenuated the number of 
dark-brown stained macrophages, suggesting reduction of macrophage infiltration in hemin-
treated ZDFs. These observations were further confirmed by quantitative ED1 scoring (Fig. 4-6B), 
which showed a significant reduction of ED1-positive cells in hemin-treated ZDFs as compared to 
ZDF-controls. 
 
4.4.7 Hemin reduced the expression of profibrotic and extracellular matrix proteins in the 
liver 
Since elevated deposition of extracellular matrix is implicated in liver damage (32-36), we 
measured the levels of profibrotic and extracellular matrix proteins such as osteopontin, collagen, 
fibronectin and TGF-β in the liver. Moreover, TGF-β is known to activate hepatic fat to accentuate 
the deposition of extracellular matrix proteins (34). In ZDF-controls the basal expression of TGF-
β was significantly elevated as compared to ZL-controls (Fig. 4-7A), but was greatly attenuated 
by hemin. 
Since TGF-β mobilizes the extracellular the matrix by stimulating fibronectin and collagen 
to cause fibrosis (55), so we also measured the expressions of fibronectin and collagen-IV. In ZDF-
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controls, the basal expressions of fibronectin and collagen-IV were significantly elevated as 
compared to ZL-controls, but were attenuated by hemin therapy (Figs. 4-7B and 4-7C). It is 
noteworthy that hemin effectively restored fibronectin to comparable levels as in the ZL-control, 
but collagen-IV was not reinstated to the levels of ZL-controls, suggesting that hemin may have 
greater selectivity against fibronectin. The reason for the selective effect is unknown. 
We also assessed the expression of osteopontin because osteopontin is implicated in 
hepatic fibrosis and injury (32). In ZDF-controls, the basal expression of osteopontin was markedly 
elevated as compared to ZL-controls, but was significantly reduced by hemin therapy, although, 
similar levels as observed in the ZL-controls were not reinstated (Fig. 4-7D). 
 
4.4.8 Hemin therapy suppressed hepatic histo-pathological lesions 
Hepatocyte ballooning injury and fibrosis are common histo-physiological denominators 
in fatty-liver diseases such as NAFLD (1, 5, 32, 34-36) To further investigate the effects of hemin 
therapy on liver lesions, we did histological and morphometric analyses using Masson’s trichrome 
staining. Our results indicate that sections from liver tissue obtained from ZL-controls had normal 
appearance and the central vein region was without hepatocyte ballooning injury (Fig. 4-8A). 
However, in ZDF-controls, there was greater hepatocyte ballooning injury with inflammatory cell 
infiltration around the central vein region, which interestingly were greatly attenuated in hemin-
treated ZDF (Fig. 4-8A). These observations were further confirmed by quantitative ballooning 
scoring (Fig. 4-8B), which showed a significant reduction of hepatocyte ballooning injury in 
hemin-treated ZDFs as compared to untreated ZDF-controls. 
To further investigate the effects of hemin therapy on hepatic morphology, fibrosis was 
assessed by Masson’s trichrome staining. Our results show that images of liver sections from the 
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ZL-controls appeared relatively healthy with little Mason’s trichrome staining (blue coloration), 
suggesting little fibrosis (Fig. 4-9). However, in ZDF-controls, greater fibrotic activity was 
observed, particularly around the portal spaces with some extension towards center-lobular zones. 
Interestingly, hemin therapy greatly reduced the fibrotic activity in ZDF (Fig. 4-9). 
 
4.5 Discussion 
The present study unveils several novel and/or important insights on the hepatoprotective 
effects of hemin therapy in the condition of obesity and type-2 diabetes including; (i) the hemin-
dependent suppression of hepatic levels of chemokines and cytokines such as MCP-1, MIP-1α, 
TNF-α, IL-6 and IL-1β implicated in hepatic injury; (ii) the reduction of plasma and hepatic 
triglycerides/cholesterol; (iii) the abrogation of extracellular matrix/profibrotic proteins in hepatic 
tissue including osteopontin, TGF-β, fibronectin and collagen; and (iv) the attenuation of 
hepatocyte ballooning injury to preserve hepatic morphology and function in ZDFs. Impaired 
hepatic function is a common phenomenon in non-alcoholic fatty liver disease (56), and with the 
rising prevalence and incidence of non-alcoholic fatty liver disease following the dramatic 
escalation of obesity, insulin resistance and overt diabetes worldwide (57), novel pharmacological 
agents capable of preserving hepatic function are needed. Accordingly, this study demonstrates 
that upregulating the HO-system with hemin abates inflammation, suppress hepatic adiposity and 
attenuate hepatocyte ballooning injury in ZDF, a model characterized by obesity, aberrant hepatic 
response to insulin, type-2 diabetes and impaired hepatic lipid metabolism (30, 31). Hepatic 
adiposity and inflammation are the hallmarks of non-alcoholic fatty liver disease (9, 56, 58). 
Therefore, the elevated basal levels of hepatic triglycerides, hepatic cholesterol, macrophage 
infiltration, pro-inflammatory cytokines/chemokines including, TNF-α, IL-6, IL-1β, MIP-1α and 
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MCP-1 are among the multifaceted pathophysiological factors that accentuate inflammation 
during the progressive deterioration of hepatic morphology and function in ZDFs. 
In the present study, a signature of the ailing hepatic morphology in ZDFs was evidenced 
the severe hepatocyte ballooning injury. However, the administration of hemin therapy to ZDFs 
abated macrophage infiltration and pro-inflammatory mediators and improved hepatic 
morphology, whereas treatment with the HO-inhibitor, SnMP accentuated the levels of 
inflammatory cytokines and chemokines. Importantly, the hemin-induced selective enhancement 
the anti-inflammatory macrophage-M2-phenotype with parallel reduction of pro-inflammatory 
macrophage M1-phenotype observed in our study is an alternative anti-inflammatory mechanism 
by which the HO-system protects hepatic tissue. Although, one study had previously reported the 
effects of HO-1 promoter in macrophage polarization (59), the actual expression levels of M1 and 
M2 macrophage phenotypes were not measured, so our study provides more solid evidence on the 
role of the HO system on M1 and M2 during macrophage polarization. However, the present study 
may be just the tip of an iceberg and further investigations are needed to fully characterize the 
effects of upregulating the HO system with hemin on macrophage polarization in ZDF. 
Besides its effects against inflammation, hemin also suppressed osteopontin, an 
extracellular matrix-proteins is implicated in hepatic fibrosis and injury (32). Similarly, other 
extracellular matrix/profibrotic proteins such as TFG-β, collagen and fibronectin that impair liver 
function (32-36), were also reduced in hemi-treated ZDFs, with corresponding reduction of hepatic 
histo-pathological lesions like hepatocyte ballooning injury and fibrosis. Hemin therapy also 
potentiated the HO-system and cGMP in ZL-control rats and abated MIP-1α, MCP-1, TNF-α, IL-
6 and IL-1β although, the effect of hemin was less-intense in ZLs as compared to ZDFs with 
aberrant HO-system. Although, the reasons for this selective effect of hemin remain unclear, it is 
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possible that the HO-system in healthy ZLs is more stable than in unhealthy ZDFs with depressed 
HO-activity. Nevertheless, future studies should be designed to investigate this observation. 
The emerging cytoprotective role of the HO system in non-alcoholic fatty liver disease has been 
well-acknowledged (60, 61). Accordingly, the HO system has been shown to alleviate hepatic 
steatosis and necroinflammation in a mice model of experimental nutritional steatohepatitis (60). 
Similarly, the anti-oxidant effect of the HO system was amongst the mechanisms conferred 
protection against non-alcoholic fatty liver disease in mice and humans (61, 62). Therefore, the 
present study is a further testimony of the important hepatoprotective role of the HO system. 
Collectively, our study indicates that hemin therapy restores hepatic morphology by 
abating hepatic adiposity, suppressing liver macrophage infiltration, inflammation, fibrosis and 
extracellular/profibrotic proteins implicated in hepatic lesions. The selective enhancement of anti-
inflammatory macrophage-M2-phenotype with parallel reduction of pro-inflammatory 
macrophage M1-phenotype and related chemokines/cytokines like TNF-α, IL-6, IL-1β, MIP-1α 
and MCP-1 are among the multifaceted mechanisms by which hemin restore hepatic morphology. 
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Figure 4-1: Effects of the HO-inducer, hemin and the HO inhibitor SnMP, on hepatic levels of 
HO-1, HO activity and cGMP. Hemin therapy greatly increased the depressed (A) HO-1 
concentration, (B) HO-activity, and (C) cGMP levels in ZDFs, whereas the HO blocker, SnMP 
nullified the effects. Treatment of hemin to ZL also resulted to increased levels of HO-1, HO-
activity and cGMP in ZLs, thought less effectively as compared to ZDFs. Bars represent means ± 
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SEM; n = 6 rats per group (*p<0.05, **p<0.01 vs Control-ZL; †p<0.05, ††p<0.01 vs Control-ZL 
or Control-ZDF; §p<0.05, §§p<0.01 vs ZL + Hemin). 
 
 
Figure 4-2: Effects of hemin, the HO inducer and SnMP, the HO inhibitor on liver levels of TNF-
α, IL-6 and IL-1β. Hemin therapy attenuated the elevated basal levels of (A) TNF-α, (B) IL-6 and 
(C) IL-1β in ZDFs, while the HO blocker, SnMP reversed the effects. Hemin therapy also lowered 
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TNF-α, IL-6 and IL-1β levels in ZLs. Bars represent means ± SEM; n = 6 rats per group (*p<0.01 
vs Control-ZL; †p<0.05, ††p<0.01 vs Control-ZL or Control-ZDF). 
 
 
 
Figure 4-3: Effects of hemin, the HO inducer and SnMP, the HO inhibitor on hepatic levels of 
MCP-1 and MIP-1α. Hemin therapy suppressed the elevated basal levels of (A) MCP-1 and (B) 
MIP-1α in ZDFs, but the HO blocker, SnMP abolished the effects of hemin. Treatment with hemin 
also reduced MCP-1 and MIP-1α in ZLs. Bars represent means ± SEM; n = 6 rats per group 
(*p<0.01 vs Control-ZL; †p<0.05, ††p<0.01 vs Control-ZL or Control-ZDF). 
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Figure 4-4: Effects of hemin, the HO inducer and SnMP, the HO inhibitor on hepatic triglycerides, 
hepatic cholesterol, plasma triglycerides and plasma cholesterol. Hemin therapy markedly reduced 
the elevated basal levels of (A) liver triglycerides, (B) liver cholesterol, (C) plasma triglycerides 
and (D) plasma cholesterol in ZDFs, whereas the HO blocker, SnMP nullified the effects. Hemin 
therapy also lowered hepatic triglycerides/cholesterol and plasma triglycerides/cholesterol in ZLs. 
Bars represent means ± SEM; n = 6 rats per group (*p<0.01 vs Control-ZL; †p<0.05, ††p<0.01 vs 
Control-ZL or Control-ZDF). 
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Figure 4-5: Effects of hemin on hepatic expression of ED1, ED2, CD206 and IL-10. 
Representative Western immunoblot and relative densitometric analyses of expressed protein 
normalized with b-actin indicates that hemin therapy suppressed the elevated basal expression of 
(A) the pro-inflammatory macrophage M1-phenotype marker, ED, but enhanced the expression of 
several anti-inflammatory macrophage M2-phenotye markers such as (B) ED2, (C) CD206 and 
(D) IL-10 in ZDFs. Bars represent means ± SEM; n = 4 rats per group (*p<0.01 vs Control-ZL, 
†p<0.05 vs Control-ZL). 
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Figure 4-6: Effect of hemin therapy on macrophage infiltration in the liver. (A) Representative 
image indicates that macrophage infiltration (ED1-positive cells stained dark brown) in liver 
sections were elevated in ZDF-controls as compared to ZL-controls, but were reduced in hemi-
treated ZDFs. (Magnification x200). (B) Quantitative analyses per field revealed that in ZDF-
controls, macrophage infiltration was markedly elevated as compared to ZL-control, but was 
significantly reduced in hemi-treated ZDFs. Bars represent means ± SEM; n = 4-6 rats per group 
(*p<0.01 vs all groups). 
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Figure 4-7: Effect of hemin therapy on liver expression of TGF-β, fibronectin, collagen-IV and 
osteopontin in ZDFs. Representative Western immunoblots, and relative densitometry revealed 
that hemin therapy markedly reduced the elevated basal expression of (A) TGF-β, (B) fibronectin, 
(C) collagen-IV and (D) osteopontin in ZDFs. Bars represent means ± SEM; n = 4 rats per group 
(*p<0.01 vs Control-ZL; †p<0.05 vs Control-ZL). 
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Figure 4-8: Effect of hemin therapy on hepatic histo-pathological lesions. (A) Representative 
image after Masson’s trichrome staining revealed severe hepatocyte ballooning injury with 
inflammatory cell infiltration around the central vein (CV) region in ZDFs, which interestingly 
were attenuated in hemin-treated ZDF (Magnification x200). (B) Semi-quantitative evaluation 
showed that hemin therapy significantly reduced hepatocyte ballooning injury in ZDFs. Bars 
represent means ± SEM; n = 4-6 rats per group (*p<0.01 vs all groups). 
A 
B 
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Figure 4-9: Effect of hemin therapy on hepatic fibrosis, determined by Masson’’ trichrome 
staining. (A) Representative image following Masson’s trichrome staining revealed greater fibrotic 
activity (blue coloration), particularly around the portal spaces with some extension toward center-
lobular zones in sections from ZDFs, but interestingly were reduced in hemin-treated ZDF 
(Magnification x200). 
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CHAPTER 5 
 
The heme oxygenase system suppresses perirenal visceral adiposity, abates 
renal inflammation and ameliorates diabetic nephropathy in Zucker diabetic 
fatty rats 
 
Joseph Fomusi Ndisang, Ashok Jadhav, Manish Mishra 
 
This chapter has been published as a research paper in 
PLOS One, January 2014, Volume 9, Issue 1, e87936 
 
Contribution: The article, PLoS One. 2014;9(1): e87936 was co-authored with my supervisor 
Joseph Fomusi Ndisang and Ashok Jadhav. This chapter describes the effects of the hemin-induced 
HO system on perirenal visceral obesity-induced diabetic nephropathy in an obese rat model of 
T2D. This study collectively suggested that both visceral and perirenal obesity severely affect the 
renal architecture and physiological functions and participates in development of nephropathy in 
obese-diabetic individuals. In this condition, HO upregulation not only reduce the renal injuries 
but also improved renal functions and suppress the development of nephropathy. In this study, I 
was involved in performing the experiments and statistical analyses along with other co-authors.  
The idea of this study was conceived by my supervisor Joseph Fomusi Ndisang and financially 
supported by the Heart and Stroke Foundation of Saskatchewan, Canada grant to Dr. Ndisang. 
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5.1 Abstract 
The growing incidence of chronic kidney disease remains a global health problem. Obesity is a 
major risk factor for type-2 diabetes and renal impairment. Perirenal adiposity, by virtue of its 
anatomical proximity to the kidneys may cause kidney disease through paracrine mechanisms that 
include increased production of inflammatory cytokines. Although, heme-oxygenase (HO) is 
cytoprotective, its effects on perirenal adiposity and diabetic nephropathy in Zucker-diabetic fatty 
rats (ZDFs) remains largely unclear. Upregulating the HO-system with hemin normalized 
glycemia, reduced perirenal adiposity and suppressed several pro-inflammatory/oxidative 
mediators in perirenal fat including macrophage-inflammatory-protein-1α (MIP-1α), endothelin 
(ET-1), 8-isoprostane, TNF-α, IL-6 and IL-1β. Furthermore, hemin reduced ED1, a marker of 
proinflammatory macrophage M1-phenotype, but interestingly, enhanced markers associated with 
anti-inflammatory M2-phenotype such as ED2, CD206 and IL-10, suggesting that hemin 
selectively modulates macrophage polarization towards the anti-inflammatory M2-phenotype. 
These effects were accompanied by increased adiponectin, HO-1, HO-activity, atrial-natriuretic 
peptide (ANP), and its surrogate marker, urinary-cGMP. Furthermore, hemin reduced renal 
histological lesions and abated pro-fibrotic/extracellular-matrix proteins like collagen and 
fibronectin that deplete nephrin, an important transmembrane protein which forms the scaffolding 
of the podocyte slit-diaphragm allowing ions to filter but not massive excretion of proteins, hence 
proteinuria. Correspondingly, hemin increased nephrin expression in ZDFs, reduced markers of 
renal damage including, albuminuria/proteinuria, but increased creatinine-clearance, suggesting 
improved renal function. Conversely, the HO-blocker, stannous-mesoporphyrin nullified the 
hemin effects, aggravating glucose metabolism, and exacerbating renal injury and function. The 
hemin effects were less-pronounced in Zucker-lean controls with healthy status, suggesting greater 
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selectivity of HO in ZDFs with disease. We conclude that the concomitant reduction of 
proinflammatory/oxidative mediators, macrophage infiltration and profibrotic/extracellular-
matrix proteins, coupled to increased nephrin, adiponectin, ANP, cGMP and creatinine clearance 
may account for improved renal function in hemin-treated ZDFs. These findings suggest that HO-
inducers like hemin may be explored against the co-morbidity of perirenal adiposity and diabetic 
nephropathy. 
 
5.2 Introduction 
Recent epidemiological data indicates that more than 1.6 billion adults worldwide are 
overweight and over 400 million are obese (1, 2). Obesity is a major risk factor for insulin-resistant 
type-2 diabetes mellitus (T2D), dyslipidemia, hypertension and impaired renal function (3-6). One 
of the common causes of morbidity and mortality in T1D and T2D patients is diabetic nephropathy, 
a micro-vascular complication of diabetes that may lead to end-stage-renal-disease (ESRD) [7]. 
The growing incidence of chronic kidney disease is widely recognized as a global health problem. 
The prevalence and incidence of ESRD is greater in patients co-morbid with obesity and 
diabetes (8). Moreover, perirenal adiposity is an independent predictor of kidney dysfunction in 
T2D (9). Thus, novel strategies that could simultaneously combat obesity, insulin resistant T2D 
and diabetic nephropathy are needed. 
It is widely acknowledged that the site of fat accumulation may be more critical for health 
than the overall amount of fat tissue (10). Moreover, adipocytes from different body compartments 
have distinct inflammatory phenotype based on their anatomical location (10). Generally, visceral 
or intra-abdominal adiposity is more-malignant than subcutaneous adiposity, although, they are 
both implicated in the pathogenesis of obesity-related cardio-metabolic complications like insulin 
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resistance, T2D and renal disease (10, 11). Perirenal adiposity, in comparison to central obesity is 
a greater risk factor for renal complications (9). Emerging evidence indicates that perirenal 
adiposity may better reflect the risks commonly associated with increased visceral fat 
accumulation and particularly those related to impaired renal function (9). By virtue of its 
anatomical and functional proximity to the kidney, perirenal adiposity may be even more 
malignant than central adiposity. Perirenal adiposity can lead to renal impairment through 
paracrine mechanisms that include increased production of inflammatory cytokines including 
tumor necrosis factor alpha (TNF-α), interleukin (IL)-6 and IL-1β and interestingly, these 
cytokines are also implicated in dysfunctional glucose metabolism (12-16). Moreover, increased 
perirenal adiposity has been shown to compress renal vessels and renal parenchyma, causing 
elevated renal interstitial hydrostatic fluid with reduction of renal and tubular flow rates (17). 
Therefore, novel formulations capable of reducing perirenal adiposity and its deleterious cytokines 
are needed to safeguard renal morphology and function. 
In diabetic nephropathy, the expression of nephrin is deregulated (18), and elevated levels 
of pro-fibrotic/extracellular matrix proteins such as collagen and fibronectin are implicated in the 
aberrant expression of nephrin (19). Nephrin is an important transmembrane zipper-like protein 
which is critical for the formation of the scaffolding of the podocyte slit diaphragm of the 
glomerular barrier, a structure that regulates the aperture size of the renal filtration barrier, 
selectively allowing the filtration of small molecules like ions, but not larger molecules like 
proteins (20-22). A defect in nephrin may cause massive excretion of proteins, hence 
proteinuria (20-22). Therefore, agents capable of reducing excessive deposition of pro-
fibrotic/extracellular matrix proteins may be useful to preserve nephrin, and thus improve renal 
dysfunction due to proteinuria. 
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Although, we recently reported the insulin sensitizing and cytoprotective effects of the 
heme oxygenase (HO) inducer, hemin, in Zucker diabetic fatty rats (ZDFs) (23, 24), the effects of 
the HO system on perirenal adiposity remains largely unclear. Similarly, the effects of upregulating 
the HO system with hemin on macrophage polarization in renal tissue have not been reported. The 
two common polarized macrophage phenotypes are the pro-inflammatory M1-phenotype and anti-
inflammatory M2-phenotype, and these subtypes are often referred to as classically activated 
macrophages (M1-macrophages) and alternatively activated macrophages (M2 macrophages) (13, 
25, 26). Importantly, we will investigate whether hemin therapy can selectively modulate M1 and 
M2 macrophages in the kidneys to counteract inflammatory insults. Whether the effects of hemin 
therapy on M2 macrophage will be accompanied by increased expression of the anti-inflammatory 
cytokine, IL-10 (27) will also be investigated. Given that macrophage-inflammatory-protein-1α 
(MIP-1α) is a chemokine implicated in macrophage infiltration (28), we will also assess the effect 
of hemin therapy on this protein. 
Therefore, this study will unveil the effects of hemin therapy on renal expression of the 
anti-inflammatory macrophage M2-phenotye, the pro-inflammatory macrophage M1-phenotype 
and related chemokines/cytokines including MIP-1α, TNF-α, IL-6 and IL-1β as well as nephrin 
and pro-fibrotic/extracellular matrix proteins such as collagen and fibronectin. Importantly, the 
effects of the HO-system on perirenal adiposity, MIP-1α, M1/M2 macrophage and nephrin in 
ZDFs have not been reported. Since the mechanisms by which hemin therapy improves renal 
function in the co-morbid conditions of obesity and insulin-resistant diabetes have not been 
completely characterized, this study will unmask novel effects of hemin on perirenal adiposity and 
diabetic nephropathy in ZDFs, and add more insights in the multifaceted complication of diabetic 
nephropathy. 
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5.3 Materials and methods 
5.3.1 Animals groups and plasma measurements 
The experimental protocol was approved by University of Saskatchewan Standing Committee on 
Animal Care and Research Ethics. Male ZDF of 12 weeks and age/sex-matched litter Zucker lean 
(ZL) rats were purchased from Charles River (Willington, MA, USA). The animals were housed 
at 21°C with 12-hour light/dark cycles, fed with fed with Purina 5008 diet and had access to 
drinking water ad libitum. After a week of acclimation, the animals were randomly assigned to the 
following experimental groups: (A) controls (ZDF and ZL), (B) hemin-treated ZDF, (C) hemin-
treated ZL, (D) ZDF treated with hemin and the HO inhibitor, stannous mesoporphyrin (SnMP), 
(E) ZDF treated with SnMP alone, and (F) ZDF and ZL treated with vehicle dissolving hemin and 
SnMP. Hemin (15 mg/kg i.p.) and SnMP (5 mg/100 g body weight, i.p.) were prepared and 
administered twice weekly for a duration of 8 weeks as we previously described (24, 29, 30). 
Fasting glucose was monitored weekly with a diagnostic auto-analyzer (BD, Franklin Lakes, NJ) 
after 6 hrs of fasting as previously reported (31-34). At the end of the 8-week treatment, the animals 
were placed in metabolic cages for 24 hrs urine collection. Proteinuria, albuminuria and creatinine 
were measured as previously reported (35). A day prior to killing, the animals were weighed, 
anaesthetized with pentobarbital sodium (50 mg/kg i.p.), killed and the perirenal fat pads dissected 
free, blotted off water and weighed using an analytical balance (Precisa XR 205SM-DR, Precisa 
Instruments Ltd, Switzerland). 
 
5.3.2 HO-1 concentration and HO activity assay 
HO activity in the perirenal adipose tissue was measured as bilirubin production using our 
established method (24, 36, 37). Briefly, the perirenal fat was homogenized on ice in 4 volumes 
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of 5∶1 K/Na 100 mmol/L phosphate buffer with 2 mmol/L MgCl2 (HO-activity buffer), centrifuged 
at 13,000 rpm for 15 minutes. Aliquots of 100 µl were collected from the supernatant and 
transferred into another beaker containing 500 µl of a mixture of 0.8 mmol/L nicotinamide 
dinucleotide phosphate, 20 µmol/L hemin, 2 mmol/L glucose-6-phosphate, 0.002 U/µl glucose-6-
phosphate dehydrogenase and 100 µl liver cytosol as source of biliverdin reductase. The reaction 
was done in darkness for 1 hour at 37°C, and was stopped by adding 500 µl of chloroform. 
Thereafter, bilirubin was extracted by vigorously agitating the tubes and centrifuging at 
13,000 rpm for 5 minutes, and the chloroform layer collected and read on a spectrophotometer at 
464 nm minus the background at 530 nm. The amount of bilirubin in each sample was determined 
spectrophotometrically (extinction coefficient for bilirubin 40 mM−1cm−1), and expressed as 
nmole/mg protein/hour. The protein content was measured using Bradford assay. As a positive 
control, spleen tissue was used. 
Perirenal fat HO-1 concentration was determined by enzyme-linked immunosorbent assay 
(ELISA) (EKS-810A, Stressgen-Assay Design, Ann Arbor, MI, USA) according to the 
manufacturer’s instructions as we previously reported (34, 38, 39). 
 
5.3.3 Histological, morphological and immunohistochemical analyses of kidney tissue 
Histology and morphometric analyses were done as we previously described (40). Whole kidney 
sections of 5 µm were cut and treated with Masson’s trichrome staining to assess collagen 
deposition. Morphologic assessment of collagen deposition was determined by a blinded 
researcher using a virtual microscope (Aperio Scan Scope Model CS, Aperio Technology Inc, 
CA), and analyzed using Aperio Image Scope V11.2.0.780 software (Aperio, e-Pathology 
Solution, CA). Each kidney section was magnified at 200x, and 20 random snaps were taken per 
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slide per group of 4-6 animals (80-120 images per group), and subsequently scored semi-
quantitatively by a blinded researcher as we previously reported (29, 40).  
Immunohistochemistry was done as we previously reported (35). Sections of 5 µm of 
whole kidney sections were treated with bovine serum albumin in phosphate buffered saline to 
block non-specific staining and incubated overnight with ED1 (1∶500 dilution, sc-59103, Santa 
Cruz Biotechnology, CA, USA) or HO-1 (1∶200 dilution, OSA-150, Stressgen Biotechnologies, 
Ann Arbor, MI, USA). Thereafter, the kidney sections were incubated with goat anti-mouse IgG 
for 30 min (1∶200 dilution; Jackson ImmunoResearch Laboratories, Inc., ME, USA). 
Immunohistochemical staining was performed using the standard avidin-biotin complex method 
with the chromagen 3,3′-diaminobenzidine (DAB) used at the final detection step. The kidney 
sections were scanned using a microscope (Aperio Scan Scope Model CS, Aperio Technology Inc, 
CA). Macrophages (brown from immune-stained sections) were quantified by manually counting 
the positively stained cells under a standard light microscope under 200X magnification in 20-22 
randomized non-overlapping fields in the cortical region of kidney section, macrophages were 
infiltrated between intertubular spaces, in the glomeruli and perivascular region. 
 
5.3.4 Western immunoblotting 
The kidney was homogenized (1∶10, w:v) in 10 mM Tris-buffered saline (20 mM Tris-
HCl, pH 7.4, 0.25 M sucrose, and 1 mM EDTA) in the presence of freshly prepared cocktail of 
protease inhibitors, centrifuged, and proteins extracted as we previously described (36, 41). The 
proteins were extracted and quantified by Bradford assay, and aliquots of 50 µg were loaded on 
SDS-polyacrylamide gel. 
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The fractionated proteins were electrophoretically transferred to nitrocellulose paper and 
non-specific bindings blocked with 3% non-fat milk, and incubated overnight with primary 
antibodies against ED1, ED2, CD206, IL-10, nephrin, collagen-IV, and fibronectin (Santa Cruz 
Biotechnology, CA, USA). Anti-mouse glucose-6-phosphate dehydrogenase (G6PDH) antibody 
(Sigma St Louis, MO, USA) was used as control (42, 43) to ascertain equivalent loading. After 
washing, blots were incubated with anti-rabbit IgG conjugated to horseradish peroxide (Bio-Rad, 
CA, USA), and the immuno-reactivity visualized using enhanced horseradish peroxide/luminol 
chemiluminescence reagent (Perkin Elmer Life Sciences, Boston, MA, USA). Densitometric 
analysis was done with UN-SCAN-IT software (Silk Scientific, Utah, USA). 
 
5.3.5 Determination of endothelin-1 
Perirenal fat ET-1 was determined by EIA (Cayman Chemical, Ann Arbor, MI, USA) as 
we previously reported (38, 39). This immunometric assay is based on a double-antibody 
‘sandwich’ technique that detects ET-1 within the range of 0-250 pg/ml. In brief, supernatants 
from homogenized perirenal fat tissues were purified by cold spike extraction, concentrated and 
the absorbance read at 405 nm in a plate reader (SpectraMax 340PC, Molecular Device, CA, USA) 
as we previously reported (29). 
 
5.3.6 Determination of TNF-α, IL-6 and IL-1β 
Perirenal fat TNF-α, IL-6 and IL-1β were assessed by ELISA (Immuno-Biological 
Laboratories Co Ltd, Takasaki-shi, Gunma, Japan) according to the manufacturer’s instructions 
and read at 450 nm in a plate reader (SpectraMax 340PC, Molecular Device, CA, USA) as we 
previously reported (29). 
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5.3.7 Determination of 8-isoprostane 
8-isoprostane is a non-invasive index of oxidative stress. This was determined by EIA 
(Cayman Chemical, Ann Arbor, MI) as we previously reported (37). The tissues were 
homogenized in phosphate buffer containing 0.005% butylated hydroxy toluene in a ratio of 10 
µL buffer/mg tissue. Subsequently, an equal volume of 15% KOH was added to the homogenate. 
The samples were incubated at 40°C for an hour, followed by centrifugation, and the supernatant 
neutralized with KH2PO4 and the absorbance read at a wavelength of 412 nm in a microplate 
reader (SpectraMax 340PC, Molecular Device, CA, USA) and expressed as picograms per 
milligram of protein. 
 
5.3.8 Determination of atrial natriuretic peptide (ANP) 
Perirenal fat ANP was quantified by EIA (Cayman Chemical, Ann Arbor, MI, USA) as we 
previously reported (38). This assay is based on the competition between unlabeled rat ANP and 
a tracer, acetylcholinesterase, linked to rat ANP for limited specific rabbit anti-rat ANP antiserum 
sites. The complex rabbit antiserum-rat ANP (free ANP or tracer) binds to the mouse monoclonal 
anti-rabbit antibody that is attached to a well. Briefly, supernatants from homogenized tissue were 
aliquoted wells containing unlabeled rat ANP and a tracer. After washing, Ellman’s Reagent 
(enzymatic substrate for acetylcholinesterase) and a chromogen added to the wells forming a 
yellow coloration that was read at 405 nm in a plate reader (SpectraMax 340PC, Molecular Device, 
CA, USA). 
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5.3.9 Measurement of cGMP 
The concentration of urinary cGMP was measured by EIA (Cayman Chemical, Ann Arbor, 
MI, USA) as previously described (36, 44). Urine samples were treated with 6% trichloroacetic 
acid at 4°C in the presence of 3′-isobutyl-1-methylxanthine to inhibit phosphodiesterase activity 
and centrifuged at 2000 g for 15 mins. The supernatant was recovered, washed three times with 
water-saturated diethyl ether and the upper ether layer was aspired and discarded while the aqueous 
layer containing cGMP was recovered and lyophilized. The dry extract was dissolved in 1 ml assay 
buffer and the cGMP content measured according to the manufacturer’s protocol and expressed as 
picomol per mg of protein. 
 
5.3.10 Determination of macrophage-inflammatory-protein-1α (MIP-1α) 
The concentration of MIP-1α was determined in homogenized perirenal and kidney tissues 
using ELISA kits (OmniKine™, Assay Biotechnology Company Inc, Sunnyvale, CA). All samples 
were assayed in triplicates following the manufacturer’s instructions. 
 
5.3.11 Determination of Plasma Adiponectin 
Adiponectin was measured by ELISA (Phenix Pharmaceuticals, Inc, Burlingame, CA, 
USA) as we previously reported (23, 31-33). In brief, plasma was aliquoted into wells of a 
microplate containing adiponectin antibody, followed by treatment with horseradish peroxidase-
conjugated secondary antibody and streptavidin. Thereafter, the absorbance was read at 450 nm 
with a microplate (SpectraMax-340PC, Molecular Device, CA, USA). 
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5.3.12 Statistical analyses 
All data are expressed as means ± SEM from at least four independent experiments unless 
otherwise stated. Statistical analyses were done using two-way ANOVA and Student’s t-test. 
Group differences at the level of p<0.05 were considered statistically significant. 
 
5.4 Results 
5.4.1 Hemin therapy abated perirenal adiposity and reinstated normoglycemia in ZDFs 
The administration of hemin to ZDFs significantly reduced perirenal adiposity (Table 5-
1). This was accompanied by a parallel reduction of hyperglycemia to normal levels (26.8 ± 4.9 
vs 7.1 ± 1.5 mmol/L, p<0.01). In contrast, the co-administration of hemin and the HO-blocker, 
SnMP abolished the effect of hemin on perirenal adiposity and blood glucose, whereas treatment 
with SnMP alone aggravated perirenal adiposity and hyperglycemia suggesting a role of the HO 
system on the regulation of perirenal adiposity and glucose metabolism. The vehicle dissolving 
hemin and SnMP had no effect on blood glycemic and perirenal adiposity (Table 5-1). 
Hemin therapy was also administered to ZL control rats. In hemin-treated ZLs, a slight but 
significant reduction of perirenal adiposity and blood glucose was observed (Table 5-1). In hemin-
treated ZDFs, perirenal adiposity and glycemia were reduced by 56.1 and 73.5% respectively 
whereas in ZLs these same parameters were reduced by 21.9 and 11.4% respectively. These effects 
were abolished by the HO-blocker, SnMP. Interestingly, the effect of hemin was more-intense in 
unhealthy ZDFs than in the healthy ZLs, suggesting greater selectivity of the actions in ZDFs with 
disease. 
Hemin and SnMP treatment caused a small reduction of body-weight (<9%) (Table 5-1). 
In ZL + hemin, ZDF + hemin, and ZDF + hemin + SnMP the loss of body-weight were 2.3, 4.6 
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and 8.7% respectively. Although, body-weight loss may cause reduction of glycemia, it is unlikely 
in this case because the slight body-weight loss in hemin- and SnMP-treated animals were 
accompanied by opposite effects on glycemia; that is a reduction of glycemia in hemin-treated 
animals, but an increase in SnMP-treated animals (Table 5-1), suggesting that the HO system may 
be endowed with intrinsic anti-diabetic effects. The loss of body-weight may not be due to toxicity 
since we recently showed that indices of toxicity such as plasma alanine aminotransferase, gamma-
glutamyltransferase and aspartate aminotransferase and were within normal range (23). 
In order to examine the role of the HO system on renal function, important indices of renal 
function including urinary proteins like proteinuria and albuminuria (34) were assayed. Our results 
indicate that the levels of proteinuria and albuminuria were significantly elevated in untreated 
ZDFs (Table 5-1). Interestingly, hemin therapy markedly abated proteinuria and albuminuria by 
74 and 64% respectively, whereas co-treatment of hemin and SnMP abolished the effects of hemin, 
while treatment SnMP alone exacerbated the excretion of these urinary proteins (Table 5-1). 
Furthermore, hemin therapy enhanced creatinine clearance in ZDFs, and thus improved renal 
function, whereas the HO-inhibitor, SnMP, nullified the effects of hemin on creatinine clearance. 
The vehicle dissolving hemin and SnMP had no effect on any of the measured parameters 
measured in ZDFs and ZLs. 
 
5.4.2 Hemin therapy enhanced HO-1 and HO activity in perirenal adipose tissue of ZDFs 
To investigate the role of the HO system on perirenal adiposity and diabetic nephropathy, 
we measured HO-1 concentration and HO activity. Our results indicate that the basal levels of HO-
1 and HO-activity in control-ZDFs were significantly reduced as compared to control-ZLs (Figs. 
5-1A and 5-1B). Interestingly, hemin therapy greatly enhanced the depressed levels of HO-1 and 
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HO activity in ZDFs, whereas the co-treatment with the HO inhibitor, SnMP reversed the effects 
of the HO inducer, hemin, while treatment with SnMP alone depleted the basal levels of HO-1 and 
HO activity (Figs. 5-1A and 5-1B). 
Hemin therapy also enhanced the levels of HO-1 and HO activity in ZL rats, although, a 
greater increment was observed in hemin-treated ZDFs (Figs. 5-1A and 5-1B). In hemin-treated 
ZLs, HO-1 and HO-activity were increased by 3.8-and 2.6-fold respectively, while the increment 
observed in ZDFs for HO-1 and HO-activity were 13.5- and 11.2-fold respectively. The higher 
increment of HO-1 and HO-activity may account for the more accentuated effects against 
hyperglycemia and nephropathy observed in ZDFs (Table 5-1). The vehicle dissolving hemin and 
SnMP had no effect on HO-1 and HO-activity in ZDFs and ZLs. 
 
5.4.3 Hemin therapy abated 8-isoprostane and ET-1 in perirenal adipose tissue of ZDF 
Given that elevated oxidative stress is among the causative factors of insulin resistance and 
tissue dysfunction, we measured 8-isoprostane, an important marker of oxidative stress (45). 
Moreover, ET-1 is implicated in cardiac and renal insufficiency (46). In untreated ZDFs, the basal 
levels of perirenal adipose tissue 8-isoprostane were markedly elevated, suggesting enhanced 
oxidative stress (Fig. 5-2A). However, hemin therapy significantly reduced the elevated levels of 
8-isoproatane by in ZDFs, whereas the co-treatment of hemin with SnMP nullified the effects of 
hemin while treatment with SnMP alone further increased 8-isoprostane levels, suggesting that 
oxidative stress is further potentiated by blockade of basal HO activity (Fig. 5-2A). Hemin therapy 
also reduced 8-isoprostane in ZL rats, although, less-intensely as compared to ZDFs. In hemin-
treated ZLs, 8-isoprostane was reduced by 2.7-fold as compared to a reduction of 3.3-fold in 
hemin-treated ZDFs (Fig. 5-2A). 
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Since 8-isoprostane stimulates ET-1 (47), and both ET-1 and 8-isoprostane are involved in 
the oxidative destruction of tissue, we also measured ET-1 in perirenal adipose tissue. Our results 
indicate that the levels of ET-1 in untreated ZDFs were significantly elevated as compared to the 
control-ZLs (Fig. 5-2B). Interestingly, hemin therapy significantly abated the elevated levels of 
ET-1 in ZDFs, while co-treatment of hemin and SnMP annulled the effect of hemin (Fig. 5-2B), 
whereas, treatment with SnMP alone further accentuated the levels of ET-1. Hemin therapy also 
reduced ET-1 in ZLs although, to a lesser magnitude as compared to ZDFs. Accordingly, a 
reduction of 2.2-fold of ET-1 was observed in hemin-treated ZLs as compared to 2.8% hemin-
treated ZDFs. The vehicle dissolving hemin and SnMP had no effect on 8-isoprostane and ET-1 
in ZDFs and ZLs. 
 
5.4.4 Hemin therapy suppressed pro-inflammatory cytokines in perirenal adipose tissue 
TNF-α, IL-6 and IL-1β are cytokines that impair renal function and glucose metabolism 
(12-15), so we investigated whether the improvement of renal function and glucose metabolism in 
hemin-treated ZDFs would be accompanied by reduction of these cytokines. Our results indicate 
that the levels of TNF-α, IL-6 and IL-1β in perirenal adipose tissue of untreated ZDFs were 
significantly elevated as compared to control-ZLs (Fig. 5-3A, 5-3B and 5-3C). Treatment with 
hemin greatly reduced TNF-α, IL-6 and IL-1β, whereas the co-application of the HO-inhibitor, 
SnMP with hemin reversed the effects of hemin, while treatment of SnMP alone further increased 
the levels of these cytokines. Hemin therapy also reduced the levels of TNF-α, IL-6 and IL-1β in 
the ZLs, although, less intensely. A reduction of 1.7-, 1.9-, and 2.5-fold of TNF-α, IL-6 and IL-1β 
respectively was observed in hemin-treated ZLs as compared to 2.2-, 2.6-, and 3.0-fold in hemin-
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treated ZDFs. The vehicle dissolving hemin and SnMP had no effect on TNF-α, IL-6 and IL-1β in 
ZDFs and ZLs. 
 
5.4.5 Hemin therapy potentiated ANP, its surrogate marker, urinary cGMP and adiponectin 
Given that ET-1 and ANP interact reciprocally (48), we investigated whether the hemin-
induced reduction of ET-1 will affect the levels of ANP. Our results indicate that the reduction of 
ET-1 (Fig. 5-2B) by hemin was accompanied by the concomitant potentiation of ANP levels (Figs. 
5-4A). Consistently, urinary cGMP, a surrogate marker of ANP (49) was significantly increased 
by hemin, while co-treatment with the HO-inhibitor, SnMP reversed the effects of hemin (Fig. 5-
4B), whereas, treatment with SnMP alone further depleted the basal levels of urinary cGMP. 
Since adiponectin is an anti-inflammatory protein (50) with renoprotective effects and insulin 
sensitizing effects (51, 52), we investigated the effects of hemin on adiponectin in ZDFs. In ZDFs, 
the basal levels of adiponectin were depressed (Fig. 5-4C). Interestingly, hemin therapy 
significantly enhanced adiponectin (Fig. 5-4A). In contrast, co-treatment of hemin with the HO-
inhibitor, SnMP annulled the hemin effects on adiponectin, while treatment with SnMP alone 
further reduced the levels of adiponectin. The vehicle dissolving hemin and SnMP had no effect 
on ANP and urinary cGMP. 
 
5.4.6 Hemin therapy abated MIP-1α in perirenal adipose tissue and kidneys 
To further evaluate the effects of the HO system on macrophage infiltration, we determined 
the levels of MIP-1α, a chemokine implicated in macrophage infiltration (28). The basal levels of 
MIP-1α in perirenal adipose tissue from control ZDFs were significantly elevated as compared to 
the ZL controls (Fig. 5-5A). Interestingly, treatment with hemin greatly attenuated the high levels 
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of MIP-1α in ZDFs although, comparable levels in ZL-controls were not reinstated. In contrast, 
the co-application of the HO-inducer, hemin with the HO-blocker, SnMP abolished the effects of 
hemin (Fig. 5-5A). Similarly, treatment with the SnMP alone exacerbated the levels of perirenal 
MIP-1α (Fig. 5-5A). 
We also investigated the effects of hemin on kidney MIP-1α levels. In kidney tissues from 
control ZDFs, MIP-1α was markedly elevated as compared to ZL control rats (Fig. 5-5B), but was 
significantly attenuated by hemin therapy. On the other hand, the co-administration of SnMP and 
hemin nullified the effects of hemin (Fig. 5-5B), while SnMP alone further increased the levels of 
MIP-1α in ZDFs. It is noteworthy that hemin appeared to be more effective in the abrogating 
kidney MIP-1α as the hemin-dependent reduction of MIP-1α reinstated comparable levels as 
observed in ZL control rats. The reasons for this selective effect remain unclear, although, tissue 
selectivity might be implicated. 
Hemin therapy also reduced MIP-1α in perirenal adipose tissue and the kidney from ZL 
control rats (Figs. 5-5A and 5-5B). The vehicle dissolving hemin and SnMP had no effect on MIP-
1α in ZDFs and ZLs. 
 
5.4.7 Hemin therapy abated inflammatory proteins implicated in insulin resistance and renal 
dysfunction 
Given that macrophage infiltration is implicated in the development of insulin-resistant T2D and 
kidney dysfunction (13, 53-56) we used specific markers such as ED1 to quantify the pro-
inflammatory M1-phenotype, and ED2, CD206 and IL10 for the assessment of anti-inflammatory 
M2-phenotype (27, 56-58) Our Western immunoblotting and relative densitometric analyses 
revealed that the basal expression of ED1 in the kidneys of ZDF-controls were significantly 
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elevated (Fig. 5-6A). Interestingly hemin therapy significantly attenuated the elevated expression 
of the pro-inflammatory M1-phenotype marker ED1 and restored ED1 to comparable levels as 
observed in ZL-controls (Fig. 5-6A). To determine whether the suppression of the pro-
inflammatory M1-phenotype by hemin would be accompanied by changes in the anti-
inflammatory M2-phenotype, we determined the expression of macrophage-M2 using specific M2 
markers such as ED2, CD206 and IL-10. Our results indicate that the basal expression levels of 
ED2, CD206 and IL-10 were markedly reduced in ZDF-controls as compared to ZL-controls. 
Interestingly, hemin therapy robustly enhanced the depressed basal expressions of ED-2 (Figs. 5-
6B), CD206 (Figs. 5-6C) and, IL-10 (Figs. 5-6D), suggesting that hemin therapy may selectively 
modulate the polarization of macrophage toward the M2-phenotype that dampens inflammation. 
It is noteworthy that hemin therapy reinstated ED2 and IL-10 to the levels of ZL-controls, but 
enhanced CD206 to levels even beyond ZL-controls. Hemin therapy also reduced ED1 in ZLs, and 
enhanced CD206 and IL-10, but did not affect ED2 in ZLs. 
 
5.4.8 Hemin therapy suppresses pro-fibrotic proteins in the kidney but enhanced nephrin 
To further explore the mechanisms by which hemin therapy reduces proteinuria, and thus 
improve renal function, we assessed the expression levels of nephrin, an important transmembrane 
protein which forms the scaffolding of the podocyte slit diaphragm, a structure that regulates the 
aperture size of the renal filtration barrier, allowing the filtration of small molecules like ions, but 
not larger molecules like proteins (18). A defect in nephrin causes massive excretion of proteins, 
hence proteinuria (18). 
Our Western immunoblotting data indicates that in ZDF-controls, the basal expression of 
nephrin in the kidneys was markedly depressed as compared to the ZL-controls (Fig. 5-7A), and 
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this coincided with marked increased in proteinuria and albuminuria, suggesting renal dysfunction 
(Table 5-1). However, treatment with hemin robustly enhanced the depressed expression of 
nephrin in ZDFs (Fig. 5-7A), reinstating comparable levels as observed in ZLs, with reduction of 
proteinuria and albuminuria (Table 5-1), and thus improved renal function. Hemin therapy did not 
affect the expression of nephrin in the healthy ZLs. 
Since, the expression of nephrin is deregulated in diabetic nephropathy (18, 56), and 
elevated levels of pro-fibrotic/extracellular matrix proteins such as collagen and fibronectin are 
implicated in the aberrant expression of nephrin (19, 56), we investigated the effects of hemin 
therapy on the expression of collagen-IV and fibronectin. Our results indicate that in ZDFs, the 
basal expression levels of collagen-IV and fibronectin were significantly elevated as compared to 
the ZL-controls (Figs. 5-7B and 5-7C). Interestingly, the administration of hemin to ZDFs 
significantly reduced the elevated expression of collagen-IV and fibronectin to levels even lower 
than in the ZL-controls (Figs. 5-7B and 5-7C). Hemin therapy also reduced fibronectin expression 
in ZLs, but did not affect collagen-IV in ZLs. The reason for this selective effect is unknown, and 
should be further investigated. It is important to note that although hemin reduced fibronectin in 
healthy ZLs, it was more effective in unhealthy ZDFs because fibronectin was reduced by 4.3-fold 
in ZDFs as opposed to 1.5-fold in ZLs. 
 
5.4.9 Hemin therapy suppressed renal fibrosis 
Histological study using Masson’s trichrome staining and morphometric analyses were 
done to further confirm the renoprotective effects of hemin. As observed in (Fig. 5-8A), ZDF-
controls displayed severe tubulo-interstitial, perivascular and glomerular fibrosis around the cortex 
and medullar as compared to ZL-controls. Similarly, kidney sections from ZDF-controls showed 
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tubular vacuolization and glomerulosclerosis. Interestingly, these renal lesions were greatly 
attenuated by hemin therapy as hemin-treated ZDFs showed reduction of glomerular, tubulo-
interstitial and perivascular fibrosis. Correspondingly, semi-quantitative analysis showed that 
hemin therapy significantly abated the elevated collagen deposition and perivascular fibrosis in 
ZDFs, reinstating similar levels as observed in ZL-controls (Fig. 5-8B). 
 
5.4.10 Hemin therapy suppressed macrophage infiltration in renal tissue by abating ED1 
Since data from our Western immunoblot experiment indicated that hemin therapy abated 
ED1 expression in the kidney (Fig. 5-6A), we use the ED1 antibody to determine macrophage 
infiltration in the kidneys by immunohistochemistry (Fig. 5-9A). Our results indicate that kidney 
sections from ZL-controls were almost devoid of the dark brown ED1 positive staining that 
characterizes macrophage infiltration. However, in untreated ZDF-controls, greater numbers of 
ED1 positive staining for macrophage was observed in several structures located in the cortex and 
medullar of the kidney including the tubulointerstitial, perivascular and glomeruli as compared to 
ZL-controls (Fig. 5-9A and 5-9B). Interestingly, in hemin-treated ZDFs, there was a significant 
reduction in the number of ED1 positively stained macrophage, suggesting reduction of 
macrophage infiltration. Correspondingly, hemin therapy significantly reduced the quantitative 
ED1 score of kidney sections (Fig. 5-9B), although, the levels of ZL-controls were not reinstated. 
 
5.4.11 Immuno-labeling of HO-1 shows elevated HO-1 in tubulointerstitial, perivascular area 
and around the glomeruli of hemin-treated ZDFs 
To further confirm the localization of HO-1 in the kidney, we did immunohistochemistry. 
Our immunohistochemical data shows very little expression of HO-1 was observed in kidney 
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tissues of ZDF control (Fig. 5-10). However, in hemin-treated ZDF, HO-1 was very conspicuous 
and widely expressed in the renal parenchyma, with particularly high expressions in the 
tubulointerstitium, perivascular area and around the glomeruli. 
 
5.5 Discussion 
The present study unveils several novel findings. These include (i) the hemin-induced 
enhancement of the anti-inflammatory macrophage M2-phenotype and corresponding reduction 
of the pro-inflammatory M1-phenotype; (ii) the suppression of perirenal adiposity and MIP-1α, a 
chemokine implicated in macrophage infiltration; (iii) the enhancement of nephrin, of nephrin, an 
important transmembrane protein critical for the formation of the podocyte slit diaphragm that 
regulates the aperture size of the glomerular filtration barrier, selectively allowing the filtration of 
small molecules like ions, but not larger molecules like proteins; and (iv) the corresponding 
reduction of proteinuria and albuminuria that was, interestingly, accompanied by increased 
creatinine clearance and thus improved renal function in ZDFs. The role of nephrin in glomerular 
filtration cannot be overemphasized. A defect in nephrin may cause massive excretion of proteins, 
hence proteinuria and renal dysfunction (20-22, 56). It is possible that in ZDFs, the high levels of 
profibrotic/extracellular matrix proteins would aggravate histological renal lesions, and this defect 
was evidenced by increased tubular vacuolization, glomerulosclerosis with severe tubulo-
interstitial, perivascular and glomerular fibrosis, all of which pathophysiological factors that 
together with the aberrant expression of nephrin may account for proteinuria and renal impairment. 
Therefore, another important observation from our study is that hemin therapy significantly 
reduced the expression of pro-fibrotic/extracellular matrix proteins such as collagen and 
fibronectin. Moreover, excessive collagen and fibronectin are among the factors that deplete 
183 
 
nephrin (17), a zipper-like protein that plays a fundamental role in the formation of the podocyte 
slit diaphragm of the glomerular barrier (18-20). 
Although, it is widely acknowledged that obesity and insulin resistant T2D are common 
causes of diabetic nephropathy and renal failure (3-5, 7), emerging evidence indicate that the 
anatomical location of adiposity reflects its adversity (10). Therefore, the presence of excessive 
visceral adipose tissue like perirenal adiposity may constitute an independent prognostic factor of 
kidney malfunction in T2D (9). Thus, the concomitant suppression of perirenal adiposity alongside 
the reduction of macrophage infiltration, the abrogation of mediators of oxidative stress like 8-
isoprostane and ET-1 (45, 59), and the attenuation of pro-inflammatory cytokines like TNF-α, IL-
6 and IL-1β (12-15) in perirenal adipose tissue by hemin are among the multifaceted mechanisms 
by which the HO system attenuates renal damage. In addition, the selective enhancement of anti-
inflammatory M2-phenotype macrophage and corresponding reduction of the pro-inflammatory 
M1-phenotype in renal tissue from hemin-treated animals may be indicative of a novel mechanism 
by which the HO system counteracts tissue inflammation. In addition, it may also suggest a role 
of hemin therapy in the modulation of macrophage polarization. 
During inflammation blood monocytes are recruited into the tissues where they 
differentiate into macrophages. Macrophage heterogeneity is a well-known phenomenon (13, 25, 
26). Generally, macrophages heterogeneity reflects the specialization of tissue-resident 
macrophages in the different microenvironments in distinct tissues like liver, adipose tissue, 
kidney and other tissues (25, 26). Within such microenvironment, macrophages can acquire 
distinct functional phenotypes (25, 26). Importantly, macrophage polarization is driven by a wide 
variety of stimuli and signals in the tissue microenvironment, and these stimuli include cytokines, 
growth factors and other agents (25, 26). The presence of these signals dictates the transcriptional 
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response that shapes the phenotype and function of the macrophages on the basis of the 
physiological or pathophysiological role acquired by the macrophage in a given tissue (25, 26). 
Therefore, changes in the levels of the pro-inflammatory cytokines observed in hemin-treated 
animals may be responsible for the selective enhancement of the anti-inflammatory M2-
phenotype. Moreover, during macrophage polarization, there is a switch of the gene expression 
program from a pro-inflammatory M1 signature to an anti-inflammatory M2-phenotype, 
depending on the tissue microenvironment and the presence of different stimuli including 
cytokines (25, 26). Interestingly, hemin therapy suppressed the levels of several cytokines 
including TNF-α, IL-6 and IL-1β, and thus there is a possibility that in the microenvironment of 
the perirenal adipose tissue, the abrogation of these cytokines may account for the selective 
polarization of macrophage towards the anti-inflammatory M2-phenotype. Nevertheless, these 
preliminary observations made in this study are just the tip of an iceberg and more-intense research 
is needed to address the many challenging questions that would be necessary for characterizing 
the role of the HO system in macrophage polarization. Moreover, the suppression of macrophage 
infiltration and reduction of extracellular matrix/profibrotic proteins reported here are consistent 
with previous studied showing that upregulating the HO system is renoprotective (35, 56, 60). 
Besides the selective enhancement of M2-phenotype, other mechanisms may account for 
the suppression of inflammation in hemin treated animals. These include the potentiation of ANP 
and the enhancement of adiponectin (50, 61, 62). Interestingly, our results indicate that hemin 
therapy enhanced ANP and its surrogate marker, urinary cGMP (49), and adiponectin has been 
shown to enhance cGMP (63). The stimulation of cGMP is an important mechanism by which 
ANP elicit its effects (64). Given that impairment of cGMP-signalling leads to anti-thy1 
glomerulonephritis (65), and the cGMP-signal transduction pathway has been shown to abate 
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inflammation (66), the enhancement of ANP and cGMP by hemin may counter-regulate the effects 
of elevated renal inflammation to improve renal function. Thus, the cGMP secondary messenger 
system is a common denominator between the HO system, ANP and adiponectin. Therefore, the 
HO-adiponectin-ANP axis may constitute a synergistic protective axis with relevance for tissue 
defence and glucose metabolism. Moreover, hemin therapy may also abate inflammation and 
improve glucose metabolism by enhancing adiponectin, an anti-inflammatory protein with 
renoprotective and insulin sensitizing effects (50-52, 67-69). Given that an ANP-mediated 
reduction of TNF-α, IL-6 and IL-1β have been linked to reduced insulin resistance (61), the 
suppression of these cytokines and potentiation of HO-adiponectin-ANP axis is important for 
enhanced glucose metabolism and improved kidney function observed in ZDFs. Therefore, the 
multifaceted mechanisms responsible for the renoprotection evoked by hemin include the 
potentiation of the HO system and related cellular targets like cGMP, ANP and adiponectin, which 
interestingly was accompanied by the reduction of collagen and fibronectin. The HO-adiponectin-
ANP axis may suppress the adverse effects of ET-1. The interaction between ET-1 and ANP is 
well known (48). For example, ANP inhibits ET-1 (70), and interestingly, the hemin-induced 
increase of ANP was accompanied by a parallel reduction of ET-1. On the other hand, ANP 
attenuates fibrosis by abating extracellular matrix/profibrotic proteins including fibronectin and 
TGF-β1 (70), while ET-1 acts in concert with TGF-β1 to stimulate fibronectin synthesis (71). Since 
ANP can also stimulate the production of adiponectin (72), a cytoprotective adipokine with anti-
inflammatory effects (50), and the present study indicates that hemin therapy enhances adiponectin 
and ANP but abates ET-1 with the reduction of renal fibrosis, it could be envisaged that the 
potentiation of the HO-adiponectin-ANP axis is an important renoprotective mechanism. 
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Our study also indicates that the effect of hemin therapy was less-pronounced in ZL-control 
rats with healthy status, suggesting greater selectivity of the HO system in ZDFs with disease. 
Alternatively, the HO system in healthy ZL-control rats may be more stable given that HO-1 and 
HO-activity in ZDFs were depressed as compared to ZLs, and interestingly, the effect of hemin on 
HO-1 and HO-activity was more accentuated in ZDFs than ZLs. It is also possible that the higher 
magnitude of HO-signalling in hemin-treated ZDFs may be responsible for the more intense anti-
diabetic and reno-protective effect in ZDFs as compared to ZLs. This is reflected in the 
physiological variables measured (Table 5-1). In hemin-treated ZDFs, fasting glucose, perirenal 
adiposity, proteinuria and albuminuria were reduced by 73.5, 56.1, 74.1 and 64.6% respectively, 
while creatinine clearance was increased by 41.7%. On the other hand, fasting glucose, perirenal 
adiposity, proteinuria and albuminuria were only reduced in hemin-treated ZLs by 11.4, 21.9, 5.9 
and 17.4% respectively, with only a 4.7% increase in creatinine clearance. It is important to note 
that although, these physiological variables in ZLs were affected by hemin, they were still within 
the acceptable physiological range. Similarly, most of the other biochemical parameters measured 
in this study were more accentuated in hemin-treated ZDFs than hemi-treated ZLs. Therefore, the 
hemin-mediated changes in physiological variables and biochemical parameters reported in this 
study are more intense in unhealthy ZDFs than healthy ZLs, suggesting greater selectivity of hemin 
in diseased conditions. Nevertheless, further investigations need to clarify the selectivity of hemin 
therapy in unhealthy ZDFs. 
Immunohistochemical labeling of HO-1 in kidney has been widely reported (60, 73-75). 
These studies indicate that HO-1 is expressed all over the renal parenchyma, with higher levels in 
tubular epithelial cells, vascular wall smooth muscle cells and the interstitium of the cortex and 
medulla (60, 73-75). Consistently, our immunohistochemical results show high HO-1 expression 
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in many areas of the renal parenchyma including the tubulointerstitium and perivascular area of 
the cortex and medullar. Interestingly, these areas intense HO-1 expression coincided with areas 
of the kidney where lesions were hemin therapy significantly reduced histopathological lesions. 
Moreover, in our study, renal lesions and kidney insufficiency was associated with severe 
histopathological lesions in tubular epithelial cells, the interstitium and other regions of the cortex 
and medullar in untreated ZDFs. These renal lesions were evidenced by increased tubular 
vacuolization, glomerulosclerosis with severe tubulo-interstitial, perivascular and glomerular 
fibrosis, and were associated with elevated macrophage infiltration and increased deposition of 
collagen, an extracellular matrix protein in untreated ZDFs. Moreover, the elevated collagen 
deposition in untreated ZDFs was associated with increased expression of fibronectin, another 
extracellular matrix protein that together with collagen are known to deplete nephrin causing 
proteinuria and renal insufficiency (19-22, 56). Given that previous studies have reported increased 
HO-1 expression in the interstitium and tubular epithelium of the cortex following the 
administration of HO-inducers (60, 74), and incidentally the interstitium and tubular epithelium 
were among the areas with significant lesion in untreated ZDF, the present study and previous 
reports in literature strongly suggest that the HO system alleviates not only tubulo-interstitial 
injury, but also suppress perivascular and glomerular fibrosis to improve renal function. 
Generally, HO-1 is activated by a wide variety of physical, chemical and 
pathophysiological stimuli (76-81). Accordingly, HO-1 may be considered a sensitive index that 
is triggered during the onset of pathophysiological alterations in tissues as an attempt to counteract 
the adverse changes. However, the pathophysiological activation of HO-1 has been shown to evoke 
only a transient or sub-threshold value of HO-activity that is incapable of activating important 
downstream signaling components of the HO system like cGMP (36, 41, 56, 80, 82-85), suggesting 
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the necessity for a more robust enhancement of HO-1 by pharmacological agents like cobalt 
proptoporphyrin and hemin (36, 41, 82-85). Thus, the transient up-regulation of HO-1 that 
accompanies many pathophysiological conditions may represent the first line of defense mounted 
by the HO system against tissue injury. Accordingly, the high expression of HO-1 in interstitial 
macrophages and tubular epithelial cells reported in the cortex and outer medullar regions of 
dysfunctional kidneys (60, 73) may be indicative of the manifestation of pathophysiological 
alterations in the kidneys. Similarly, in our study we observed renal insufficiency characterized by 
elevated proteinuria/albuminuria and reduced creatinine clearance in untreated ZDFs. However, 
these renal defects were attenuated by potentiating the HO system and its downstream signaling 
molecule cGMP by hemin therapy. 
Collectively, the present findings indicate that the concomitant enhancement of ANP, 
cGMP, adiponectin and creatinine clearance, alongside the corresponding reduction of perirenal 
adiposity and the suppression of pro-inflammatory/oxidative mediators, macrophage infiltration, 
albuminuria and proteinuria may account for the improved glucose metabolism and improved renal 
function in hemin-treated ZDFs. These data suggest that HO-inducers like hemin may be explored 
against the co-morbidity of perirenal adiposity and diabetic nephropathy. 
 
5.6 Limitations 
Although, the present study underscores the renoprotective effects of hemin therapy in 
diabetic nephropathy, and suggest that the suppression of extracellular matrix proteins like 
collagen-IV and fibronectin in hemin-treated ZDF are accompanied by increased expression of 
nephrin and improved renal function, these observations should be cautiously interpreted because 
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this study does not provide unequivocal data that demonstrate the interaction among HO-1, 
collagen-IV, fibronectin and nephrin in the glomeruli. 
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Figure 5-1: Effects of hemin, the HO inducer and SnMP, the HO inhibitor on HO-1 and HO 
activity of perirenal adipose tissue from ZDF and ZL rats. (A) The basal HO-1 levels in ZDF rats 
were lower than in age/sex-matched ZL-control rats, but were increased by hemin, whereas SnMP 
nullified the hemin effect. (B) The basal HO activity in ZDF rats was depressed as compared to 
ZL-control rats. Treatment with hemin markedly enhanced HO activity, whereas SnMP annulled 
the hemin effect. Hemin also enhanced HO-1 and HO activity in ZL rats, though less effectively 
as compared to ZDF rats. Bars represent means ± SEM; n = 6 rats per group (*p<0.05 vs all 
groups, †p<0.05, ††p<0.01 vs all groups; §p<0.05 vs all groups). 
 
192 
 
 
Figure 5-2: Effects of hemin, the HO inducer and SnMP, the HO inhibitor on 8-isoprostane and 
ET-1 of the perirenal adipose tissue from ZDF and ZL rats. (A) The basal 8-isoprostane levels in 
ZDF rats were markedly elevated as compared to ZL-control rats, but were significantly reduced 
by hemin, whereas SnMP nullified the hemin effect. (B) The basal ET-1 levels in ZDF rats were 
significantly elevated as compared to ZL-control rats, but were reduced by hemin, whereas SnMP 
nullified the hemin effect. Hemin also reduced 8-isoprostane and ET-1 in ZL rats, but less 
effectively as compared to ZDF rats. Bars represent means ± SEM; n = 6 rats per group 
(*p<0.05 vs all groups, †p<0.05, ††p<0.01 vs all groups; §p<0.05 vs all groups). 
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Figure 5-3: Effects of hemin, the HO inducer and SnMP, the HO inhibitor on TNF-α, IL-6 and 
IL-1β, of the perirenal adipose tissue from ZDF and ZL rats. Hemin therapy significantly reduced 
the elevated levels of (A) TNF-α, (B) IL-6 and (C) IL-1β in ZDF rats, but the hemin effects were 
reversed by co-treatment with the HO blocker SnMP, while treatment with SnMP alone further 
increased the levels. Hemin also reduced TNF-α, IL-6 and IL-1β in ZL rats, but less effectively as 
compared to ZDF rats. Bars represent means ± SEM; n = 6 rats per group (*p<0.05, **p<0.01 vs all 
groups; †p<0.05, ††p<0.01 vs all groups; §p<0.05, §§p<0.01 vs all groups).  
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Figure 5-4: Effect of hemin, the HO inducer and SnMP, the HO inhibitor on plasma ANP, urinary 
cGMP and plasma adiponectin in ZDFs and ZLs. Hemin therapy significantly increased the 
depressed basal levels of (A) ANP, (B) urinary cGMP and (C) plasma adiponectin in ZDF rats, 
but was reversed by co-treatment with the HO blocker SnMP, while treatment with SnMP alone 
further depleted the basal levels. Hemin also increased plasma ANP, urinary cGMP and plasma 
adiponectin in ZL rats. Bars represent means ± SEM; n=6 rats per group (*p<0.05 vs all 
groups, †p<0.01 vs all groups, §p<0.05 vs all groups). 
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Figure 5-5: Effect of hemin on macrophage-inflammatory-protein-1 alpha (MIP-1α) in perirenal 
adipose tissue and the kidneys of ZDF. Hemin therapy significantly reduced the elevated levels of 
MIP-1α in (A) perirenal adipose tissues and (B) kidney from ZDF, but the hemin-effect was 
annulled by co-treatment with the HO blocker SnMP, while treatment with SnMP alone further 
increased the levels Bars represent means ± SEM; n = 6 rats per group (*p<0.01 vs all 
groups; †p<0.05 vs all groups; §p<0.01 vs all groups). 
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Figure 5-6: Effect of hemin on the expression of ED-1, ED2, CD206 and IL-10 in renal tissues of 
ZDF. Representative Western immunoblots, and relative densitometry indicates that hemin 
therapy significantly (A) reduced ED-1, but (B) enhanced ED2, (C) increased CD206, and (D) 
enhanced IL-10 expression in ZDF. Bars represent means ± SEM; n = 4 rats per group (*p<0.05, 
**p<0.01 vs ZL-Control; §p<0.05, §§p<0.01 vs ZL-Control; #p<0.01 vs ZL-Control; @p<0.01 vs 
ZDF Control). 
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Figure 5-7: Effect of hemin on the expression of collagen-IV, fibronectin and nephrin in renal 
tissues of ZDF. Representative Western immunoblots, and relative densitometry indicates that 
hemin therapy significantly (A) enhanced the expression of nephrin but, (B) abated collagen-IV 
expression, and (C) reduced the expression of fibronectin in ZDF. Bar represent means ± SEM;  
n = 4 rats per group (*p<0.01 vs all groups; #p<0.05, # #p<0.01 vs ZL-Control; @p<0.01 vs ZDF-
Control). 
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Figure 5-8: Masson’s trichrome staining of collagen deposition and fibrosis the in kidney. (A) 
Representative images of kidney section from two different rats. Sections from untreated ZDF-
controls (panels A-iii and A-iv) indicate severe fibrosis in tubulointerstitial, perivascular and 
glomerulus as compared with ZL-control rats (panels A-i and A-ii), which interestingly were 
attenuated by hemin (panels A-v and A-vi). (Magnification×200) (B) Semi-quantitative evaluation 
showed that hemin reduced collagen deposition. Bars represent means ± SEM; n = 4-6 rats per 
group (*p<0.05 vs all groups).  
A 
B 
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Figure 5-9: Effect of hemin therapy on kidney macrophage infiltration (A) Representative images 
of kidney section from different rats. The images reveal that macrophage infiltration (ED1-positive 
cells stained dark brown in kidney sections were elevated in ZDF-controls (panels A-iii and A-iv) 
as compared to ZL-controls (panels A-i and A-ii), but interestingly were reduced by hemin 
(panels A-v and A-vi). (Magnification×200). (B) Quantitative analyses per field indicating that in 
ZDF-controls macrophage infiltration was significantly elevated as compared to ZL-control, but 
was significantly attenuated by hemin therapy. Bars represent means ± SEM; n = 4-6 rats per group 
(*p<0.01 vs all groups). 
 
A 
B 
Kidney ED1 (macrophage infiltration) 
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Figure 5-10: Immunolabelling of HO-1 in the kidney of ZDF-control and ZDF-treated with hemin 
therapy. Representative images of kidney section from different rats reveal that HO-1 is more 
expressed in ZDF + hemin group (panels iv-vi) as compared to the ZDF-control group (panels i-
iii). (Magnification×200).  
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CHAPTER 6 
Role of the Nrf2/HO axis in pancreatic repair and/or regeneration in a type-1 
diabetic rat model  
 (unpublished thesis work) 
Manish Mishra and Joseph Fomusi Ndisang 
 
 
6.1 Abstract 
Nuclear factor-(erythroid-derived 2)-like 2 (Nrf2) and heme oxygenase (HO) synergism associated 
mechanisms are the crucial regulator of inflammation, oxidative stress and abnormal glucose 
metabolism, and tissue injury in type-1 diabetes mellitus (T1D). We previously reported that HO 
upregulation reduced pancreatic lesions and improved pancreatic functions in streptozotocin 
(STZ)-induced diabetes, however, the mechanisms of HO-mediated reduction in pancreatic lesions 
were not clear. To understand the HO-associated pancreatic repair mechanisms, the effects of 
upregulating the HO system on proteins implicated in pancreatic repair and/or regeneration were 
examined in STZ-induced diabetes. Diabetes was induced with STZ, while the HO system was 
upregulated with hemin.  Our results demonstrate that the hemin-induced HO system enhanced the 
expression of stem cell markers (c-Kit and Sca-1), proteins of regeneration (β-catenin, Islet-
1, GLUT2) and transcriptional factors (Oct3/4, Pax2, Nkx6.1) in the pancreas, suggesting their 
involvement in pancreatic repair and /or regeneration. Furthermore, hemin therapy effectively 
reduced inflammation through selective enhancement of ED2, CD206 and CD36 (anti-
inflammatory M2-phenotype markers), while it suppressed ED1 (proinflammatory M1-phenotype 
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marker) expression. Additionally, hemin therapy ameliorated oxidative stress through enhancing 
total antioxidant capacity and through Nrf2 transcriptional factor activation. Hemin-mediated 
reduction of inflammation and oxidative stress was associated with improved glucose metabolism 
through augmentation of insulin signaling components such as IRS-1, IRS-2, PI3K and GLUT4 in 
the liver and soleus muscle. In conclusion, the present findings suggest that hemin-mediated 
activation of the Nrf2/HO axis is one of the mechanisms that enhance of expression of proteins of 
pancreatic repair and /or regeneration, and improve glucose metabolism.  
 
6.2 Introduction 
Type-1 diabetes (T1D) is an autoimmune condition of tissue injury and impaired glucose 
metabolism affecting 7-12% of the world’s population (1,2). Increasing T-cell-mediated -cell 
apoptosis, insulin insufficiency and hyperglycemia are the characteristic features of T1D that are 
associated with altered pancreatic morphology and functions (3,4). Additionally, hyperglycemia-
induced systemic inflammation and oxidative stress equally contribute to tissue injury and 
metabolic dysfunction in several other vital organs such as liver, muscle and kidney that results in 
life threatening consequences (1,4,5).  
Clinically, T1D is managed by insulin therapy and islet transplantation (2,6,7). However, 
insulin-mediated allergies, variability in insulin action and hypoglycemia and immune-mediated 
graft rejection and low efficiency are the major concerns that reduce the effectiveness of insulin 
therapy and islet transplantation in T1D treatment (2,6,7). In these dysfunctional conditions, 
development of strategies against tissue injuries and metabolic dysfunction are important 
priorities. 
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Experimental studies in rodents showed that the pancreas has a reasonable potential to 
repair and/ or regenerate in various conditions of injuries (8,9). During pancreatic injury, dying 
pancreatic cells are replaced by replication of pre-existing cells or through neogenesis (8-11). 
Thus, promoting pancreatic repair and /or regeneration by various means may be very beneficial 
to reduce T1D-induced comorbidities. However, the contribution of a slower replication process 
is thought to be insufficient for the required cellular replacement in pancreas because due to 
autoimmunity assault, only a marginal number of -cells remain alive in the pancreatic islet 
(12,13). 
Furthermore, studies in rodents showed that during pancreatic injury, there are a number 
of proteins and transcriptional factors such as c-Kit, Sca-1, octamer-binding transcription factor 
3/4 (Oct3/4), paired homeodomain transcription factor-2 (Pax2), β-catenin, insulin gene enhancer 
protein-1 (Islet-1), homeobox protein Nkx6.1, and glucose transporter-2 (GLUT2) expressed in 
the pancreas and participates in pancreatic repair and/ or regenerative process (14-21). Thus, 
identification and characterization of these markers is very useful to define the repair and /or 
regenerative mechanism of the pancreas.  
During the past, few years, several observations have supported the cytoprotective 
functions of heme oxygenase (HO) system in experimental T1D (22). Additionally, HO 
metabolites, biliverdin ferritin and carbon monoxide are shown to promote tissue health and 
functions in various conditions of diabetes-induced tissue inflammation and oxidative injuries 
(22).  Interestingly, in our previous observations in streptozotocin (STZ)-induced diabetes and 
deoxycorticosterone-acetate-induced hypertension model, HO upregulation through hemin 
significantly reduced pancreatic injuries (vacuolization interstitial edema, monocyte infiltration 
and fibrosis) while insulin levels were improved (4,23). Similarly, hemin treatment reduced 
213 
 
pancreatic lesions in STZ diabetic rats (5). However, the mechanisms of HO-mediated tissue 
restoration of pancreatic morphology are unknown. It is reported that nuclear factor (erythroid-
derived 2)-like 2 (Nrf2) governs several cytoprotective effects of the HO system via regulation of 
its transcriptional activation (24,25). However, during T1D, the modulatory role of Nrf2/HO 
synergism on inflammation and oxidative stress-induced pancreatic injury, and dysregulated 
glucose metabolism is not clearly understood.   
Thus, to investigate the regulatory role of the Nrf2/HO axis in pancreatic injury, repair and/ 
or regeneration and glucose metabolism in more depth, a rat model of STZ-induced diabetes is 
used that mimics several pathological features of T1D, such as increasing -cell death, pancreatic 
inflammation and tissue injury and elevated levels of blood glucose (3,4). We hypothesized that 
Nrf2/HO synergism will modulate the negative consequences of inflammation, oxidative stress 
such as abnormal insulin signalling and pancreatic injuries while promoting pancreatic repair 
and/or regeneration in diabetic STZ animals. 
 
6.3 Materials and methods 
6.3.1 Animal treatment and biochemical parameters 
All experimental procedures were followed in accordance with a protocol approved by the 
Animal Care Committee at the University of Saskatchewan and Canadian Council on Animal Care. 
Male 5-week old Sprague Dawley (SD) rats were purchased from Charles River Laboratories 
(Willington, MA) and kept at 12-hours of light and dark cycles and fed with a regular laboratory 
chow diet and given free access to drinking water ad libitum. Our experimental design included 
the following treatment groups: (i) controls (citrate buffer-treated SD rats), (ii) streptozotocin 
(STZ) group, (iii) STZ + hemin group, and (iv) STZ + hemin + CrMP group. Diabetes was induced 
with a single and high dose of streptozotocin (Sigma, St Louis, MO.) (150 mg/kg body weight, 
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intraperitoneal injection (ip) in 0.1 mol/L citrate buffer, pH 4.5) in animals of the STZ group, STZ 
+ hemin group and STZ + hemin + CrMP group as previously reported (4). The citrate buffer-
treated SD control group was also treated with 0.1 mol/L citrate buffer, pH 4.5 in which we 
dissolved the streptozotocin. After 72 hours of streptozotocin injection, the diabetic state of the 
animals is confirmed by the presence of polyuria, polydipsia, polyphagia and increased blood 
glucose levels (>20 mmol/L) using the blood glucose analyzer (Abbott Diabetes Care Inc. 
CA94502, USA). Animals whose glucose levels were >20 mmol/L were considered as diabetic 
and used in experiments. 
HO-inducer hemin (30 mg/kg body weight i.p., Sigma, St Louis, MO) and HO-blocker 
chromium mesoporphyrin [(CrMP) 4 mol/kg body weight i.p.; Porphyrin Products (Logan, UT)] 
were prepared as previously reported and administered after 1 week of STZ administration, 
biweekly for 4 weeks (4). Physiological parameters (body weight, drinking water, urine) were 
measured weekly before and during the treatment period. Additionally, at the end of the study, the 
animals (11 weeks old) were fasted in metabolic cages and urine samples were collected for 24 
hrs. Thereafter, the rats were weighed and anaesthetized with isoflurane (50 mg/kg i.p.) and blood 
and plasma samples were collected. After that animals were sacrificed and pancreas, liver, soleus 
muscle, were removed in pre-chilled PBS, cleaned and weighed and frozen in liquid nitrogen and 
stored at -80°C for further analysis.  
Total antioxidant capacity of pancreatic tissue was measured by enzyme-linked 
immunoassay through using a commercial kit for total antioxidant (Cayman Chemicals) through 
an immunosorbent assay as previously reported (23). In brief, pancreatic tissue samples were 
homogenized in PBS buffer with a cocktail of protease inhibitors and treated with Trolox (6-
hydroxy-2, 5, 7, 8-tetramethylchroman-2-carboxylic acid), met-myoglobin, and chromogen and 
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the absorbances were read at 750 nm with a microplate reader (Spectra Max, Molecular Devices). 
The results were expressed as Trolox equivalent antioxidant capacity (TEAC) per milligram of 
protein. 
 
6.3.2 Western immunoblotting 
Frozen (-80°C) liver, pancreas, soleus muscle was homogenized with 
radioimmunoprecipitation assay buffer (RIPA) (50 mM Tris-HCl pH 7.8, 150 mM NaCl, 0.1% 
SDS, 0.5% sodium deoxycholate, 1% triton x-100) in the presence of a freshly prepared cocktail 
of protease inhibitors. The total protein concentration in supernatant was quantified by a detergent 
compatible protein quantification kit (DCTM Protein Assay Kit, Bio Rad). Here 50-75 g of total 
protein was electrophoresed on 8-12% SDS-polyacrylamide gels. After electrophoresis of total 
proteins, the fractionated proteins were transferred to a nitrocellulose membrane (0.45 m, Bio 
Rad) and blocked with 3-5% non-fat dry milk or bovine serum albumin for 1.5 hrs to prevent non-
specific binding. Further, the membranes were incubated overnight at 4°C with primary antibodies 
against HO-1 (Stressgen-1:800), Nrf2, ED1, CD36, GLUT4, c-Kit and Sca-1, Oct3/4, Pax2, 
Nkx6.1 and GLUT2 (Santa Cruz-1:1000), ED2, CD206, PI3K, Islet-1 (Santa Cruz-1:800), IRS-1 
and IRS-2 (Santa Crutz-1:750), β catenin (Abcam-1:5000). After primary antibody hybridization, 
blots were washed 3 times for 5 minutes each in 1x TBST (20 mM Tris-Cl, 150 mM NaCl, 0.1% 
tween 20, pH 7.6), and further incubated with secondary IgG horseradish peroxide conjugate 
antibody (Bio Rad) for 2 hrs at room temperature. After secondary antibody hybridization, blots 
were washed 3 times for 15 minutes each in 1x TBST to remove non-specific antibody. Finally, 
enhanced horseradish peroxide/luminol chemiluminescence reagent (Perkin Elmer Life Sciences, 
Boston, MA USA) was used to visualize the immuno-reactivity. -actin antibody (Sigma St Louis, 
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MO, USA) was used as a housekeeping protein control to confirm uniform loading. Enhanced 
horseradish peroxide/luminol chemiluminescence reagent (Perkin Elmer Life Sciences, Boston, 
MA USA) was used to visualize the immuno-reactivity. Relative densitometry of respective bands 
on blots was done using UN-SCAN-IT software (Silk Scientific, Utah, USA). 
 
6.3.3 Statistical analysis 
All data were expressed as mean ± SEM from at least four independent experiments unless 
otherwise stated. Statistical analyses were done using Student’s t-test, analysis of variance 
(ANOVA) and analysis of variance for repeated measures followed by post-hoc analysis 
(Bonferroni post hoc analysis) wherever appropriate (IBM SPSS Statistics, IBM Analytics, USA). 
Group differences at the level of p<0.05 were considered statistically significant. 
 
6.4 Results 
6.4.1 Hemin therapy enhanced HO-1 and Nrf2 in STZ-rats  
Our data showed that diabetic STZ-rats, exhibited several enhanced parameters of the 
diabetic state such as polydipsia, polyurea and fasting blood glucose. Hemin-treatment 
significantly reduced these parameters due to its intrinsic antidiabetic effects (4). In contrast, in 
the CrMP group, hemin-induced reduction of these parameters was greatly attenuated (Table 6-1).  
Diabetes significantly reduced the body weight in STZ-rats. Body weight was also lower 
in the hemin-treated and CrMP group (Table 6-1). However, there was no significant difference in 
body weight between the diabetic STZ-group and the hemin-treated group or CrMP group.  
Moreover, all three study groups showed a higher pancreatic weight (g/kg body weight) compared 
to controls. The increase in pancreatic weights were comparatively lower in hemin-treated and 
CrMP-group of animals. The differences in pancreatic weight (g/kg body weight) were not 
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statistical significant between STZ-rats and hemin-treated rats. In contrast, in CrMP group, the 
reduction of pancreatic weights was statistically significant compared to diabetic animals. Since 
we observed an increase in pancreatic weight (g/kg body weight) in diabetic STZ-rats which may 
be due to presence of pancreatic edema that characterised by increasing fluid retention and 
pancreatic swelling in response of STZ-induced toxicity (4,26). 
We further investigated the effects of hemin therapy on expression of HO-1 and Nrf2 
proteins which are known to have modulatory impact on tissue injuries and glucose metabolism 
(25). Our results indicated that the basal expression of HO-1 and Nrf2 in the control group was 
8.8- and 11.01-fold lower than the hemin-treated group and there was no significant increase in 
HO-1 and Nrf2 expression in the diabetic STZ-group compared to the control group. Hemin-
treatment significantly augmented the supressed basal expression of both HO-1 and Nrf2 in 
pancreatic tissue by 5.3-fold, and 13.7-fold compared to the STZ-group (Figs. 6-1A, 6-2A) 
respectively. 
 
6.4.2 Hemin therapy counteracted inflammation in STZ-rats 
Enhanced macrophage infiltration is a primary cause of tissue injury and dysfunctional 
metabolism in T1D (5, 27, 28). To determine the effects of hemin-therapy on macrophage-induced 
inflammation in STZ rats, several markers of macrophages ED1 (M1-macrophages), ED2, CD206, 
CD36 (M2-macrophage) were analysed (29, 30). Immunoblotting data indicated that the 
expression of ED1 is highly elevated in pancreas and liver of the diabetic STZ-group (14.1-fold 
and 4.3-fold) compared to the controls (Figs.6-3A, Fig 6-4A). Although, hemin did not completely 
supress the ED1 expression to the control level (5.6-fold, and 1.49-fold higher), it was significantly 
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attenuated in both pancreas and liver tissues (1.3-fold, 1.12-fold), compared to the diabetic STZ-
group.  
To investigate further hemin-induced effects on inflammation, the expressions of ED2, 
CD206 and CD36 markers (M2-phenotype) were analyzed in the pancreas and liver tissue that are 
shown to be associated with maintenance of the anti-inflammatory status (30). Our results showed 
that the expressions of ED2 and CD206 markers were significantly supressed in the diabetic STZ-
group compared to the controls and hemin treated group (Figs. 6-3B, C, Fig 6-4B, C). There was 
no significant difference in the expression of ED2, CD206 markers in the hemin treated- group 
compared to the controls in pancreas and liver. However, the hemin-treated group showed a 
significant enhanced expression of ED2 in both pancreas and liver (2.56-fold, 1.53-fold) (Figs. 6-
3B, Fig 6-4B), while enhanced CD206 expression is only documented in the liver (1.55-fold) 
compared to the diabetic STZ-group (Fig. 6-4C).  
Furthermore, in the diabetic STZ-group, the expression of CD36 markers in the pancreas 
and liver did not differ significantly, compared to the control group (Figs. 6-3C, Fig 6-4D). 
However, the hemin-treated group showed a significant increase of CD36 expression in both 
pancreas and the liver compared to the control and the diabetic STZ-group. These observations, 
collectively suggest that hemin-induced enhanced selectivity towards M2 macrophages is the 
underlying mechanism through which hemin counteracts inflammation in STZ-rats. 
  
6.4.3 Hemin therapy potentiates insulin signaling components in STZ-rats  
Given that increasing inflammation and oxidative stress are negative modulators of insulin 
signalling and glucose metabolism in diabetes (4, 22). To elucidate the effects of hemin therapy 
on insulin signalling and glucose metabolism in diabetic STZ-rats, major insulin signaling 
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components (IRS-1, IRS-2, PI3K and GLUT4) were examined in metabolically active liver and 
soleus muscle. 
Our results showed that the diabetic conditions significantly attenuated the expressions of 
IRS-1, IRS-2, PI3K and GLUT4 in liver of diabetic STZ-liver compared to the control group (Fig. 
6-5 A-D). Similar reduction of these components was also observed in soleus muscle for IRS-1, 
IRS-2 and GLUT4, however, the decrease of PI3K expression was not statistically significant (Fig. 
6-6 A-D). In contrast, hemin therapy significantly enhanced the expression of these components 
in both liver and soleus muscle compared to diabetic STZ-rats. The increases in the expression of 
IRS-1 were (1.28-fold, 10.5-fold), IRS-2 (0.56-fold, 2.3-fold), PI3K (1.0-fold, 1.3-fold) and 
GLUT4 (2.1-fold, 2.9-fold) higher in the liver and soleus muscle compared to diabetic STZ-rats 
(Figs.6-5 A-D, Fig. 6.6 A-D). Interestingly, the expressions of IRS-2, GLUT4 in liver and IRS-1 
in soleus muscle were significantly increased in hemin-treated animals than control counterparts. 
 
6.4.4 Enhancement of total antioxidant capacity with hemin in the pancreas of STZ-rats 
Since, pancreatic tissues are more susceptible to oxidative stress-induced comorbidities due 
to low antioxidant levels (31), we also examined the effect of hemin on total antioxidant capacity 
in the pancreas which is an important index of oxidative stress (23). Our results indicate that the 
diabetic STZ-group (1.83-fold) and CrMP-group (1.7-fold) showed a significantly lower total 
antioxidant capacity than controls (Fig. 6-7). In contrast, in the hemin-treated group, the total 
antioxidant capacity was significantly increased by 2.9-fold and 2.7-fold compared to diabetic 
STZ-rat and CrMP groups. However, the differences in the values of total antioxidant capacity 
between either the hemin treated group and control group or diabetic STZ-group and CrMP group 
were not significant. These results suggested that hemin therapy reduced the oxidative stress 
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through potentiation of total antioxidant capacity. In contrast, hemin-mediated effects on 
enhancement of pancreatic total antioxidant capacity were abated by CrMP treatment. 
 
6.4.5 Hemin therapy enhanced the expression of markers of pancreatic repair and/or    
regeneration in STZ-rats 
Given that T1D is an abnormal condition of increasing tissue injury and metabolic 
dysregulation (4,5) and enhancement of pancreatic repair and/or regenerative capabilities have 
cytoprotective benefits. To examine the effects of hemin on pancreatic repair and/or regeneration 
and functions during T1D, several markers (c-Kit, Sca-1, Oct3/4, Pax2, β-catenin, Islet-1, Nkx6.1, 
and GLUT2) that are implicated in pancreatic repair and/ or regeneration were analysed in pancreas 
of STZ-rats (14-21). Our results showed that the expressions of c-Kit and Sca-1, Oct3/4, Pax2, β-
catenin, Islet-1, Nkx6.1, and GLUT2 were significantly lower in diabetic STZ-rats compared to 
controls (Figs. 6-8 A, B, 6-9 A, B, D, 6-10 A, B).  
The expressions of c-Kit, Oct3/4 and Islet-1, and Pax2, Nkx6.1 and GLUT2 in hemin 
treated group were not statistically different compared to the control group. However, the 
expression of Sca-1 and β-catenin were significantly lower in the hemin-treated group than 
controls (Figs. 6-8 B, 6-9 C). Interestingly, hemin-treatment significantly increased the expressions 
of c-Kit, Sca-1, Oct3/4, Pax2, β-catenin and Islet-1, Nkx6.1 and GLUT4 in pancreas compared to 
diabetic STZ-rats. The expressions of c-Kit (4.8-fold), Sca-1 (5.9-fold), Oct3/4 (3.8-fold), Pax2 
(5.9-fold), β-catenin (2.1-fold), Islet-1 (2.2-fold), Nkx6.1 (1.03-fold) and GLUT4 (2.8-fold) were 
higher in hemin-treated rats compared to diabetic STZ-rats (Figs. 6-8, 6-9, 6-10). These results 
suggested that hemin therapy has significant modulatory effects on the expression of markers of 
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pancreatic repair and/or regeneration. These effects of hemin therapy on expression of pancreatic 
markers are novel and have not been previously reported.   
 
6.5 Discussion 
 The data from our study suggested the multifaceted mechanisms of hemin through which 
it counteracts inflammation, oxidative stress and potentiates insulin signalling to improve glucose 
metabolism in STZ rats, a model of T1D (4). Treatment with hemin upregulated both Nrf2 and 
HO-1. This was associated with the enhancement of several proteins implicated in pancreatic 
repair and regeneration including c-Kit, Sca-1, Oct3/4, Pax2, β-catenin, Islet-1, Nkx6.1 and 
GLUT2.   
Interestingly, recent studies underscore a regulatory role of Nrf2 in diabetic wound repair 
and the tissue regeneration process in various organs such as skeletal muscle, kidney and liver (32-
36). Similarly, the HO system has been implicated in tissue regeneration (37,38), thus, it is possible 
that Nrf2/HO synergism may play a reasonable role in pancreatic repair. To test this hypothesis, 
we analysed several proteins, markers and transcriptional factors in pancreatic homogenates that 
are implicated in pancreatic repair and /or the regeneration process, such as stem cell marker (c-
Kit, Sca-1), markers of early β-cells and islet development (Oct3/4, Pax2, β-catenin, Islet-1), and 
functional markers of β-cells maturation and functions (Nkx6.1, GLUT2) (14-21). A depressed 
expression of these markers was observed in the STZ-treated diabetic group, suggesting that the 
diabetic condition negatively regulates the expression of these markers in the pancreas and due to 
this reason, the tissue regenerative capabilities of the pancreas is markedly reduced during 
diabetes. The enhancement of c-Kit, Sca-1, Oct3/4, Pax2, β-catenin, Islet-1, Nkx6.1, GLUT2 in 
pancreas of STZ rats is a novel observation.  
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It is evident that enhanced macrophage infiltration is the primary characteristic of injured 
pancreas during T1D (28-39). In our experiments, diabetes induction through STZ was associated 
with several folds increased expression of proinflammatory M1 markers of macrophages in the 
STZ-group in both pancreas and liver which is indicative of inflammatory injury. In contrast, 
hemin-induced Nrf2/HO axis was associated with reduction of inflammation in pancreas and liver. 
It is reported that during inflammation, macrophages can exhibit distinct phenotypes i.e. the 
classical M1-phenotype which is pro-inflammatory and the alternative-activated M2-phenotype 
that is known to have anti-inflammatory effects (30, 40). To resolve inflammation, these 
macrophages can switch their existing phenotype, for example M1-M2 transition, through a 
polarisation process (30,40). 
In our experiments, Nrf2/HO-mediated anti-inflammatory effects were executed through 
selective enhancement of M2-phenotype expression of macrophage (ED2, CD206 and CD36) 
which are known to be anti-inflammatory and participate in tissue repair (30,40). The selective 
enhancement of M2-markers (ED2, CD206 and CD36) and parallel reduction in M1-phenotypic 
expression of ED1 is a novel mechanism by which upregulated Nrf2/HO reduced inflammation in 
STZ-rats which has not been previously reported in pancreas and liver of STZ-rats. 
Elevated oxidative stress also a major contributor of tissue injury and metabolic 
dysfunction in T1D (4,5,41) and pancreatic tissue is highly vulnerable against oxidative stress in 
T1D due to their intrinsic weaker antioxidant defence (31). In this situation, potentiation of 
antioxidant capacity of the pancreas will have cytoprotective benefits. The data from the present 
study showed that hemin-mediated upregulation of the Nrf2/HO axis was associated with 
enhanced total antioxidant capacity of the pancreas, which is a measurement of several important 
antioxidant enzymes (superoxide dismutase, catalase, and glutathione peroxidase) and antioxidant 
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molecules (albumin, ceruloplasmin, ferritin, ascorbic acid, α-tocopherol, β-carotene, reduced 
glutathione, uric acid, and bilirubin). Our data indicated that the diabetic condition is associated 
with reduced levels of antioxidant status in STZ-rats compared to controls and the hemin-treated 
group and HO blockage further supressed the expression of antioxidant levels in pancreatic tissue. 
In contrast, antioxidant capacity of the pancreas is significantly augmented through hemin 
treatment.  
It is reported that HO-metabolites biliverdin and ferritin have potent antioxidant effects 
(22), in addition, hemin therapy also enhanced the expression of antioxidant response 
transcriptional factor Nrf2 in pancreas which is a positive modulator of not only HO-mediated 
cytoprotective functions but also confers cytoprotection through production of antioxidant 
enzymes (24,25). Since, hemin augmented both HO and Nrf2 in pancreas, it is obvious that hemin-
induced enhanced antioxidant capacity is a direct effect of Nrf2/HO axis upregulation and 
associated enhancement of antioxidant enzymes. The lower basal expression level of Nrf2 in 
control subjects may be due to downregulation of Nrf2 activation through Kelch-like erythroid 
cell-derived factor which is only known to activate Nrf2 in various conditions of inflammation and 
oxidative stress (24,25). In contrast, suppressed expression of Nrf2 in the STZ-treated diabetic 
group was indicative of a dysregulated Nrf2 activation mechanism during diabetes (24,25, 42). 
It is known that inflammation and oxidative stress are negative modulators of glucose metabolism 
through suppression of insulin signaling components such as IRS-1, IRS-2, PI3K and GLUT4, in 
metabolic important tissues (4,43-47), and for physiological regulation of glucose, optimal 
functions of insulin signaling components are an essential requirement. Since hemin-induced 
Nrf2/HO axis attenuated inflammation and oxidative stress in diabetic animals, it is expected that 
these cytoprotective effects would be accompanied by improvement in the insulin signalling 
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mechanism and glucose metabolism. The data from the present study indicate that the diabetic 
condition significantly supressed the expression levels of insulin signaling components (IRS1, 
IRS2, PI3K, and GLUT4) in the liver and soleus muscle. However, hemin-mediated Nrf2/HO axis 
upregulation enhanced the expression of these components compared to the diabetic STZ-group 
in both liver and soleus muscle.  Furthermore, hemin-mediated potentiation of insulin signalling 
components was associated with lowering of fasting blood glucose levels in diabetic animals 
(Table 6-1). These observations collectively indicated that although, hemin-treatment did not 
completely normalize the fasting blood glucose levels to the control levels, 4 wks of hemin regimen 
showed an effective suppression of the elevation of blood glucose level in STZ rats that is 
suggestive of improved glucose metabolism and increased insulin contents in diabetic animals. 
These observations were in line with previously published reports that during diabetes reduction 
of inflammatory and oxidative mechanisms have a positive impact on glucose metabolism in 
various conditions of inflammatory and oxidative-stress-induced tissue insult (4).  
Taken together, the present study implicates the role of Nrf2/HO axis in regulation and 
maintenance of glucose metabolism through enhanced expression of insulin signalling components 
and reduction of hyperglycemia in the STZ-induced diabetes condition. 
 
6.6 Conclusion 
In conclusion, upregulation of Nrf2/HO axis, selective enhancement of M2-macrophage 
markers (ED2, CD206, CD36), potentiation of antioxidant capacity and insulin signalling 
components (IRS-1, IRS-2, PI3K, GLUT4) are the multifaceted mechanisms through which hemin 
suppresses tissue insults while improving glucose metabolism in STZ rats. The hemin-mediated 
potentiation of the Nrf2/HO axis and reduction of tissue comorbidities and dysfunctional 
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metabolism is associated with enhancement of several markers (c-Kit, Sca-1, Oct3/4, Pax2, β-
catenin, Islet-1, Nkx6.1, GLUT2) implicated in pancreatic repair and/or regeneration in STZ rats. 
Thus, our present study underscores the important modulatory role of hemin therapy in 
improvement of tissue repair and metabolism during T1D and suggested that hemin-based 
strategies will be part of therapeutic protocols for T1D treatment in the future. 
 
Table 6-1: Effects of hemin (HO-1 inducer) and CrMP (HO-1 blocker) treatment on physiological 
variables in STZ-induced diabetic Sprague Dawley (SD) rats  
 
Table 6-1: Effects of hemin and CrMP-treatment in STZ-treated diabetic rats. Statistical analysis 
was done using analysis of variance (ANOVA) and analysis of variance for repeated measures 
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followed by post hoc analysis. Values are means  SEM for n=4-6 rats per group. STZ, 
streptozotocin-induced diabetic; CrMP, chromium mesoporphyrin ap<0.05 vs control group; 
bp<0.01 vs control group; cp<0.05 vs STZ group; dp<0.01 vs STZ group; ep<0.01 vs STZ + hemin 
group; fp<0.05 vs STZ + hemin + CrMP group; gp<0.01 vs STZ + hemin + CrMP group. 
 
 
Figure 6-1: Effects of the HO-1 inducer, hemin on HO-1 expression in the pancreas of diabetic 
STZ-rats. (A) Hemin treatment enhanced HO-1, whereas the control group showed lower basal 
expression of HO-1 and there was no increase in HO-1 expression in the STZ-treated diabetic rats. 
Statistical analysis was done using Student’s t-test. Bars represent means ± SEM; n = 4 rats per 
group (*p<0.01 vs control group and STZ group).  
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Figure 6-2: Effects of the HO-1 inducer, hemin on Nrf2 expression in the pancreas of diabetic 
STZ-rats. (A) Hemin enhanced Nrf2, whereas the basal level of Nrf2 was significantly lower in 
control group while significantly abated in STZ-treated diabetic group compared to hemin-treated 
group. Statistical analysis was done using Student’s t-test. Bars represent means ± SEM; n = 4 rats 
per group (*p<0.05 vs control group and STZ group). 
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Figure 6-3: Effects of HO-1 inducer, hemin on ED1, ED2, and CD36 in the pancreatic tissue of 
diabetic STZ-rats. Hemin therapy (A) reduced ED1, but (B) enhanced ED2, (C) increased CD36 
in STZ-treated diabetic rats. Statistical analysis was done using Student’s t-test. Bars represent 
means ± SEM; n = 4 rats per group (*p<0.05 vs all groups; @p<0.05 vs all groups).   
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Figure 6-4: Effects of HO-1 inducer, hemin on ED1, ED2, CD206 and CD36 in the liver of 
diabetic STZ-rats. Hemin therapy (A) reduced ED1, but (B) enhanced ED2, (C) increased CD206 
(D) enhanced CD36 in STZ-treated diabetic rats. Statistical analysis was done using Student’s t-
test. Bars represent means ± SEM; n = 4 rats per group (*p<0.05 vs all groups).   
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Figure 6-5: Effects of HO-1 inducer, hemin on IRS-1, IRS-2, PI3K and GLUT4 in the liver of 
diabetic STZ-rats. Hemin therapy significantly enhanced the expression of insulin components (A) 
IRS-1, (B) IRS-2, (C) PI3K, and (D) GLUT4 in STZ-treated diabetic rats. Statistical analysis was 
done using Student’s t-test. Bars represent means ± SEM; n = 4 rats per group (*p<0.05 vs all 
groups, @p<0.05 vs all groups). 
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Figure 6-6: Effects of HO-1 inducer, hemin on IRS-1, IRS-2, PI3K and GLUT4 in the soleus 
muscle of diabetic STZ-rats. Hemin therapy significantly enhanced the expression of insulin 
components (A) IRS-1, (B) IRS-2, (C) PI3K, and (D) GLUT4 in STZ-treated rats. Statistical 
analysis was done using Student’s t-test. Bars represent means ± SEM; n = 4 rats per group 
(*p<0.01 vs all groups, @p<0.01 vs all groups, #p<0.05 vs STZ+ hemin group only). 
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Figure 6-7: Effects of hemin on total antioxidant capacity in the pancreas of diabetic STZ-rats. 
Hemin therapy significantly enhanced the total antioxidant capacity of pancreas in STZ-treated 
diabetic rats. Statistical analysis was done using analysis of variance (ANOVA) followed by post 
hoc analysis. Bars represent means ± SEM; n = 6 rats, control and hemin group, n = 4, STZ-treated 
diabetic rats and n = 5 rats, CrMP group (*p<0.01 vs STZ and STZ + hemin + CrMP group; 
@p<0.01 vs control group and STZ + hemin group, #p<0.01 vs control group). 
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Figure 6-8: Effects of hemin on expression of stem cell markers in the pancreatic tissue of diabetic  
STZ-rats. Hemin therapy significantly enhanced the expression of stem cell markers (A) c-Kit and 
(B) Sca-1 in STZ-treated diabetic rats. Statistical analysis was done using Student’s t-test. Bars 
represent means ± SEM; n = 4 rats per group (*p<0.01 vs all groups, #p<0.05 vs control and STZ 
group, @p<0.01 vs control group only). 
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Figure 6-9: Effects of hemin on expression of markers of early -cells development in pancreatic 
tissue of diabetic STZ-rats. Hemin therapy significantly enhanced the expression of (A) Oct3/4 
(B) Pax2, (C) β-catenin and (D) Islet-1 in STZ-treated rats. Statistical analysis was done using 
Student’s t-test. Bars represent means ± SEM; n = 4 rats per group (**p<0.05 vs all groups, 
*p<0.01 vs all groups, @p<0.05 vs all groups).  
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Figure 6-10: Effects of hemin on expression of markers of -cells maturation and functions in the 
pancreatic tissue of diabetic STZ-rats. Hemin therapy significantly enhanced the expression of (A) 
Nkx6.1 and (B) GLUT2 in STZ-treated diabetic rats. Statistical analysis was done using Student’s 
t-test. Bars represent means ± SEM; n = 4 rats per group (*p<0.01 vs all groups). 
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Figure 6-11: Summary of results. Abbreviations used; Heme oxygenase-1 (HO-1), Nuclear 
factor-(erythroid-derived 2)-like 2  factor (Nrf2),  Classical M1-macrophages; Alternative-
activated M2-macrophages; Cluster of differentiation-68 (ED1) macrophages; Cluster of 
differentiation-163 (ED2) macrophages; Cluster of differentiation-206 (CD206) macrophages; 
Cluster of differentiation-14 (CD14) macrophages; Cluster of differentiation-36 (CD36) 
macrophages; Tyrosine-protein kinase protein (c-Kit); Stem cell antigen-1 (Sca-1); Octamer-
binding transcription factor-3/4 (Oct3/4); Paired homeodomain transcription factor-2 (Pax2); Beta 
catenin (β-catenin); Insulin gene enhancer protein-1 (Islet-1); Homeobox protein Nkx6.1; Glucose 
transporter 2 (GLUT2); Insulin receptor substrate-1 (IRS-1); Insulin receptor substrate-2 (IRS-2); 
Phosphoinositide 3-kinase (PI3K); Glucose transporter 4 (GLUT4). 
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CHAPTER 7 
GENERAL DISCUSSION 
 The data presented in this thesis strongly suggest that  inflammation and oxidative stress 
are among the major pathophysiological driving forces that cause  tissue injury and compromise 
function  in metabolic diseases, and unveil novel multi-faceted mechanisms through which  
upregulation  of the HO-system potentiate insulin signaling, enhance glucose and lipid metabolism 
with corresponding improvement of pancreas, liver, kidney and heart function in animal models 
of obesity, diabetes, and hypertension. 
 
7.1 Role of HO against inflammation  
It is known that obesity, diabetes, and hypertension are the inflammatory conditions and 
macrophages are the major cellular entity that participates in both inflammation initiation and 
progression. Enhanced macrophage accumulation of proinflammatory M1-macrophages and 
augmentation of proinflammatory cytokines and chemokines (TNF-α, IL-6, IL-1β, MCP-1, MIP-
1α) are the key events during these conditions that not only initiate tissue injury but also define the 
severity and progression of these conditions (5-7,27-29,347-351). During these conditions, 
excessive adiposity and elevated levels of lipid derivatives such as triglycerides and cholesterol 
are leading causes of inflammation initiation in metabolic tissues. In response, macrophages 
accumulate in fat laden tissues and initiate inflammation-induced tissue injury mechanisms 
through overproduction of proinflammatory cytokines and chemokines (5,7,27-29,347-351). In 
several studies related to obesity, diabetes, and hypertension an increased accumulation of 
macrophages and elevated levels of proinflammatory cytokines and chemokines have been 
observed (5,7,27-29,347-351). The availability of protein markers for proinflammatory 
macrophages, such as ED1, give a great opportunity to trace this phenomenon in various tissue 
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(27,28). The present study shows that the condition of obesity, diabetes and hypertension are 
characterized by enhanced expression of pro-inflammatory ED1 macrophages in various inflamed 
tissues such as liver, heart, kidney, and pancreas that suggests increased inflammatory events in 
response to increasing obesity, diabetes and blood pressure elevation (10,15,16). However, HO 
upregulation through hemin is associated with marked reduction of ED1 expression that is 
suggestive of reduction in inflammation. Although, hemin-associated HO upregulation was 
associated with abated ED1, the mechanism through which hemin executed this protective effect 
was not known. In the scientific literature, it is reported that M2-macrophages, distinct functional 
subsets of resident macrophages, are involved in tissue repair and lowering of inflammation (22-
24). Based on this information, several M2 macrophage markers (ED2, CD206, CD36, and CD14) 
were selected to investigate the hemin-induced anti-inflammatory mechanism in the present study 
(352-355). The data from the present study indicate that hemin treated animals showed an 
enhanced expression of M2-macrophages. This selective enhanced expression of M2-macrophages 
is suggestive of HO-mediated regulation of macrophage polarization event. Thus, the data of the 
present study indicate that hemin-induced HO upregulation was associated with regulation of 
macrophage polarization through which it selectively enhanced the anti-inflammatory M2 
macrophages while restricted proinflammatory M1-macrophages in the injured tissue. The 
collective effect of this selectivity is a marked suppression of inflammation induced injuries in the 
vital organs liver, heart, kidney, and pancreas.  
Chemokines and cytokines are implicated in the inflammatory effects of the M1-
macrophage phenotype. It is known that M1-macrophages are the major producers of 
proinflammatory cytokines and chemokines (TNF-α, IL-6, IL-1β) and (MCP-1, MIP-1α) during 
tissue inflammation (22-24), and the data presented in this thesis confirmed the presence of the 
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proinflammatory cytokines and chemokines in liver, kidney and cardiac tissue. Thus, it is expected 
that HO-associated reduction of proinflammatory ED1 macrophages will be accompanied with a 
parallel reduction of macrophage associated enhanced production of TNF-α, IL-6, IL-1β, MCP-1, 
MIP-1α. The data indicated that HO upregulation significantly inhibited the TNF-α, IL-6, IL-1β, 
MCP-1, MIP-1α expression levels in liver, heart and kidney. These observations further supported 
the role of HO-associated modulation of inflammation during obesity, diabetes, and hypertension.  
Based on these observations, the presented data collectively suggested that the hemin-
induced selective inhibition of M1-macrophages was associated with augmentation of M2-
macrophage markers (ED2, CD206, CD36, CD14) which is one mechanism by which the HO-
system may reduce the elevated levels of inflammatory cytokines and chemokines associated 
cytotoxic tissue injury in metabolic dysfunctional states like obesity, diabetes, and hypertension. 
Thus, the data from the present study indicate that during metabolic tissue injury, hemin-mediated 
suppression of inflammation signalling has a protective significance that leads to improved tissue 
health and physiological functions during obesity, diabetes, and hypertension. 
 
7.2 Role of HO against oxidative stress  
Oxidative stress is another major player of tissue destruction of liver, heart, kidney and 
pancreas that governs tissue injury through induction of inflammation via proinflammatory 
cytokines and tissue fibrotic response in obesity, diabetes, and hypertension (109-114). In addition, 
during the conditions of obesity, diabetes, and hypertension, elevated levels of oxidative stress 
mediators also inhibit the insulin signalling mechanism and assist in development of insulin 
resistance and altered glucose metabolism, which collectively result in tissue dysfunction and 
failure (109-114). 
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Elevated fat derivatives, like triglycerides, cholesterol and hyperglycemia are detrimental 
to tissue morphology and functions via production of oxidative stress (109-114). During conditions 
of obesity and diabetes, overproduction of these oxidative stress generating molecules have been 
documented and suggest their participation in oxidative tissue injuries (109-114).  In addition, 
tissue infiltrating macrophages are also shown to produce oxidative stress in the local tissue 
environment (5,7,115-118). Thus, collectively elevated oxidative stress participates in oxidative 
damage to tissue. Moreover, during T1D, where the pancreatic tissue has a low antioxidant 
capacity compared to other tissues, elevated oxidative stress causes significant damage to both 
endocrine and exocrine tissues (8,160,161), thus, in this condition, enhancement of an antioxidant 
defense mechanism is necessary. 
The data of the present study also shows oxidative stress-induced injury in liver, kidney, 
and heart through elevation of a marker of lipid peroxidation and vascular oxidative stress (8-
isoprostane and ET-1) (8,16,17,19,144,150-153,356). In both obesity and diabetes, elevated levels 
of 8-isoprostane and ET-1 are observed that is suggestive of the presence of an oxidative 
environment. However, in hemin-treated animals these markers were significantly attenuated in 
liver, kidney and cardiac tissue. Interestingly, the data in STZ rats indicated that hemin therapy 
significantly augmented the total antioxidant capacity of pancreatic tissue and upregulates the 
antioxidant related transcriptional factor Nrf2. But the question arises how the hemin induced HO-
system participates in reduction of oxidative stress. It is reported that catabolic functions of the 
HO-system generates anti-inflammatory molecules like carbon monoxide and antioxidants like 
biliverdin and ferritin (356). In addition, the Nrf2/HO axis is shown to activate transcription of a 
number of antioxidant enzymes (357,358). Thus, the augmentation of antioxidant Nrf2 signaling 
and production of antioxidant molecules such as biliverdin and ferritin are the mechanisms through 
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which the hemin induced HO-system protects the tissue from oxidative injuries and this beneficial 
impact results in improvement of tissue morphology and functions.  
 
7.3 Role of HO upregulation on body weight 
Hemin therapy has been shown to be associated with a slight reduction in body weight 
measurements in all rat models (ZF, ZDF, SHR, STZ). The inhibition of HO either with CrMP or 
SnMP also further slightly decreased body weight in all experimental animals. Interestingly, hemin 
therapy also caused a weight reduction in the WKY genetic control of SHR rats or Zucker lean 
control rats. Due to this body weight reducing effect of hemin, one may consider the toxic effects 
of hemin in experimental animals. However, our previous experimental observations suggested 
that the above reduction in body weight was not due to an effect of hemin toxicity since toxicity 
parameters such as plasma gamma-glutamyl transferase, aspartate aminotransferase, and alanine 
aminotransferase were in the normal range (359). 
 
7.4 Role of HO upregulation on blood glucose and blood pressure  
Although, SHR rats and ZF rats were normoglycemic, hemin treatment further decreased 
glucose levels while HO inhibition in the CrMP group enhanced glycemic levels. Interestingly, 
hemin-mediated reduction of glucose levels was also seen in control Zucker lean animals, while 
HO-inhibitor group was associated with elevated blood glucose.  
The data from the present study showed that hemin-therapy significantly reduced the fasting blood 
glucose levels in hyperglycemic ZDF and STZ rats, in contrast HO- inhibition through either CrMP 
group or SnMP acerbated the hemin-mediated glucose lowering effects. These observations 
collectively suggested the potent regulatory role of the HO-system in blood glucose lowering and 
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matched previously published reports where the HO-system metabolite carbon monoxide 
participates in insulin release through stimulation of islets (360-362). Furthermore, in hypertensive 
SHR-rats, hemin-induced HO upregulation effectively regulated blood pressure elevation while 
HO blockage through CrMP ameliorates the hemin-mediated lowering effect on blood pressure. 
The blood pressure regulating effects of hemin was in line with our previously published reports 
(363,364), and was associated with HO-mediated increased expression of sGC proteins and 
increased cGMP levels in SHR rats. Thus, the HO-induced lowering of blood glucose and blood 
pressure is suggestive of reduction of hyperglycemic-induced and pressure induced tissue injury 
during hypertension and diabetes.  
 
7.5 Role of HO upregulation on tissue injury  
The comorbid conditions of oxidative stress and inflammation in obesity, diabetes, and 
hypertension negatively affect the tissue morphology of liver, kidney and heart. Moreover, the 
physiological functions of these tissue are greatly disturbed and collectively develop into 
pathological conditions of fatty liver disease, nephropathy and cardiomyopathy if not managed 
efficiently. Data from the present study indicate that elevated adiposity in ZF rats resulted in 
significant enhancement of heart tissue weight which is indicative of hypertrophied changes of 
cardiac tissue (365-367). In addition, adiposity also greatly disturbed several functional 
hemodynamic parameters in cardiac tissue such as an increase in arterial systolic and diastolic 
pressure, mean arterial pressure, left ventricular (LV) developed pressure, total peripheral 
resistances, +dp/dt(max), heart rate and LV diastolic and systolic wall thickness (365-367). 
Furthermore, obesity downregulated the cardiac functional parameters such as decreased LV end-
diastolic and systolic volume, stroke volume, and cardiac output. The obesity-induced cardiac 
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tissue injury was associated with enhanced expression of profibrotic mediators such as collagen-
IV, fibronectin and TGF-β (368,369). Cardiac histological and morphometric analyses of obese 
ZF rats showed increased cardiomyocyte longitudinal muscle-fiber thickness and cardiac 
hypertrophy (365-367). In contrast, hemin therapy, significantly reduced heart weight close to the 
lean counterpart. Left ventricular thickness and expression of profibrotic collagen-IV, fibronectin 
and TGF-β that are the important factors for cardiac hypertrophy were greatly attenuated by hemin 
(365,366,368,369). Histological analysis further confirmed these observations, where hemin 
therapy significantly reduced cardiomyocyte longitudinal muscle-fiber thickness, scarring and 
interstitial and perivascular collagen deposition which are the important indices of cardiac 
hypertrophy (367), while HO blockage enhanced the hypertrophied cardiac tissue. Additionally, 
hemin associated reduction of cardiac hypertrophy was associated with improvement in 
hemodynamic parameters which were deviated in response to obesity. Hemodynamic parameters 
such as increased arterial systolic and diastolic pressure, mean arterial pressure, left ventricular 
(LV) developed pressure, total peripheral resistances, +dp/dt (max), heart rate and LV diastolic and 
systolic wall thickness were suppressed by hemin therapy while cardiac functions (LV end 
diastolic and systolic volume, stroke volume and cardiac output) were improved (365-367). 
Similarly, in obese diabetic ZDF animals, hemin-treatment reduced hepatic hypertrophy as 
indicated by a reduced liver-to-body weight ratio which is an important indicator hypertrophic 
liver (370) and reduction of profibrotic mediators such as TGF-β, fibronectin and collagen-IV 
implicated in hepatic fibrosis (371-376). However, hemin therapy showed a greater selectivity for 
reduction of fibronectin compared to collagen-IV. In addition, histological measurement showed 
that hemin therapy significantly reduced histopathological lesions of liver tissue as evident by 
hepatocyte ballooning injury and fibrosis in ZDF control animal (377,378). 
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Increasing perirenal adiposity is a critical factor in renal dysfunction and injury and renal 
failure in obesity and diabetes (379-381). Hemin therapy significantly reduced perirenal adiposity 
in obese diabetic ZDF rats while HO inhibition nullified the hemin-mediated suppressive effect on 
perirenal adiposity. Enhanced renal fibrosis is a major event during obesity and diabetes that 
severely affected renal functions and reduced the expression of nephrin which is an important 
protein of podocyte functions (10,382-386). In addition, renal pathological features such as 
albuminuria, proteinuria and creatinine clearance were greatly affected (10,382-386). The data 
from the present study showed that hemin treatment in ZDF animals was associated with marked 
reduction of profibrotic fibronectin and collagen-IV expression. Histological analysis further 
showed that in hemin treated ZDF animals, renal histopathological lesions were greatly reduced 
through suppression of collagen deposition, tubular vacuolization, glomerulosclerosis, and 
perivascular fibrosis while nephrin expression was enhanced. The collective effect of these 
reduced renal pathologies through hemin treatment was associated with suppression of 
albuminuria, proteinuria with enhanced creatinine clearance. Thus, the data from the present study 
indicate that hemin-mediated HO-induction has a cytoprotective role in hepatic, renal and cardiac 
injuries during obesity and diabetes, that collectively results in improved cardiac, renal and hepatic 
functions. 
 
7.6 Role of HO upregulation on insulin signaling  
 In obese, diabetic and hypertensive subjects, elevated levels of inflammatory and oxidative 
stress mediators are negative regulators of insulin signalling and glucose metabolism and during 
these conditions, insulin signalling is greatly attenuated (5,6,54-57,61,73,77,85,91,120,167-
169,179-181,308). 
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Additionally, these inflammatory/oxidative mediators cause effective suppression of insulin-
receptor-phosphorylation-mediated activation, thus, interfering in insulin-mediated activation of 
the insulin signalling mechanism (5,6,54-57,61,73,77,85,91,120,167-169,179-181,308). 
Moreover, the expression of important insulin signalling components such as IRS-1, IRS-2, PI3K 
and GLUT4 is also reduced that collectively results in abnormal or suppressed insulin signalling 
and development of insulin resistance in metabolically active tissues (5,6,54-
57,61,73,77,85,91,120,167-169,179-181,308). The data from the present study showed the role of 
the above described negative consequences of inflammation and oxidative stress in dysregulated 
insulin signalling during obesity, diabetes, and hypertension. In hypertensive animals (SHR), 
obese animals (ZF-rats), and T1D-diabetic (STZ-rats) animals, the expression of insulin signalling 
components such as IRS-1, IRS-2, PI3K and GLUT4 was greatly attenuated in liver, soleus muscle 
and heart leading to abnormal glucose metabolism. Similarly, the altered or low expression of 
insulin signalling components were reported in our previous published report in ZDF model of 
T2D (15,341,359). However, hemin treatment greatly enhanced the expression of these 
components and potentiated the insulin signaling mechanism in both the obese and diabetic 
models.  
Furthermore, it is reported that, enhanced HO-1 activity and increased production of carbon 
monoxide has a potent stimulating effect on cGMP expression, that is an important mediator of 
improved insulin signalling and metabolism (346,359,387). Hemin-treatment also increased 
cGMP levels in SHR, ZDF, ZF rats. In contrast, the ablation of HO greatly suppressed the 
expression and levels of these homeostatic and functional components of insulin signalling. In 
addition, in obese ZF-rats, the glucose tolerance test and a homeostasis model assessment of 
insulin resistance experiments showed that hemin therapy was associated with improvement of 
250 
 
insulin sensitivity, and glucose tolerance with suppressed the insulin resistance. Hemin treatment 
also enhanced adiponectin in ZF and ZDF rats that was shown to have a potent role in the insulin 
sensitizing mechanism during obesity and diabetes and hypertension (18,388,389).The data from 
the present study collectively suggested that hemin associated reduction of inflammation, 
oxidative stress and potentiation of insulin signalling components (IRS-1, IRS-2, PI3K, GLUT4) 
and  augmentation of cGMP and adiponectin are the major mechanisms through which HO 
improves glucose metabolism in conditions of obesity, diabetes and hypertension. 
 
7.7 Role of HO upregulation on markers of pancreatic repair and/or regeneration 
 Increasing inflammation and oxidative stress and low antioxidant capacity are key 
contributors to enhanced pancreatic injuries during T1D (160,161). In this condition, reduction of 
these tissue destructive conditions and enhancement of pancreatic repair would have 
cytoprotective advantage. Our previous studies showed that hemin therapy significantly reduced 
pancreatic lesions in both T1D and hypertensive rats through suppression of vacuolization, 
interstitial edema, mononuclear infiltration and acinar cell necrosis (8,9), however, the underlying 
mechanisms behind this cytoprotection and repair was unknown. It is reported in several models 
of rodents that during pancreatic injuries, several tissue repair and regeneration processes are 
activated and participate in resolution of tissue injuries. 
 The data from the present study showed that, hemin treatment not only reduced pancreatic 
inflammation and oxidative injuries but also enhanced several protein markers and transcriptional 
factors that are implicated in pancreatic repair and regeneration. The immunoblotting data from 
the present study in STZ rats showed that 4-wks hemin treatment significantly enhanced several 
markers implicated in pancreatic repair or regeneration, such as stem cell markers (c-Kit, Sca-1), 
markers of early β-cell growth and islet development (Oct3/4, Pax2, β-catenin, Islet-1) and β-cell 
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maturation and function (Nkx6.1, GLUT2) in the STZ pancreas. In contrast, the expression of 
these markers was greatly attenuated in diabetic STZ rats. The collective effect of the enhanced 
markers of pancreatic repair and or/ regeneration was associated with reduction in hyperglycemia. 
Thus, it is suggested that the hemin-induced HO-upregulation, participates in the enhancement of 
pancreatic repair and/or regeneration markers that may be a reason for reduction of pancreatic 
injury observed in our previous study (8,9).  
 Although, the data from present study indicate the enhancement of several markers of 
pancreatic repair and/ or regeneration, it seems that hemin therapy induced pancreatic regeneration 
by which it enhances the repair of injured pancreas. However, our study has some limitations. The 
present study only evaluated the effect of hemin-therapy on several markers of pancreatic repair 
and/ or regeneration at a whole animal level through measurement of expression of marker, in this 
situation, it is hard to confirm the individual contribution of these markers in pancreatic repair 
since the present study lacks the other data support. In addition, the present study did not use any 
genetic cellular tagging methods to trace the effect of hemin therapy on individual cells, for 
example β-cells. However, in the present study and past observation from our laboratory  (359), 
hemin-mediated potentiation of insulin signalling, insulin levels and reduction of hyperglycemia 
are indicative of a positive influence of hemin therapy on pancreatic regeneration. Since, in recent 
years, pancreatic regeneration in the adult stage is greatly challenged by a number of studies 
(205,207,226,234-237,239-244),  more investigation and data support are required at the molecular 
level to confirm the regenerative potency of hemin therapy. 
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CONCLUSION 
My thesis represented a comprehensive study on the novel and multifaceted effects of the 
upregulated HO system on hepatic, renal, cardiac, pancreatic tissue injury, glucose homeostasis 
and tissue functions in conditions of obesity, diabetes, and hypertension. The data presented in this 
thesis demonstrated the potential role of the HO-inducer hemin in reduction of inflammation and 
oxidative stress-induced tissue comorbidities such as fibrosis and histopathological lesions in 
hepatic, renal and cardiac tissue while enhancement of repair and/or regenerative markers in the 
pancreas was observed. Additionally, hemin-mediated HO upregulation was associated with 
improvement in glucose metabolism through reduction of insulin resistance, hyperglycemia and 
potentiation of insulin signaling components. 
The novel observations of the present study are as follows; 
1) The hemin-induced HO system significantly reduced the inflammatory macrophage 
infiltration through the enhancement of macrophage polarization in which HO selectively 
enhanced the expression of anti-inflammatory M2-phenotype with corresponding 
suppression of the pro-inflammatory M1-phenotype in obese, diabetic and hypertensive 
rats. 
2) Hemin-induced HO system attenuates pro-inflammatory chemokines/cytokines (TNF-α, 
IL-6, IL-1β, MCP-1, MIP-1α) and oxidative mediators (8-isoprostane and ET-1), while it 
enhanced antioxidant capacity and the antioxidant signalling transcriptional factor Nrf2 in 
obese, diabetic and hypertensive rats. 
3) Hemin-mediated HO upregulation attenuates fibrosis, hypertrophy and histopathological 
lesions in the liver, cardiac and renal tissue via marked suppression of both ECM and 
profibrotic mediators, collagen-IV, fibronectin and TGF-β in obese and diabetic rats. 
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4) Hemin-induced HO significantly enhanced the glucose metabolism through potentiation of 
insulin signaling components (IRS1, IRS2, PI3K and GLUT4) and adiponectin while 
suppressing hyperglycemia, insulin resistance and glucose intolerance in obese, diabetic 
and hypertensive rats 
5) Hemin-induced HO significantly enhanced the expression of Nrf2 transcription factor, and 
markers implicated in pancreatic repair and/or regeneration, such as stem cell markers (c-
Kit, Sca-1), markers of early β-cell development (Oct3/4, Pax2, -catenin, Islet-1), and 
markers of β-cell maturity and functions (Nkx6.1 and GLUT2) in pancreas of diabetic rats.  
6) Collectively, these data suggest that HO reduced tissue inflammation (TNF-α, IL-1β, IL-
6, MCP-1, MIP-1α),  oxidative mediators (8-isoprostane, ET-1), profibrotic mediators 
(TGF-β, collagen-IV, fibronectin) and improved glucose metabolism through potentiation 
of the components of insulin signaling (IRS-1, IRS-2, PI3K, GLUT4) and adiponectin are 
the major mechanisms through which HO confers cytoprotection and metabolic regulation 
in conditions of tissue injury and metabolic dysfunction such as obesity, diabetes, and 
hypertension. 
 
SIGNIFICANCE 
Cellular injury and metabolic dysfunction are the hallmark features of obesity, 
hypertension and diabetes. Increasing inflammation and oxidative stress are considered as the 
major driving forces behind this altered cellular homeostasis and present a life-threatening risk. 
Several pharmaceutical advancements are currently in use to counteract these abnormal situations, 
but the desired outcome is still lacking due to intrinsic complexity and multigenic origin of these 
metabolic complications. Additionally, these conditions not only cause local tissue dysfunctions 
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but also systemically affect the whole physiological system. Thus, in this vulnerable condition, an 
effective alternative management tool is urgently required that efficiently counteracts these 
metabolic abnormalities at both the local and systemic levels. 
In this context, the present study, provide a reasonable support for the use of hemin based 
therapeutic protocols in treatment of obesity, diabetes and hypertension associated metabolic tissue 
injury and dysfunction. Although, the hemin-based drug Penhematin® is already approved for 
treatment for the blood related disorder porphyria by the Food and Drug Administration, its use in 
metabolic disease is still restricted to rodent research. The data presented in this study provide 
valuable information regarding the potential beneficial effects of hemin therapy in rodents that 
could overcome tissue injury and metabolic dysregulation during obesity, diabetes and 
hypertensive conditions without any related drug toxicity. Thus, it is expected that in the future, 
hemin based strategies will be part of the pharmaceutical interventions for treatment of 
complications related to obesity, diabetes and hypertension in humans. 
 
APPENDICES 
Appendix A:  Mishra M, Ndisang JF. A critical and comprehensive insight on heme oxygenase 
and related products including carbon monoxide, bilirubin, biliverdin and ferritin in type-1 and 
type-2 diabetes. Curr Pharm Des. 2014; 20(9):1370-91. 
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